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Abstract
The European Commission asked EFSA for a scientiﬁc opinion on the risks for animal and human
health related to the presence of quinolizidine alkaloids (QAs) in feed and food. This risk assessment is
limited to QAs occurring in Lupinus species/varieties relevant for animal and human consumption in
Europe (i.e. Lupinus albus L., Lupinus angustifolius L., Lupinus luteus L. and Lupinus mutabilis Sweet).
Information on the toxicity of QAs in animals and humans is limited. Following acute exposure to
sparteine (reference compound), anticholinergic effects and changes in cardiac electric conductivity are
considered to be critical for human hazard characterisation. The CONTAM Panel used a margin of
exposure (MOE) approach identifying a lowest single oral effective dose of 0.16 mg sparteine/kg body
weight as reference point to characterise the risk following acute exposure. No reference point could
be identiﬁed to characterise the risk of chronic exposure. Because of similar modes of action for QAs,
the CONTAM Panel used a group approach assuming dose additivity. For food, the highest mean
concentration of Total QAs (TotQAs) (i.e. the 6 most abundant QAs) was found in lupin seed samples
classiﬁed as ‘Lupins (dry) and similar-’. Due to the limited data on occurrence and consumption, dietary
exposure was calculated for some speciﬁc scenarios and no full human health risk characterisation was
possible. The calculated margin of exposures (MOEs) may indicate a risk for some consumers. For
example, when lupin seeds are consumed without a debittering step, or as debittered lupin seeds high
in QA content and when ‘lupin-based meat imitates’ are consumed. For horses, companion and farm
animals, other than salmonids, the available database on adverse effects was too limited to identify
no-observed-adverse-effect levels and/or lowest-observed-adverse-effect levels and no risk
characterisation was possible. For salmonids, the CONTAM Panel considers the risk for adverse effects
to be low.
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Summary
The European Commission asked the European Food Safety Authority (EFSA) for a scientiﬁc opinion
on the risks for animal and human health related to the presence of quinolizidine alkaloids (QAs) in
feed and food, in particular in lupins and lupin derived products. The CONTAM Panel provided an
opinion that comprised:
• information on QAs occurring in Lupinus species and varieties that are relevant for animal and
human consumption in Europe. These are Lupinus albus L. (white), Lupinus angustifolius L.
(blue or narrow-leaved), Lupinus luteus L. (yellow) and Lupinus mutabilis Sweet (Andean or
pearl). In particular the present assessment is conﬁned to the evaluation of the most relevant
QAs present in the seeds of these lupin species (i.e. angustifoline, a-isolupanine, lupanine,
13a-OH-lupanine, lupinine, multiﬂorine, sparteine, tetrahydrorhombifoline, 13a-
tigloyloxylupanine).
• evaluation of the toxicity of these QAs considering all the relevant toxicological endpoints and
assessment of the human and animal health risks due to the estimated dietary exposure to
these QAs of the EU population and farm animals, horses and companion animals.
Information on the toxicokinetics and metabolism of QAs in humans and experimental animals is
limited to sparteine and lupanine. Both compounds are rapidly absorbed, widely distributed and rapidly
eliminated in urine mainly unchanged or as oxidised metabolites. Genetic polymorphisms in CYP2D6
(occurring in 5–10% of Caucasians, also called poor metabolisers) may affect sparteine oxidation in
humans leading to a slower elimination. Similarly, scarce data are available on ‘absorption, distribution,
metabolism, and excretion’ (ADME) in farm animals, horses and companion animals. In ruminants,
there is extensive absorption and slow elimination of lupanine and 5,6-dehydrolupanine. In pigs,
lupanine is extensively absorbed and excreted in urine mainly unmodiﬁed, together with the
metabolites isolupanine and 13-OH-lupanine. There is no evidence of the formation of conjugated
metabolites of sparteine, lupanine or their metabolites in any species. No information is available to
assess transfer rates of QAs in food of animal origin; however, based on indirect evidence, possible
transfer to milk should be considered.
Acute toxicity studies in mice and guinea pigs indicate that sparteine is approximately two- to
three-fold more toxic than lupanine. In rats, lupanine and 13a-OH-lupanine have a similar toxicity. Mice
appear to be more sensitive than rats to acute toxicity of lupanine. Notwithstanding the differences in
toxicities of sparteine, lupanine and 13a-OH-lupanine, the acute symptoms following oral
administration of these QAs are similar in all species, with death resulting from respiratory failure and
toxic effects affecting the central nervous system (CNS).
None of the repeated dose studies on QAs were carried out using pure compounds, but they were
all based on diets containing seed extracts or ﬂour from various lupin species and were all performed
in the rat. These studies could not be used for the evaluation of QA toxicity.
Angustifoline, 13a-OH-lupanine, lupanine, lupinine, sparteine, 13a-tigloyloxylupanine, cytisine, 3b-
OH-lupanine, 17-oxosparteine were unable to bind or intercalate into DNA. Lupanine and extracts of
Lupinus termis (the main QA being lupanine) did not induce gene mutations in standard bacterial
assays and in mammalian cells in vitro or micronuclei in vivo. The data on sparteine are too limited to
conclude regarding genotoxicity.
In humans, a large part of the information on the toxicity of QAs is conﬁned to sparteine, mainly
because of its therapeutic use in the past as an antiarrhythmic and oxytocic drug. In the treatment
of cardiac arrhythmia, the recommended daily dosage for (-)-sparteine sulfate was in the range of
800–1,000 and 400–500 mg/day for short-term and for long-term therapy, respectively. Adverse effects
of anticholinergic nature were reported at these therapeutic doses. The lowest dose mentioned with
antiarrhythmic effects was 20 mg (equivalent to 0.16 mg sparteine/kg body weight (bw) for a person
with a body weight of 70 kg). Individual variations in sensitivity to sparteine sulfate are explained by
the genetic polymorphisms in CYP2D6, with poor metabolisers being considered as a group at higher
risk to develop side effects. When sparteine sulfate was given as a single oral dose of 100–150 mg to
pregnant women because of its oxytocic properties, vomiting was the only adverse effect reported.
The symptoms of intoxication with sparteine are dizziness, drowsiness, headache, sweating,
mydriasis and myasthenia. Sparteine blocks the transmission of signals from the nerves to the muscles
like curare, which may lead to respiratory arrest and death. From a poisoning case, it is known that a
dose of 30 mg of sparteine/kg bw was fatal to a young child. No adverse effects were observed after
administration to volunteers (including poor metabolisers) of single oral doses of 10 mg of either
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lupanine or 13a-OH-lupanine (each equivalent to 0.14 mg/kg bw for a person with a body weight of
70 kg).
Human cases of poisoning with lupin seeds are infrequent and rarely lead to a fatal outcome.
However, case reports of poisoning in children suggest that these are more susceptible to intoxication
than adults, and doses of lupin alkaloids from 10 mg/kg bw onwards may be lethal. Intoxication have
been associated with inadequate debittering of lupin seeds by consumers, while no case of poisoning
has been associated with consumption of industrially produced lupin seed-based food.
A study designed to determine the lethality of selected QAs in laying hens conﬁrmed the higher
acute toxicity (two- to three-fold) of sparteine in comparison to lupanine reported in mammals. The
large majority of relevant repeated-dose studies in livestock species were not performed to investigate
the toxicity of QAs, but aimed at studying the lupin impact on zootechnical performances (feed intake,
weight gain, milk and egg production). Lack of speciﬁc toxicity studies together with considerable
differences in total and speciﬁc QA content among lupin seeds from different species/cultivars did not
allow identiﬁcation of a no-observed-adverse-effect level (NOAEL)/lowest-observed-adverse-effect level
(LOAEL) for most food producing species. These were replaced by suggested tolerated concentrations/
doses speciﬁcally referring to seeds from a single lupin species/cultivar. The only studies performed
with pure QAs (i.e. lupinine and sparteine) were conducted in rainbow trout and allowed identifying
similar NOAEL values for lupinine and sparteine (1 mg/kg bw per day) and a LOAEL of 2.5 mg/kg bw
per day for lupinine and 3.5 mg/kg bw per day for sparteine. No relevant studies have been identiﬁed
for horses and companion animals.
Several modes of action have been identiﬁed for QAs, the most important acute toxic effect being
the inhibitory action on acetylcholine receptors (AChRs) in the CNS, in the peripheral autonomic
system and on the motor endplates. This produces an anticholinergic syndrome with paralysis of
respiratory muscles causing respiratory failure and death. The different QAs appear to bind with
different afﬁnity to AChRs and also their preference for nicotinic AChRs (nAChRs) or muscarinic AChRs
(mAChRs) seems to differ. QAs may also cause, with different potencies, inhibition of voltage-
dependent ion channels, with these effects possibly underlying their antiarrhythmic effect. The
uterotonic effects of sparteine appear to be mediated via an increased production of prostaglandin F.
Although most data are on sparteine, afﬁnities to AChRs of other QAs relevant in this opinion appear
to be in the same range or lower than those of sparteine. Scarce data on other modes of action of a
few QAs indicate that these QAs are similarly or less active than sparteine. No studies investigating
possible additive effect of QAs were identiﬁed.
The anticholinergic effects and the effects on the electrical conductivity of the heart following acute
exposure to QAs are the critical effects for the human hazard characterisation. The mode of action of
sparteine and its pharmacological proﬁle as an anticholinergic substance are considered similar to
those of other main alkaloids in lupin seeds (lupanine, 13a-OH-lupanine and lupinine). Therefore, the
CONTAM Panel considers it appropriate to use a group approach and apply the principle of dose
additivity with equal potencies of the QAs for their combined effect. In the absence of dose–response
information for other QAs, the CONTAM Panel decided to base the hazard characterisation on
sparteine, which has a higher potency than other QAs. The available data were considered insufﬁcient
to propose health-based guidance values (HBGVs) and instead an MOE approach using the lowest
single oral active dose of 0.16 mg sparteine/kg bw as reference point was selected to characterise the
risk following acute exposure. No reference point could be identiﬁed to characterise the risk following
chronic exposure.
The occurrence of QAs in lupin-based food samples was estimated using a data set of 1,035
analytical results from 99 food samples provided by 2 data providers. Information on the lupin species
was reported only in some cases, with the samples being equally distributed between L. albus and
L. angustifolius. Lupanine was the most abundant QA in seeds from these lupin species followed by
13a-OH-lupanine and angustifoline. Total QAs (TotQAs) as the sum of the 6 most abundant QAs
present in the data set (lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine
and a-isolupanine) were also calculated. The highest mean concentration of TotQAs was found in lupin
seed samples classiﬁed as ‘Lupins (dry) and similar-’ (429 mg/kg). These are sold as dry seeds and can
be consumed upon rehydration, debittering, boiling or as ﬂour for home-made dishes (pancakes/
crepes or pasta). High mean concentrations of TotQAs were also found in ‘lupin-based coffee imitates
ingredients’ (331 mg/kg), while lower values (> 10-fold) were found in ‘canned or jarred legumes’,
‘meat imitates’, or ‘pasta plain uncooked’.
Lupin seeds with a high concentration of QAs need to be debittered before consumption. Between
89 and 97% of the QAs present in seeds are removed by water treatment and boiling. Because of the
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limited amount of data on occurrence and consumption, the CONTAM Panel decided to calculate acute
dietary exposures for some speciﬁc food groups under speciﬁc scenarios. In a ﬁrst scenario, exposure
due to lupin seed consumption was estimated but it was assumed that no reduction of the QA content
occurred because of the lack of debittering of dry lupin seeds by the consumer. The P95 acute dietary
exposure was 761 and 1,700 lg/kg bw per day for lupin seeds with average and high TotQA content.
In a second scenario, the concentration of TotQA was assumed to decrease by 89% following soaking
and boiling in water of the lupin seeds and P95 exposures were 84 and 187 lg/kg bw per day for an
average and high QA content, respectively. The third scenario was based on ready-to eat lupin seeds
and resulted in P95 exposures of 44–46 lg/kg bw per day (lower bound (LB)–upper bound (UB)).
Higher P95 dietary exposures of 194–228 lg/kg bw per day (LB–UB) were reached in the fourth
scenario reﬂecting consumption of lupin-based meat imitates. All these scenarios reﬂect the exposure
of adults and scenarios 1, 2 and 3 could not be calculated for other age groups due to limitations in
the consumption data. In addition, exposure from certain lupin-based foods such as pasta, bread and
coffee imitates could not be assessed. Consequently, no full risk characterisation was possible.
There is uncertainty linked to the reference point of 160 lg sparteine/kg bw. This reference point
for QAs is based on the effects of sparteine which is the most potent QA with respect to toxicity.
However, sparteine occurs only in trace amounts according to the data submitted to EFSA
and, according to clinical experience, doses 7.5–10 times higher than the reference point ensure a
reliable antiarrhythmic effect. Therefore, the CONTAM Panel concluded that MOEs > 1 do not indicate
a health concern. In the event that lupin seeds were not debittered and for a scenario reﬂecting
dietary exposure from lupin-based meat imitates the CONTAM Panel calculated MOE values in the
range of 0.1–0.8. These MOEs may indicate a concern. In a scenario applying a reduction factor for
debittering, the calculated MOEs are of lower concern (0.9; high QA concentration) or no concern (1.9;
average QA concentration). MOEs > 1 were calculated for ready-to-eat lupin seeds that had an
average QA content.
Dietary exposure of farm animals, horses and companion animals was estimated using a data set
containing both feed and food samples (n = 54) provided by two data providers. Lupanine and 13a-
OH-lupanine accounted for about 36% of the TotQA in these samples. Exposures to QAs by farm
animals, horses and companion animals were estimated using maximum recommended inclusion rates
of lupin seeds in livestock diets and represent worst-case scenarios. In addition, insufﬁcient data on
levels of QAs in lupin seeds were available to allow P95 estimates of exposure to be made. In the
category ‘Ruminants and horses’, the highest exposure was for lactating goats (3.3 mg/kg bw per
day). For pigs and poultry, the highest exposure was for fattening chickens and laying hens (3.5 mg/kg
bw per day). For salmonids, the exposure was 1.6 mg/kg bw per day and for rabbits 4.4 mg/kg bw
per day. For cats and dogs the exposure was 0.6 mg/kg bw per day.
For the animal health risk characterisation, the CONTAM Panel applied a group approach for
salmonids and used a NOAEL of 1 mg/kg bw per day for the relevant QAs in this opinion. The mean
dietary exposure of salmonids is above the NOAEL but below the LOAEL of 2.5 mg/kg bw per day. The
CONTAM Panel considers the risk for adverse effects in salmonids to be low. For the other species, the
available database on adverse effects was too limited to identify overall NOAEL/LOAELs. In an
alternative approach, the CONTAM Panel identiﬁed doses of QAs present in lupin seeds that can be
tolerated with respect to zootechnical performance. However, such a dose is only applicable to lupin
seeds with similar QA composition and does not allow a full characterisation of the risk. For cattle and
rabbits, the mean dietary exposure is well below the tolerated dose. For pigs and chickens, the mean
dietary exposure in the same range as the dose that can be tolerated.
This risk assessment relates to lupin seeds and lupin-derived products with a QA proﬁle comparable
with that of the submitted data and should not be extrapolated to lupin seeds with a different QA
proﬁle (e.g. lupin seeds from species and/or varieties high in sparteine).
The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of QAs
in lupin seeds and lupin-derived products is substantial due to the limited data on toxicity, occurrence
and consumption. The CONTAM Panel recommends the generation of more data related to the
toxicokinetics, toxicity and occurrence of QAs as well as to the consumption of lupin seeds and lupin-
based foods in order to reﬁne the risk assessment.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Background
Quinolizidine alkaloids (QAs) mainly occur in lupin species and other plants of the Genisteae tribe.
They are secondary metabolites for defense against pathogens and other predators. QAs are
biosynthesized from lysine in green tissues of the plant and stored in all organs of the plant, including
seeds (Boschin and Resta, 2013).
The level of QAs depends on genotype, presence of pathogens, environmental effects and soil
characteristics. More than 170 QAs have been identiﬁed in different Lupinus species and the alkaloid
pattern is highly variable among different species (Boschin and Resta, 2013).
Lupins and lupin-derived products are listed in the Catalogue of feed materials.1
Lupin-based products, such as lupin proteins, are gaining attention to replace animal proteins and
other plants ingredients in several foods such as bakery products, imitation dairy and meat products,
and beverages.
Terms of Reference
In accordance with Art. 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the
European Food Safety Authority for a scientiﬁc opinion on the risks for animal and human health
related to the presence of QAs in feed and food, in particular in lupins and lupin derived products.
1.2. Interpretation of the Terms of Reference
More than 500 lupin species, comprising wild and domesticated species, have been described
worldwide (Wink et al., 1995). Lupin species contain so called lupin alkaloids as important secondary
metabolites. ‘Lupin alkaloids’ is a general term that comprises the QAs, but also other alkaloids such as
piperidines (e.g. ammodendrine) and indoles (e.g. gramine). Lupins also contain other antinutritional
factors such as phytic acid, saponins and tannins. Following the terms of reference, the present
assessment is conﬁned to the evaluation of QAs. Furthermore, only QAs occurring in lupin species and
varieties that are relevant for animal and human consumption in Europe (i.e. Lupinus albus (white
lupin), Lupinus angustifolius (blue or narrow-leaved lupin), Lupinus luteus (yellow lupin) and Lupinus
mutabilis (Andean or pearl lupin)) are considered in this Scientiﬁc Opinion. The allergenic potential of
lupin proteins has been addressed in previous EFSA opinions (EFSA, 2006; EFSA NDA Panel, 2014) and
is also not dealt with in the present evaluation. Lupins are the main host of the fungus Diaporthe
toxica, which produces phomopsins. Phomopsins are a family of mycotoxins that has been evaluated
by EFSA in a previous opinion (EFSA CONTAM Panel, 2012) and are also considered not part of the
present assessment.
1.3. Supporting information for the assessment
1.3.1. Chemistry
QAs are a broad group of secondary metabolites present in all species of the genus Lupinus and
related genera from the Genisteae tribe. Biosynthetically, QAs are derived from lysine that is converted
to cadaverine, which is the central intermediate from which all QAs are formed. QAs have quinolizidine
as a core structure that consists of two fused 6-membered rings with a nitrogen atom at the
bridgehead (see Figure 1). QAs found in lupin can have a bicyclic, tricyclic or tetracyclic structure. The
11 QAs that are considered most relevant with respect to occurrence in lupin species for human and
animal consumption in Europe are shown in Figure 1. A more comprehensive overview of QA chemical
structures and some physical properties of QAs present in the genus Lupinus are listed in Appendix A.
Some other alkaloids found in lupin species are also listed in Appendix B.
With respect to the stereochemistry of sparteine, lupanine and lupinine, (-)-sparteine was detected
in L. luteus and other lupin species (Merck Index, 2006; Blaschek et al., 2006), (+)-lupanine was
found in L. angustifolius and racemic lupanine in L. albus (Merck Index, 2006) and (-)-lupinine was
identiﬁed in L. luteus and other lupin species (Merck Index, 2006). It should be noted that in cases
1 Commission Regulation (EU) No 68/2013 of 16 January 2013 on the Catalogue of feed materials. OJ L 29, 30.1.2013, p. 1.
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where the stereochemical conﬁguration of sparteine, lupanine and lupinine is not indicated in the text,
it was not deﬁned in the underlying reference.
1.3.2. Analytical methods
Extraction and puriﬁcation
QAs can be extracted from ground lupin seeds with acidic solutions (0.1–1 N HCl or trichloroacetic
acid) (Wink et al., 1995; Boschin et al., 2008; Kamel et al., 2016), optionally preceded by a hexane
defatting step (Boschin et al., 2008). Liquid–liquid extraction of alkaline or alkalinised extracts with
chloroform or dichoromethane using Extrelut columns yields an enriched extract containing the QAs
(Wink et al., 1995; Boschin et al., 2008). Although less frequently, dilute sodium hydroxide solutions
have also been used to extract QAs from the seeds (Hatzold et al., 1983). Direct extraction of ground
seeds by maceration in the presence of organic solvents such as chloroform and diethyl ether has also
been described (Pothier et al., 1998).
Titration and TLC methods
The total alkaloid content in seeds can be estimated by titration of the QAs in their salt free form,
with p-toluenesulfonic acid in combination with a pH colour indicator, e.g. tetrabromophenolphthalein
ethyl ester (Ruiz, 1977) or bromocresol green (Ruiz et al., 1977). The limit of quantiﬁcation (LOQ) of
these methods is around 100 mg/kg seeds (Ruiz, 1977). Chloroform extracts obtained by the
extraction procedure described above, upon titration gave a reasonable indication of the total alkaloid
content (Ruiz, 1978). Nevertheless, a drawback of the method is that it will determine QAs together
with other co-extracted alkaloids present in lupin seeds.
Thin-layer chromatography (TLC) can be used to obtain qualitative information on the QA
composition of lupin seeds. Separation on silica gel plates and visualisation can be accomplished with
Dragendorff’s reagent and ultraviolet (UV) light (Muzquiz et al., 1994). A quantitative 2D-TLC method
has been described by Karlsson and Peter (1978).
GC-based methods
Analytical methods based on capillary high resolution gas chromatography (GC) have been in
widespread use since the early 1980s. Notably the research group of Wink has published a large
number of papers on the analysis of lupin seeds and other plant parts using GC methods, culminating
in their overview paper of 1995, in which the spectral data and QA compositions for 56 different lupin
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Figure 1: Quinolizidine core structure and the most relevant quinolizidine alkaloids for human and
animal consumption in Europe found in Lupinus species
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species are presented (Wink et al., 1995). In essence, the methods in use today are still very similar to
the methods developed in the 1980s. Typically GC systems are equipped with either an aspeciﬁc ﬂame
ionisation detector (FID), a nitrogen speciﬁc detector (nitrogen-phosphorus detector, NPD) or they are
coupled to a mass spectrometer (MS), typically generating electron impact (EI) spectra (Boschin and
Resta, 2013). By using speciﬁc non-polar stationary phases (typically HP-1 (DB-1) or HP-5 (DB-5)) in
combination with Kovats retention indexes, databases containing spectral information on a large
number of QAs have been made available (Wink et al., 1995; National Institute of Standards and
Technology (NIST) database).2 Detection limits (LOD) are generally not reported, as they are
considered sufﬁcient for the analysis of lupin seeds and other plant parts. However, the LOQ of the
method becomes relevant for analysis of food products containing lupin seeds as an ingredient or for
processed foods. Resta et al. (2008) and Boschin et al. (2008) reported for lupanine an LOQ of 2 mg/kg
(LOD = 1 mg/kg) in ﬂour. Reinhard et al. (2006) reported for lupanine, angustifoline and 13a-OH-
lupanine, LODs of 1, 2 and 6 mg/kg, respectively, in ﬂour.
Derivatisation of QAs is not necessary for analysis of lupin seeds, but it is sometimes used to obtain
lower LODs, particularly in complex matrices, such as food (Reinhard et al., 2006). After derivatisation,
the LOD for angustifoline improved to 0.3 mg/kg and for 13a-OH-lupanine to 0.5 mg/kg.
Due to the lack of available reference standards, quantiﬁcation is often performed by comparison of
relative peak areas to that of an available standard, e.g. sparteine or lupanine (Boschin and Resta,
2013). This may introduce considerable uncertainty in the reported concentrations (Resta et al., 2008).
LC-based methods
Liquid chromatography (LC)-based methods are not often used for the determination of QAs.
Wysocka and Chrzanowska (2004) used an high-performance liquid chromatography (HPLC) method
with a chiral analytical column and UV detection at 220 nm to study the enantiomeric purity of
lupanine in L. albus and L. angustifolius cultivars. The (+)- and (-)-enantiomers of lupanine could be
separated on a Chiralcel OD column (Wysocka and Chrzanowska, 2004; Przybył and Kubicki, 2011).
Green et al. (2015a) used a liquid chromatography coupled mass spectrometry (LC–MS) method to
quantify the major QAs of Lupinus leucophyllus (anagyrine, lupanine, 5,6-dehydrolupanine and an
unidentiﬁed QA with mass 248) in serum of Holstein cows that had been orally dosed with dried
L. leucophyllus plant material. The estimated LOQs were around 10 ng/mL in serum. Sparteine,
lupinine and lupanine are sometimes included in multi analyte methods covering a wider range of plant
toxins (Mol et al., 2011; Carlier et al., 2015). A conference abstract reports on the development of a
liquid chromatography tandem mass spectrometry method (LC–MS/MS) for the major QAs in lupin ﬂour
(Mulder and de Nijs, 2015). QAs were extracted from the ﬂour with an acidic aqueous solvent. The
extracts were analysed without further clean-up except membrane ﬁltration. The LOQs were < 1 mg/kg,
but no further details were disclosed. Vanerkova et al. (2014) also report in a conference abstract on
the development of an LC–MS/MS method for lupanine, lupinine and sparteine in lupin seeds with LOQs
of 2.6, 3.3 and 0.14 mg/kg, respectively.
Analytical standards, certiﬁed reference materials and proﬁciency testing schemes
The availability of commercial QA reference standards is limited. Lupanine, lupinine and sparteine
are available from a number of different suppliers, but the other QAs are either available from a single
source only or not available at all. Isotopically labelled analogues are also not available. No certiﬁed
materials are commercially available and no proﬁciency testing schemes for testing of QAs in lupin
seeds or lupin products have been identiﬁed.
1.3.3. Botanical origin, varieties and cultivation
The genus Lupinus belongs to the family of Fabaceae (Leguminosae), a large family of plants, to
which also important food and feed crops such as beans (e.g. fava beans (Vicia faba), peas (Pisum
sativum), lentils (Lens culinaris), peanuts (Arachis hypogaea) and soybeans (Glycine max) belong. Of
these food crops only lupins are known to produce QAs (Wink, 2003). Within the Fabaceae family, the
genus Lupinus is placed in the tribe Genisteae, which comprises also the brooms (a general term
describing species of the genera Cytisus, Genista, Spartium) and Laburnum (golden rain). Almost all
species of the Genisteae tribe produce QAs (Wink and Mohamed, 2003; Boschin and Resta, 2013). An
estimated 250–500 different lupin species have been described in the literature, the majority of them
2 https://www.sisweb.com/software/ms/nist.htm [accessed in December 2018].
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found only in North or South America (so called New World lupin species). In Europe and North Africa,
only 12 species occur (so-called Old-World lupin species) (Wink et al., 1995; Boschin and Resta, 2013).
Lupin seeds are rich in protein which makes them an interesting alternative crop for e.g. soybeans.
Worldwide, four lupin species are cultivated on a commercial scale for food and feed purposes:
L. albus, L. angustifolius, L. luteus and L. mutabilis (Gresta et al., 2010; Boschin and Resta, 2013;
Carvajal-Larenas et al., 2016; Magalh~aes et al., 2017).
The main use of lupin seeds globally is as a high protein feed for livestock, where it is used as an
alternative to oilseed meals, while only approximately 4% is grown for food (Lawrance, 2007).
Furthermore, lupin seeds represent a small proportion of the total amount of feed used for livestock.
In 2016/17, EU-grown lupin seeds accounted for approximately 5% of the EU produced high-protein
oilseeds (soybean meal, rapeseed meal and sunﬂower meal) and less than 2% of the oilseeds (EU
produced and imported) used in the manufacture of compound feeds.3
In Figure 2, the production of lupin seeds in countries of the European Union (EU) over the period
2002–2016 is presented. Data are available from the FAOSTAT database,4 but these are not speciﬁed
for the different lupin species. In the EU, Poland has emerged in recent years as the main producer of
lupin seeds, with a current annual production above 200,000 tonnes. Germany (ca. 50,000 tonnes/year)
and France (ca. 16,000 tonnes/year) are also important producers.
Globally, since the mid-1980s Australia is the biggest producer of lupin seeds, mostly
L. angustifolius (Figure 3). In the last decade of the 20th century, Australia dominated the global
market with a market share of over 90% and an annual production of more than 1 million tonnes
(FAOSTAT4; Lawrance, 2007; Sweetingham and Kingwell, 2008). Since then, production has steadily
declined to around 50% of the world production. In recent years, the Russian Federation has become
an important producer of lupin seeds, mostly L. luteus (Sweetingham and Kingwell, 2008). Because
the large-scale production of lupin seeds is concentrated in only a few countries, the global yearly
production can ﬂuctuate signiﬁcantly, due to a strong dependence on the prevailing weather conditions
(Lawrance, 2007; Sweetingham and Kingwell, 2008; OGTR, 2013).
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Figure 2: Lupin seed production in EU countries in the period 2002–2016 (based on data extracted
from FAOSTAT)
3 Source: The compound Feed Industry in the EU Livestock Economy (FEFAC.eu).
4 http://www.fao.org/faostat/en/#home. The FAOSTAT database provides free access to food and agriculture data for over
245 countries and territories and covers all FAO regional groupings from 1961 to the most recent year available.
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Wild lupin species contain high amounts of the bitter tasting QAs. Nevertheless, in the
Mediterranean region the origins of domestication of L. albus can be traced back to 4,000 years ago
(Kurlovich, 2002). Traditionally, the levels of QAs in the seeds have been substantially reduced by
soaking the beans in salted water and washing. In the 20th century, breeding efforts have resulted in
the successful introduction of low-alkaloid containing varieties, so called ‘sweet lupins’ (Hondelmann,
1984; Muzquiz et al., 1994; Frick et al., 2017). Often, a discrimination between sweet (less than
500 mg/kg total QAs) and bitter varieties (more than 10,000 mg/kg total QAs) is made (Pilegaard and
Gry, 2008). However, semi-sweet and semi-bitter varieties are also common (Boschin et al., 2008).
The EU database on registered plant varieties5 currently lists 23 varieties of L. albus, 50 varieties of
L. angustifolius and 14 varieties of L. luteus. L. albus is grown predominantly in countries of the
Mediterranean region, L. angustifolius is produced primarily in Eastern Europe and Germany while
L. luteus is mainly cultivated in Poland. L. mutabilis is not grown on a commercial basis in the EU
(Magalh~aes et al., 2017).
In Appendix C, the biosynthetic pathway towards the formation of QAs is shown. QAs are derived
from the amino acid lysine that is converted into cadaverine by the enzyme lysine decarboxylase
(LDC). From two molecules of cadaverine, after a cascade of steps, the bicyclic (-)-lupinine is formed,
while by combination of three molecules of cadaverine, via an intermediate diiminium cation, the
tetracyclic QAs such as (-)-sparteine, (+)-lupanine and (-)-multiﬂorine are formed (Golebiewski and
Spenser, 1988). Further diversiﬁcation can occur via hydroxylation and esteriﬁcation (Bunsupa et al.,
2013). The palette of QAs produced is often speciﬁc for the individual lupin species (Wink et al., 1995).
Appendix D, Tables D.1–D.4 give an overview of levels of QAs in seeds of the species L. albus,
L. luteus, L. angustifolius and L. mutabilis. The results shown in Appendix D and summarised in
Table 1 are from papers in which the chemical analysis is carried out by GC or HPLC. As seen
in Table 1, lupanine is in general the most abundant QA in L. albus, L. angustifolius and L. mutabilis.
In L. luteus lupinine is the most common QA together with sparteine. Lupinine is only found in
L. luteus while sparteine is also found in the three other species but in L. albus and L. angustifolius
only in minor amounts. As it can be seen from Table 1, the amount of the QAs can differ considerably
within the same species. In addition, the total concentration of QAs as well as the distribution and the
concentration of the individual QAs from the same varieties change with growth place and year. For
example, the total concentration of the cultivar Mulititalia (L. albus) differs from 2,448 mg/kg to
6,292 mg/kg when the seeds are grown in two different growing seasons at two different places in
Italy (Annicchiarico et al., 2014; see Appendix D, Table D.1).
The occurrence of QAs in the four relevant lupin species has also been reviewed by the Nordic
Council of Ministers in 2008 (Pilegaard and Gry, 2008), by Carvalja-Larena in 2016 and most recently
by the Bundesinstitut f€ur Risikobewertung/German Federal Institute for Risk Assessment (BfR) in 2017.
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Figure 3: Global production of lupin seeds in the period 2002–2016, according to FAOSTAT
5 http://ec.europa.eu/food/plant/plant_propagation_material/plant_variety_catalogues_databases/search/public/index.cfm The
EU database of registered plant varieties offers a search tool for all the agricultural and vegetable plant varieties whose seed
can be marketed throughout the European Union. The database provides a rapid and easy access to the data which,
according to the seed marketing legislation, have been published in the Ofﬁcial Journal.
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Appendix D, Table D.5 summarises the outcome of these reviews. The results shown in Table D.5
support the results shown in Table 1, since also here lupanine is in general the most commonly found
QA in L. albus, L. angustifolius and L. mutabilis while for L. luteus it is lupinine and sparteine. In
addition, the results in Table D.5 show that the contribution of the same QA can differ considerably
within the same species.
Table 1: Summary of the occurrence of quinolizidine alkaloids in seeds of the species L. albus,
L. luteus, L. angustifolius and L. mutabilis
Variety(a)
Total amount
(mg/kg)
Quinolizidine alkaloids
identiﬁed
Contribution of individual quinolizidine
alkaloids to the total amount(b),(d)
L. albus
Bitter < 1,000–23,600 Lupanine
Albine
Multiﬂorine
Angustifoline
a-Isolupanine
13a-OH-Lupanine
Sparteine
13a-Tigloyloxylupanine
58–92%
0.63–19%
7.6–11%
1.1%
0.30–1.0%
0.68%
0.13%
0.08%
Bitter 14,516 Lupanine
Albine
13a-OH-Lupanine
Angustifoline
13a-Tigloyloxylupanine
Tetrahydrorhombifoline
11,219 mg/kg
1,012 mg/kg
492 mg/kg
268 mg/kg
102 mg/kg
24 mg/kg
Sweet 50–1,656 Lupanine
13a-OH-Lupanine
13a-Angeloyloxylupanine
Albine
Angustofoline
13a-Tigloyloxylupanine
a-Isolupanine
Tetrahydrorhombifoline
26–1,378 mg/kg
3–157 mg/kg
Not detected-88 mg/kg
10–162 mg/kg
Not detected–65 mg/kg
Not detected–44 mg/kg
Not detected–22 mg/kg
1.0–13 mg/kg
Not stated 146–49,100 Lupanine
13a-OH-Lupanine
13a-Angeloyloxylupanine
Multiﬂorine
Albine
Angustifoline
13a-Tigloyloxylupanine
a-Isolupanine
Sparteine
28-77%
2.4–33%
< 1–23%
1–22%
0.02–16%
0.29–10%
8.9%
< 1%
< 1%
Not stated 38-52,380 Lupanine
13a-OH-Lupanine
Albine
Angustifoline
Multiﬂorine
13a-Tigloyloxylupanine
a-Isolupanine
13a-Angeloyloxylupanine
Lupinine
Tetrahydrororhombifoline
Sparteine
17–46,240 mg/kg
Not detected–4,710 mg/kg
10–2,596 mg/kg
Not detected–750 mg/kg
Not detected–616 mg/kg
Not detected–348 mg/kg
Not detected–250 mg/kg
Not detected–112 mg/kg
Not quantiﬁed–50 mg/kg
6.5–44 mg/kg
2.1 mg/kg
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Variety(a)
Total amount
(mg/kg)
Quinolizidine alkaloids
identiﬁed
Contribution of individual quinolizidine
alkaloids to the total amount(b),(d)
L. angustifolius
Bitter 20,600 Lupanine
13a-OH-Lupanine
Angustifoline
Tetrahydrorhombifoline
a-Isolupanine
Sparteine
71%
17%
5.8%
2.8%
1.2%
0.1%
Bitter 10,800–19,800 Lupanine
13a-OH-Lupanine
a-Isolupanine
4,000–12,900 mg/kg
5,000–6,600 mg/kg
213–237 mg/kg
Sweet 840–1,800 Lupanine
13a-OH-Lupanine
a-Isolupanine
Sparteine
Angustifoline
Tetrahydrorhombifoline
4.0–50%
19–21%
6.4–14%
2.5–4.8%
2.7–4.4%
0.0–1.0%
Sweet 44–2,120 13a-OH-Lupanine
Lupanine
Angustifoline
a-Isolupanine
18–943 mg/kg
18–862 mg/kg
7–226 mg/kg
8–90 mg/kg
Not stated 652–19,176 Lupanine
13a-OH-Lupanine
Angustifoline
a-Isolupanine
Multiﬂorine
Tetrahydrorhombifoline
Sparteine
36–70%
12–37%
10–30%
< 1–12%
0.95%
< 1%
< 1%
Not stated 15–24,950 Lupanine
Angustifoline
a-Isolupanine
13a-OH-Lupanine
Sparteine
7.4–20,570 mg/kg
< LOQ–3,830 mg/kg
40–550 mg/kg
5.6–26 mg/kg
< LOQ–10 mg/kg
L. luteus
Sweet 389–895 Sparteine
Lupinine
Lupanine
2–234 mg/kg
3–281 mg/kg
6.4–37 mg/kg
Not stated 1,020(c) Lupinine
Sparteine
13a-OH-Lupanine
Lupanine
Tetrahydrorhombifoline
27–60%
30–56%
6.3%
< 1–2.9%
< 1%
Not stated 9–10,630 Sparteine
Lupinine
13a-OH-Lupanine
Lupanine
7.1–7,890 mg/kg
0–2,420 mg/kg
< LOQ–10 mg/kg
< LOQ–0.5 mg/kg
L. mutabilis
Not stated 31,000(e) Lupanine
Sparteine
13a-OH-Lupanine
Tetrahydrorhombifoline
13a-Angeloyloxylupanine
Angustifoline
13a-Tigloyloxylupanine
a-Isolupanine
Multiﬂorine
47–58%
7.4–16%
7–15%
2–3.5%
1.6–2%
1%
0.3–1%
0.3–< 1%
0.14–< 1%
LOQ: limit of quantiﬁcation.
(a): As stated in the literature.
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1.3.4. Previous risk assessments
No previous animal health risk assessments on QAs, lupins or lupin derived feed have been
identiﬁed by the CONTAM Panel.
In 1996, the UK Advisory Committee on Novel Food and Processes has published a report on seeds
from L. angustifolius (FSA, 1996) in which they, considering advice from the Food Advisory Committee
and the Committee on Toxicity (COT), concluded that seeds and products from L. angustifolius are
safe for use provided that an alkaloid level of 200 mg/kg is not exceeded in seeds or products thereof
as any anticipated human exposure would be signiﬁcantly lower than the NOAEL of 1,000 mg lupin
alkaloids/kg diet identiﬁed by the Committee on Toxicity of Chemicals in Food.6
In 1998, the French Directorate General of Health has issued a favourable opinion regarding the
use of ﬂour from L. albus var. ARES in food, provided that the alkaloid levels in such ﬂour remain
below 200 mg/kg (Direction generale de la sante, 1998).
In 2001, the Australia New Zealand Food Authority (ANZFA), the former Food Standards Australia
New Zealand (FSANZ), published a risk assessment on lupin alkaloids in food (ANZFA, 2001). It was
concluded that the no-observed-effect level (NOEL) of 90–105 mg/kg body weight (bw) per day for
lupin alkaloids of L. angustifolius and L. luteus obtained in subchronic rat studies (Ballester et al.,
1980; Butler et al., 1996; Robbins et al., 1996) is about three times higher than the lethal dose of
about 30 mg/kg bw seen in human poisoning cases with lupin alkaloids where sparteine was the major
alkaloid. It was suggested that the rat is not appropriate to derive tolerable exposure levels in humans.
Thus, ANZFA derived a provisional tolerable daily intake (PTDI) of 35 lg/kg bw per day based on
reports of lupin consumption which indicate that in humans daily doses of 0.35 mg lupin alkaloids/kg
bw do not cause adverse effects, and adding an uncertainty factor (UF) of 10 to account for intra-
individual variations. Dietary exposure was estimated assuming that 5% of all ﬂour-based products
consumed contained 10% lupin ﬂour and assuming an alkaloid level of 130 mg/alkaloids per kg for
lupin seeds intended for human consumption (Robbins et al., 1996). Based on a P95 ﬂour consumption
of 244.8 g/day and a body weight of 70 kg, ANZFA concluded that this leads to a 95th percentile
dietary exposure of 2 lg lupin alkaloids/kg bw per day which is well below the PTDI of 35 lg/kg bw
per day.
In 2008, the Nordic Council of Ministers issued a toxicological review and recommendations on
alkaloids in edible lupin seeds (Pilegaard and Gry, 2008). They noted that humans, and especially
children, seem to be more sensitive towards lupin alkaloids than rodents. The lethal dose in children
was estimated to be 11–25 mg/kg bw, while oral rat LD50s range from 1,700 to 2,300 mg/kg bw. As a
consequence, they concluded that the results available from several repeated dose studies with rats
are of limited value. They also noted that several non-edible lupin species have been associated with
developmental effects in livestock animals. The QA anagyrine is believed to cause ‘crooked calf
disease’7 in offspring of cows that consume lupins. Consumption of Lupinus consentinii is associated
with developmental effects in lambs and calves. Its major QA is multiﬂorine, according to the authors
‘structurally related’ to anagyrine and occurring in edible lupins in amounts of up to 18% of the total
alkaloid amount. In the absence of consumption data, daily intake levels of alkaloids were calculated
for adults and children assuming that adults (60 kg bw) eat 300 g bread and 100 g pasta each
containing 15% lupin ﬂour and in addition 50 g lupin seeds as a snack. For children (20 kg bw), it was
assumed that they eat 150 g bread, 75 g pasta and 30 g lupin seeds. In a ﬁrst scenario, a
concentration of 200 mg alkaloids/kg lupin seeds was used and in a second scenario 500 mg/kg. In a
third scenario, it was assumed that only lupin seed snacks containing 500 mg alkaloids/kg are
consumed. Resulting daily intakes for adults and children were 0.32 and 0.57 mg/kg bw (ﬁrst
scenario), 0.79 and 1.4 mg/kg bw (second scenario) and 0.42 and 0.75 mg/kg bw (third scenario),
respectively.
(b): Given as percentage of total QA or alkaloids unless another unit is given. See Appendix D for further details. Not all QAs
were detected in all samples.
(c): Two references but only in one of the references the total amount is given. See Appendix D for further details.
(d): Not detected and Not quantiﬁed: QA not detected but no quantitative LOD or LOQ given; < LOQ: LOQ shown in
Appendix D; < 1: Contribution of QA not quantiﬁed but given as < 1%.
(e): Only one paper reporting the total amount of QAs was identiﬁed.
6 https://cot.food.gov.uk/sites/default/ﬁles/cot/cotannualreport1995.pdf
7 The disease is characterized by twisted or bowed limbs (arthrogryposis), twisted or bowed spine (scoliosis or kyphosis), twisted
neck (torticollis), cleft palate, or a combination of any of them.
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The BfR has recently assessed human health risks from the intake of QAs, such as lupanine,
lupinine, and sparteine, as components of lupin seeds derived from various lupin species, e.g. L. albus,
L. angustifolius, L. luteus and L. mutabilis (BfR, 2017a,b). Based on the available data, the BfR
considered lupanine, lupinine and sparteine to act via a similar mode of action and likely in an additive
way, sparteine showing the highest potency. The limited information available on the dose effect
relationships, did not allow to identify a NOAEL for humans. Altogether, the analysis of the reported
cases revealed that intoxication has been repeatedly attributed to the insufﬁcient debittering of lupin
seeds by consumers. Since consumption data on foods in Germany that contain lupin seeds or a
processed form thereof (e.g. lupin ﬂour) were lacking, a representative ‘Consumer survey on the
consumption of lupin seeds’ commissioned by the BfR was conducted throughout Germany in 2016.
The proportion of consumers who had consciously eaten lupin seed-based food was small (9.2% of
respondents). For the acute exposure estimation, the BfR assumed a total QA concentration of
200 mg/kg lupin seeds. The highest acute dietary QA exposure was estimated for ‘Lupini beans as a
snack’ (0.286 mg/kg bw per day) and ‘Patties’ (0.229 mg/kg bw per day). Estimated acute total QA
intake via foods from the remaining categories ranged from 0.003 to 0.057 mg/kg bw per day.
Estimates for chronic total QA intake were calculated based on an assumed total QA concentration of
60 mg/kg seeds and were the same for consumers of ‘Lupini beans as a snack’ and ‘Patties’ with a
median of 0.013 mg/kg bw per day. When assessing the risks, BfR concluded that the data situation
on the effects and in particular on the dose-response relationships of the individual alkaloids and their
interactions is sparse and not sufﬁcient for the derivation of health-based guidance values (HBGVs).
For the assessment of acute risks, BfR compared total intakes of QAs to the pharmacological threshold
dose of sparteine of 0.2 mg/kg bw reported by Blaschek et al. (2006) and Thies (1986), which was
chosen as a reference point. BfR concluded that the margin of exposure (MOE) to this reference point
should be more than 1 to account for the uncertainty in the data base, including higher sensitivities of
special population groups, such as pregnant women and poor metabolisers (PMs). Thus, BfR
considered the MOE of 1, which resulted for the two above mentioned food categories of ‘Lupini beans
as a snack’ and ‘Patties’, as inadequate. For the remaining food categories, the MOE lay between 4 and
70. With respect to chronic risks, BfR noted, that current knowledge did not allow deriving a
toxicological reference point.
1.3.5. Legislation
In this opinion, where reference is made to Regulations, the reference should be understood as
relating to the most recent amendment, unless otherwise stated.
Article 2 of Council Regulation (EEC) No 315/938 stipulates that food containing a contaminant in
an amount unacceptable for public health shall not be placed on the market, that contaminant levels
should be kept as low as can reasonably be achieved and that, if necessary, the European Commission
may establish maximum levels for speciﬁc contaminants. These maximum levels (MLs) are laid down in
the Annex of Commission Regulation (EC) No 1881/20069 and may include MLs for the same
contaminants in different foods, analytical detection limits and reference to the sampling and analysis
methods to be used. Currently, no MLs are set for QAs in food.
Council Directive 2002/32/EC10 regulates undesirable substances in products intended for animal
feed. Annex I to this regulation contains a list with MLs for certain inorganic and organic feed
contaminants. QAs are currently not considered in this Directive. Only sweet lupins (SLs) can be used
for animal feeding as speciﬁed in the Catalogue of feed materials.11 Commission Regulation (EC) No
1121/2009 of 29 October 200912 deﬁnes SLs as ‘those varieties of lupins producing seed comprising
not more than 5% bitter seeds. The bitter seed content shall be calculated in accordance with the test
set out in Annex II to this Regulation.’
8 Council Regulation (EEC) No 315/93 of February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–5.
9 Regulation (EC) No 1881/2006 of the European Parliament and the Council of 19 December 2006 setting maximum levels for
certain contaminants in foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
10 Directive 2002/32/EC of the European Parliament and the Council of 7 May 2002 on undesirable substances in animal feed. OJ
L 140, 30.5.2002, p. 10–21.
11 Commission Regulation (EU) No 68/2013 of 16 January 2013 on the Catalogue of feed materials. OJ L 29 30.1.2013, p. 1–64.
12 Commission Regulation (EC) No 1121/2009 of 29 October 2009 laying down detailed rules for the application of Council
Regulation (EC) No 73/2009 as regards the support schemes for farmers provided for in Titles IV and V thereof. OJ L 316,
2.12.2009, p. 27–64.
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The Novel Food Catalogue13 contains products of animal and plant origin subject to the Novel Food
Regulation (EU) 2015/228314 based on information provided by EU Member States. It serves as an
orientation whether or not certain products need to be authorised under the Regulation. L. albus,
L. angustifolius and L. luteus are included in the catalogue but neither of them requires authorisation
as they have been marketed prior to 15 May 1997.
In Australia and New Zealand, an ML of 200 mg lupin alkaloids/kg apply for lupin ﬂour, lupin kernel
ﬂour, lupin kernel meal and lupin hulls and ML of 5 mg/kg for sparteine in alcoholic beverages.15
2. Data and methodologies
2.1. Methodology for data collection and study appraisal
A call for an ‘Extensive literature search and selection for relevance of studies related to the
chemistry and toxicity of glycoalkaloids and QAs in food and feed’ aiming at identifying and evaluating
literature related to the present assignment (and to another mandate of the CONTAM Panel on
glycoalkaloids which is not further considered here). The call was launched as a Reopening
competition for a speciﬁc contract under multiple framework contract CT/EFSA/AMU/2014/01 Lot 2.
The University of Chemistry and Technology Prague was awarded with the contract and a ﬁnal project
report has been delivered in November 2017 and was published together with the present opinion
(University of Chemistry and Technology Prague, 2019). Brieﬂy, following standardised protocols for
identiﬁcation and evaluation (as described in University of Chemistry and Technology Prague, 2019)
potentially relevant studies/reviews issued in the period from 1950 to 2017 (the search was carried out
on 29 June 2017) were identiﬁed and the numbers of publications were as follows per scientiﬁc area.
Analytics/chemistry determination of chemical identity, formation: 1,021; Toxicokinetics: 103; Mode of
action: 88; In vivo toxicity: 60; In vitro toxicity: 15; Observations in humans: 13; Adverse effects in
farm animals, horses and companion animals: 61; Food occurrence: 1,042; Feed occurrence:
1,042 and factors inﬂuencing levels of QAs: 180. The total number of papers identiﬁed was 1,768. A
series of publications was identiﬁed as relevant for more than one scientiﬁc area. The abstracts of
these publications were then again screened by the Working Group members, and a total of
175 publications were considered as potentially relevant for the assessment and the originals were
retrieved. Furthermore, a search was done to identify papers that were published after the search was
carried out or that were not captured in the search above (see Appendix E for further details).
In addition, a ‘snowballing’ approach16 was applied (see Jalali and Wohlin, 2012) in order to obtain
any additional relevant information not captured in the systematic research.
The publications were used in the assessment if considered as relevant by applying expert
judgement. It should be noted that lupin species other than L. albus, L. angustifolius, L. luteus and
L. mutabilis also contain QAs that are relevant for the current assessment, therefore also studies with
L. caudatus, L. leucophyllus, L. argenteus, L. montanus, L. exaltatus, L. termis and L. mexicanus were
considered for the hazard identiﬁcation and characterisation.
In addition, the draft opinion underwent a public consultation from 23 May 2019 to 5 July 2019.
The comments received and how they were taken into account when ﬁnalising the scientiﬁc opinion
were published in an EFSA Technical Report (EFSA, 2019). During this public consultation additional
information was submitted to EFSA (see Documentation provided to EFSA). Following a comment
submitted during the public consultation, an additional literature search was conducted in Sciﬁnder.17
Following screening of title and abstract, 60 references were retrieved for screening of the full text.
13 http://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm
14 Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1–22.
15 Australia New Zealand Food Standards Code – Schedule 19- Maximum levels of contaminants and natural toxicants.
Registered 18 April 2017. Id F2017C00333. https://www.legislation.gov.au/Series/F2015L00454
16 Identifying articles that have been cited in articles found in a search.
17 Search string: Substance Identiﬁer “sparteine” > substances (1) > get references (1543) > reﬁne “1960-1980”. Results: 408.
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2.2. Food and feed occurrence data submitted to EFSA
2.2.1. Data collection
Following a mandate from the European Commission, occurrence data on QAs were acquired via
the call for collection of occurrence data on chemical contaminants in food and feed, issued by the
DATA Unit. European national authorities and similar bodies, research institutions, academia, food
business operators and other stakeholders were invited to submit analytical data on QAs in food and
feed. The data submission followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a) using the data model ‘Standard sample description’
(SSD1 or SSD2) (EFSA, 2010a, 2013). At the moment of data extraction,18 a total of 1,465 analytical
results on 13a-OH-lupanine, 13a-angeloyloxylupanine, 13a-tigloyloxylupanine, albine, angustifoline,
a-isolupanine, lupanine, lupinine, multiﬂorine, sparteine, tetrahydrorhombifoline in feed (n = 390) and
food (n = 1,075) were available in the EFSA Chemical Occurrence database.
2.2.2. Data validation and analysis
Chemical occurrence data were managed following the EFSA standard operating procedures (SOPs)
on ‘Data collection and validation’ and on ‘Data analysis of food consumption and occurrence data’ to
guarantee an appropriate quality of the data used in the exposure assessment. Special attention was
devoted to the identiﬁcation of duplicates and to different parameters such as ‘Sampling strategy’,
‘Sampling method’, ‘Sampling year’, ‘Sampling country’, ‘Analytical methods’, ‘Reporting unit’, ‘LOD/LOQ’,
and to the correctness of the food classiﬁcation codiﬁcation of the different samples under FoodEx2
classiﬁcation system (see Section 2.3.3). In the analysis of QA occurrence data, the left-censored data
(results below LOD or below LOQ) were treated by the substitution method detailed in the EFSA
scientiﬁc report ‘Management of left-censored data in dietary exposure assessment of chemical
substances’ (EFSA, 2010b) as an option in the treatment of left-censored data. The lower bound (LB) is
obtained by assigning a value of zero (minimum possible value) to all samples reported as lower than
the LOD or LOQ. The upper bound (UB) is obtained by assigning the numerical value of the LOD to
values reported as higher than the LOD and the LOQ to values reported as higher than the LOQ
(maximum possible value), depending on whether LOD or LOQ is reported by the laboratory.
In this Scientiﬁc Opinion, the ‘Total QA’ (TotQA) concentration was calculated by summing the
concentrations (expressed as mg/kg) of lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-
tigloyloxylupanine and a-isolupanine. For calculation of the UB TotQA, the LOD or LOQ was used for
each substance for which a left-censored result was reported.
2.3. Food and feed consumption data
2.3.1. Food consumption
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. Details
on how the Comprehensive Database is used are published in the Guidance of EFSA (2011). The food
consumption data gathered by EFSA in the Comprehensive Database are the most complete and
detailed data currently available in the EU. The latest version of the Comprehensive Database updated
in 2018 contains results from a total of 60 different dietary surveys carried out in 25 different Member
States covering 119,458 individuals. The age classes considered are the following:
• Infants: < 12 months old
• Toddlers: ≥ 12 months to < 36 months old
• Other children: ≥ 36 months to < 10 years old
• Adolescents: ≥ 10 years to < 18 years old
• Adults: ≥ 18 years to < 65 years old
• Elderly: ≥ 65 years to < 75 years old
• Very elderly: ≥ 75 years old.
Four additional surveys provided information on speciﬁc population groups: ‘Pregnant women’ (≥ 15
to ≤ 45 years old for Latvia; 17 to 46 years for Portugal) and ‘Lactating women’ (≥ 28 to ≤ 39 years for
18 On 3/1/2019.
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Greece; 18 years to 45 years for Estonia). When for one country and age class two different dietary
surveys were available, only the most recent one was used. Dietary surveys and the number of
subjects available for acute exposure assessment to QAs (43 surveys from 25 countries) are described
in Table A.1 of Annex A. Consumption data were collected using single or repeated 24-h or 48-h
dietary recalls or dietary records covering from 3 to 7 days per subject. Because of the differences in
the methods used for data collection, direct country-to-country comparisons can be misleading.
Detailed information on the different dietary surveys available in the Comprehensive Database can be
found on the dedicated page of the EFSA website (http://www.efsa.europa.eu/en/food-consumption/
comprehensive-database).
2.3.2. Feed consumption
Lupin seeds may be fed as the whole seed or ground, and incorporated with other feed materials in
manufactured compound feeds (as complete or complementary feedingstuffs). Lupin seeds and meal
are used predominantly in ruminant diets as a source of protein (typically 30–40% depending on the
variety of lupin). Their use in the diets of single-stomached animals has been limited mainly due to the
lower concentrations of certain essential amino acids when compared with other protein sources such
as soybean meal. For poultry, high inclusion rates tend to be restricted to avoid problems associated
with excess moisture in the excreta (resulting in ‘wet-sticky droppings’) due to the high levels of lupin
non-starch polysaccharides. SLs are used in aquaculture, where the seeds are usually dehulled to
improve digestibility.
Details of the assumed feed intakes and live weights for different farmed animals, horses and
companion animals have been obtained from a number of different sources, details of which are given
in Appendix G.
2.3.3. Food classiﬁcation
Consumption and occurrence data were classiﬁed according to the ‘Exposure hierarchy’ of the
FoodEx2 classiﬁcation system (EFSA, 2015). This is based on a food list of 2,673 entries, referred as
‘basic FoodEx2 code’, aggregated into food groups and broader food categories in a hierarchical
parent-child relationship (up to 7 levels). In addition, a catalogue of 28 ‘facets’ is available in order to
describe further characteristics of the foods, such as physical state (e.g. powder, liquid, etc.) or
processing technology (e.g. grinding, milling, crushing, etc.).
2.3.4. Feed classiﬁcation
Feed samples were as well classiﬁed according to the ‘Feed hierarchy’ of the FoodEx2 system
(EFSA, 2015). This is based on the catalogue of feed materials speciﬁed in the Commission Regulation
(EU) No 68/2013 and the feed classiﬁcation provided by Regulation (EU) No 575/2011 (and following
modiﬁcations).
2.4. Methodology for Exposure assessment
2.4.1. Human exposure assessment
The CONTAM Panel decided to assess acute exposure to TotQAs for consumers of lupins seeds or
lupin-based foods according to four scenarios that are detailed in Section 3.3.1. For this aim, food
consumption data from the EFSA Comprehensive Database were extracted for the following FoodEx2
categories: ‘Lupins seeds without pods’ and ‘Meat imitates’, as a proxy of the consumption of lupins
seeds or lupin-based foods. Average and high (P95) exposure was calculated for different countries
and population groups, when the number of consumption days was sufﬁcient to allow the calculations
of reliable statistics (details in Section 3.3.1). Acute exposure was assessed independently for each
food category, the daily consumption amount (standardised by the individual’s body weight) was
multiplied for the highest reliable percentile of the corresponding occurrence data. When the number
of samples was too small to allow the calculation of a percentile (below 11 observations), the average
occurrence level was used. Occurrence data were considered under the LB and UB approach, when
there was no difference only one approach was shown. All analyses were run using the SAS Statistical
Software (SAS enterprise guide 5.1).
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2.4.2. Animal exposure assessment
Ideally, animal exposure assessment would be based on levels of QAs in species-speciﬁc compound
or complementary feeds, together with their assumed levels of intake. However, no data on QA levels
in compound/complementary feeds were available, and therefore exposures have been estimated
based on levels of QAs in the seeds and recommended levels of inclusion in the diets of farm livestock,
details of which are given in Appendix G.
According to EFSA (2011), caution is needed when calculating acute exposure (95th percentile)
where data on less than 60 samples are available, since the results may not be statistically robust. Due
to the limited database, it has not been possible to estimate 95th percentile exposures.
2.5. Methodology for Risk characterisation
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO (2009), which include hazard identiﬁcation and characterisation, exposure
assessment and risk characterisation. In addition to the principles described by WHO (2009), EFSA
guidance pertaining to risk assessment has been applied for the present assessment. In brief, the
EFSA guidance covers the procedures currently used within EFSA for the assessment of dietary
exposure to different chemical substances and the uncertainties arising from such assessments. For
details on the speciﬁc EFSA guidance applied see Appendix F.
3. Assessment
3.1. Hazard identiﬁcation and characterisation
3.1.1. Toxicokinetics and metabolism
3.1.1.1. Laboratory animals and humans
Except for sparteine, there is little or no information on the toxicokinetics and metabolism of QAs
that may occur in feed and food. Sparteine, as sparteine sulfate, was used as a drug to treat cardiac
arrhythmias and induce uterine contractions in labour, and as a phenotypic marker of cytochrome P450
(CYP) 2D6 drug metabolism activity (Thies, 1986).
Sparteine19
Sparteine elimination was studied in rats following intra-arterial or portal venous administration of
sparteine sulfate (50 mg/kg bw equivalent to 27.7 mg/kg bw sparteine20) (Van der Graaff et al., 1986).
In rats with bile ﬁstula, no sparteine was recovered in the bile collected during 3 h, and about 25% of
the dose was present as a metabolite of sparteine, of which the identity could not be established.
Further studies in rats showed that sparteine was oxidised to lupanine as veriﬁed by the
chromatographic retention time and the mass spectrum similar to a standard (Chaudhuri and Keller,
1990). At a dose of 50 mg/kg bw sparteine intraperitoneally (i.p.), both lupanine and 2,3-
dehydrosparteine were observed in rat urine, whereas following sparteine in doses up to 16.8 mg/kg
bw only lupanine was detectable in urine. At the latter dose of sparteine, pretreatment of the rats with
the CYP inhibitor SKF 525A reduced the urinary lupanine substantially indicating a role of CYP in the
formation of lupanine. Pretreatment with disulﬁram, an inhibitor of aldehyde dehydrogenase, a
cytosolic enzyme, and CYP2E1 (Emery et al., 1999), also inhibited lupanine formation indicating that
conversion of sparteine to lupanine could take place via an intermediate, and likely was involving both
microsomal and cytosolic enzymes. The conversion of sparteine to lupanine did not occur in in vitro
studies using rat liver microsomes or 9,000g supernatant (S9).
In humans, orally administered sparteine sulfate (200 mg corresponding to 110.8 mg of sparteine
base, assuming that sparteine sulfate is used in the form of the pentahydrate) was rapidly absorbed
(about 70%) with a maximum concentration in plasma after about 45 min (Dengler et al., 1970).
Dengler and co-workers (1970) also used rats and found that sparteine rapidly distributed to most
19 In cases where the stereochemical conﬁguration of sparteine is not indicated in the text, it was not deﬁned in the underlying
reference. With regard to the antiarrhythmic drug Depasan®, the active ingredient was deﬁned as (-)-sparteine sulfate (Rote
Liste, 1983).
20 According to Milne (2018) and The Merck Index (2006), it is assumed that sparteine sulfate is used in the form of the
pentahydrate (MW: 422.54). A dose of 50 mg sparteine sulfate pentahydrate/kg bw would then correspond to a dose of 27.7
mg sparteine/kg bw (MW: 234.38).
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organs reaching much higher concentrations in comparison with plasma, particularly, in lungs,
adrenals, spleen and kidney. Elimination took place with a half-life in plasma of about 2 h in both rats
and humans. Following intravenous injection to humans (200 mg of sparteine sulfate) about 35% of
the dose was recovered unchanged in urine during 24 h.
In humans, sparteine is oxidised by CYP2D6 to two metabolites, 2,3-dehydrosparteine, being the
major metabolite, and 5,6-dehydrosparteine, a minor metabolite (Eichelbaum et al., 1986). Results
from extensive experiments are in agreement with the hypothesis that the oxidation at least at the
2,3-position proceeds by direct carbon oxidation and not via N1-oxidation as was ﬁrst suggested
(Eichelbaum et al., 1979a; Guengerich, 1984; Ebner et al., 1996). There are several polymorphisms in
CYP2D6 and two distinct phenotypes have been identiﬁed: PMs of sparteine (5–10% of Caucasians)
and extensive metabolisers (EMs). In addition, a subgroup of the latter have been identiﬁed as ultra-
rapid metabolisers of sparteine (about < 1–2% in the Scandinavian populations, but a larger fraction of
the Spanish (8%) and Ethiopian (29%) populations) (Bathum et al., 1998). The PMs phenotype has a
strong impact on the elimination of sparteine as in this group elimination takes place as unchanged
compound entirely via a low capacity renal excretion. In contrast, the elimination proceeds largely via
metabolites in EMs. The resulting plasma clearance in PMs decreased to one-third and the plasma half-
life increased from about 2.5 h in EMs to about 6.8 h in PMs (Eichelbaum et al., 1979b). As unchanged
sparteine and conversion to the two dehydrosparteine metabolites could only account for 60% of the
dose in urine (Eichelbaum et al., 1979a,b), suggestions have been made for the missing dose of
sparteine: formation of other metabolites, and further metabolism or degradation of the
dehydrosparteine metabolites. There are no reports that humans may convert sparteine into lupanine
even if this is a major metabolite in the rat. There is no information on whether conjugated
metabolites might be formed from sparteine and its metabolites.
Lupanine
Wittenburg and Nehring (1965) conducted two experiments with Wistar rats, which were given
lupanine as lupanine hydrochloride in the feed. In a ﬁrst experiment, 3.4 mg lupanine/g feed (dry
weight (dw)) was given as a single portion of feed (23.2–33.1 mg/rat; bw not speciﬁed). About 60%
of the consumed dose was excreted in urine during day one. In a second experiment lasting for 29
days, rats were administered lupanine in feed in increasing concentrations (4 days 1, 4 days 3, 4 days
6 and 4 days 9 mg/g feed (dw). In both experiments, between 70 and 80% of the amount of lupanine
consumed was excreted, 50–70% in urine and 10–14% in faeces. About half of the total amount was
excreted unchanged and the rest as OH-lupanine21 (30–40% of the lupanine intake). No accumulation
of lupanine in the rats took place.
The disposition of lupanine and 13a-OH-lupanine were investigated in two groups of humans,
namely CYP2D6 PM (N = 4) and EMs (N = 7) (Petterson et al., 1994). The compounds (10 mg) were
given in gelatine capsules followed by 700 mL of water to fasting participants. The design was a
randomised cross-over test with a 2 weeks wash-out period between the two compounds. The
ingested QAs were rapidly excreted into urine with total recoveries at 72 h ranging from 89% to
103%, and it did not differ between PM and EM groups. The half-lives in urine were on average about
6 h, ranging from 3 to 11 h for both compounds and both groups. Lupanine was excreted as
unchanged compound, with traces of 13-OH-lupanine. Most subjects exposed to 13a-OH-lupanine
excreted the unchanged compound, whereas two subjects excreted 14% and 34% as lupanine.
Because no difference between CYP2D6 PM and EM individuals was observed, the CONTAM
Panel concluded that, unlike in the case of sparteine, there is no clear indication for an involvement of
CYP2D6 in the metabolism of lupanine or 13a-OH-lupanine.
There is no information on whether conjugated metabolites might be formed from lupanine and its
metabolites.
3.1.1.2. Farm animals, horses and companion animals
There is little information in farm animals, horses and companion animals on the absorption,
distribution, metabolism, and excretion (ADME) of the QAs considered in 1`this Scientiﬁc Opinion. Most
studies deal with wild lupins from non-European countries (i.e. L. caudatus, L. leucophyllus and
L. argenteus) containing teratogenic alkaloids (e.g. anagyrine) which are of no interest for the current
21 The carbon atom at which the hydroxylation took place is unspeciﬁed in the paper. However, the CONTAM Panel assumed that
this is the 13-OH-lupanine.
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opinion. Such studies will be taken into consideration in the following section only in the case they
provide information on the fate of QAs considered in this Scientiﬁc Opinion.
Cattle
In an in vitro study aimed at investigating the impact of rumen microbiota on L. luteus alkaloids,
Aguiar et al. (1998) incubated lupanine or sparteine, both at 1 mM concentrations, with cattle ruminal
liquor. No signiﬁcant metabolic degradation of either alkaloid was observed up to 36 h incubation.
Blood plasma levels of alkaloids from L. caudatus were studied in single dosed cattle, sheep, and
goats of unspeciﬁed breed and age (Gardner and Panter, 1993). Aerial plant parts were dried and
ground and QAs were measured with a GC-FID method. The plant material had a total alkaloid
concentration of 19,200 mg/kg, and consisted of 8% lupanine, 22% 5,6-dehydrolupanine, 22%
anagyrine and three unidentiﬁed alkaloids. Blood samples were collected up to 56 h post-dosing. As
regards cattle, cows (N = 2) received 3 g dried plant material/kg bw. Although the alkaloids could be
detected in plasma as soon as 15 min after dosing, lupanine as well as 5,6-dehydrolupanine appeared
to be characterised, contrary to humans and experimental animals, by a slow absorption and a
protracted elimination; indeed both compounds peaked approximately 8 h after treatment and the
levels remained ‘moderately high up to 28 h post-dosage’.
The plasma disposition of lupin alkaloids was examined in cows (unspeciﬁed age and breed) with
(group A, N = 6) or without (group B, N = 6) a history of delivery of calves affected by lupin-induced
arthrogryposis (Gay et al., 2004). Dried and ground L. leucophyllus (aerial plant parts) was used with
a measured (GC-FID) total alkaloid concentration (on a dried plant basis) of 16,700  1,700 mg/kg.
The composition consisted of six alkaloids, of which two remained unidentiﬁed, 5,6-dehydrolupanine
(3,900  400 mg/kg), lupanine (1,000  100 mg/kg), 11,12-seco-12,13-didehydromultiﬂorine22 (2,500
 200 mg/kg) and anagyrine (3,300  300 mg/kg). Animals receiving a single dose of 2 g plant
material per kg bw by gavage, were subjected to blood sampling up to 48 h post-dosing and the main
toxicokinetic (TK) parameters were measured for the alkaloids mentioned above, except for 11,12-
seco-12,13-didehydromultiﬂorine that was present only at very low concentrations. No differences
between the two groups were observed and similar TK values were found for 5,6-dehydrolupanine and
lupanine. The data point to a slow absorption, with the time to reach the maximum plasma
concentration (Tmax) ranging between 10 and 24 h, and a rather long persistence as indicated by a
calculated mean residence time (MRT) in the range 29–149 h.
In a more recent study aimed at identifying reliable biomarkers of exposure to teratogenic lupins
(Green et al., 2015a), Holstein steers (N = 4, 289  13 kg bw) were orally dosed once with dried
ground L. leucophyllus (aerial plant parts). The material was analysed by GC–MS and had a total
alkaloid concentration of 18,660  1,130 mg/kg. Four alkaloids were present: lupanine (6.90 
0.40 mg/kg), 5,6-dehydrolupanine (3.94  0.16 mg/kg), anagyrine (5.14  0.39 mg/kg) and an
unidentiﬁed alkaloid (based on the molecular weight (248 g/mol) it can be assumed to be a QA). The
calculated dosages were 17.2, 9.9, 12.9, and 6.7 mg/kg bw, respectively. Blood samples were taken up
to 96 h after dosing. Lupanine was slowly but extensively absorbed reaching the highest maximum
plasma concentration (Cmax) (5,056  1,094 ng/mL) and the slowest Tmax (15.5  7 h) among the
four examined compounds, also showing a relatively long elimination half-life (7  0.5 h). By contrast,
5,6-dehydrolupanine seemed to be absorbed to a much lower extent (632  141 ng/mL) but in a
more rapid manner (Tmax 3.5  0.5 h), but being also slowly excreted (6.7  0.5 h).
A study was designed to disclose breed-related differences in lupin-mediated inhibition of fetal
activity (expressed as number of movements/5 min) (Green et al., 2015b). To test the possible
inﬂuence of lupin alkaloid disposition on the mentioned endpoint, the main TK parameters of lupanine,
5,6-dehydrolupanine and anagyrine were determined in cows. To this end, Angus (N = 6, 382  39 kg
bw) or Holstein (N = 5, 435  46 kg bw) pregnant heifers at gestation day 49–51 were dosed once
with 1.1 kg dried and ground L. leucophyllus (aerial plant parts) per kg bw. The plant material had the
same alkaloid concentration as described above (Green et al., 2015a); blood sampling was carried out
up to 72 h. While similar kinetic parameters were recorded for 5,6-dehydrolupanine, clear breed-
related differences were observed for lupanine. Tmax was higher in Holstein (12 h) than in Angus cows
(8 h). In addition, at 8, 12 and 24 h, Holstein heifers had up to about 50% higher serum lupanine
concentrations than their Angus counterparts. By contrast, as reﬂected by a longer elimination half-life
(11.4  1.4 h vs. 5.6  0.5 h) lupanine tended to persist for a longer time in Angus than in Holstein
heifers.
22 Reported by the authors as methylalbine.
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Sheep
The in vitro ruminal degradation of pure sparteine (up to 5.4 mM) or of sparteine extracted from
‘sweet’ or ‘bitter’ lupins was investigated (Lanca et al., 1994). In either case no signiﬁcant metabolic
degradation of sparteine was detected up to 24 h incubation.
In the study by Gardner and Panter (1993) cited above, sheep (N = 2) were administered with a
single oral dose of a L. caudatus dried aerial plant parts (7.8 g/kg bw) (see above for further details).
In blood, lupanine and 5,6-dehydrolupanine peaked at about 8 and 24 h, respectively; after treatment
showing sustained high values of total alkaloids (range 2–3.5 lg/mL); blood levels of lupanine were
about half of those of 5,6-dehydrolupanine. The concentrations of both alkaloids decreased slowly and
both compounds could still be detected 56 h post-dosing.
In a further study (Lopez-Ortiz et al., 2004), ground silvery lupin (L. argenteus) (aerial plant parts)
was analysed for its alkaloid concentration by GC-FID. It contained a total alkaloid content of
16,400 mg/kg. Besides three unidentiﬁed alkaloids, lupanine (8.2%), 5,6-dehydrolupanine (11.5%)
and anagyrine (28.8%) were the main components. Ten Columbia ewes (age not reported) were
administered with a single oral dose of ground plant (8.5 g/kg bw corresponding to 139 mg total
alkaloids/kg bw) and blood samples were taken up to 60 h. Measurable amounts of alkaloids were
already present in serum after 0.5 h and could be detected up to 48 h post administration. Peak levels
were reached within three hours. Longer absorption- and elimination half-life values were recorded for
5,6-dehydrolupanine (1.67  0.20 h and 7.88  0.78, respectively) compared to lupanine
(0.76  0.20 h and 4.47  0.55, respectively). Interestingly, longer elimination half-life values for
lupanine were observed in sheep intentionally fed with a nutrient deprived diet resulting in a low body
condition and treated as reported above.
Goats
The above cited paper of Gardner and Panter (1993) was the only report involving goats that could
be identiﬁed. In that study, the toxicokinetics of QAs was compared to that of cows and sheep. Goats
(N = 2) were treated with a single oral dosage of L. caudatus dried aerial plant parts (7.8 g/kg bw)
(see above for further details). Plasma levels of lupanine and 5,6-dehydrolupanine peaked at around
3 h and declined slowly, being still detectable after about 30 h. While peak levels of either compound
were comparable to those of cows, their concentrations were about half those displayed by sheep.
Pigs
In the study by Wasilewko et al. (1997), ﬁve barrows (i.e. male castrated pigs) of unspeciﬁed breed
and an initial weight of 15 kg were equipped with a post-valvular T-shape caecum cannula and fed a
standard diet free of QAs for 7 days. Pigs were subsequently exposed to a standard diet fortiﬁed with
increasing lupanine concentrations (100, 150, and 200 mg/kg diet, each on three consecutive days) for
9 days. Samples of digesta (caecum content) and urine were collected (collection period not reported),
pooled and analysed for alkaloid concentration using capillary GC and GC–MS (sensitivity not reported).
No intact lupanine was found in the caecal content, suggesting an extensive absorption of the alkaloid;
urine was found to contain mostly the parent compound along with the metabolites isolupanine and
OH-lupanine (unspeciﬁed).23 No lupanine was detected in urine collected after 8 days on an alkaloid-
free diet.
Rabbits
Liver microsomes were incubated with sparteine concentrations in the range 5 lM to 4 mM; the
parent compound and its metabolites were determined by GC-FID. Only a single metabolite, 2,3-
dehydrosparteine, was formed, the reaction showing a Michaelis constant (Km) of 36  2 lM and a
maximum velocity (Vmax) of 70  10 nmol/mg protein/30 min. The rate of metabolite formation was
unaltered when microsomes from phenobarbital (PB)- or TCDD-induced rabbits were used and no
metabolism occurred in the presence of puriﬁed ﬂavin monooxygenase (FMO) (Ohnhaus et al., 1985).
Taken together, results indicate that in the rabbit the formation of 2,3-dehydrosparteine involves a non
PB- or TCDD-inducible CYP (possibly CYP2D). No further reports on QA toxicokinetics in rabbits could
be retrieved.
23 Quantitative data not shown in the paper.
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Poultry, ﬁsh, horses, cats and dogs
No adequate data on the toxicokinetics of QA could be retrieved for poultry, ﬁsh, horses, cats, and
dogs.
3.1.1.3. Transfer
In general, due to their weak basic nature, plant alkaloids, including QAs, are expected to be
excreted in dairy milk. Although indirect evidence has been provided of the excretion of teratogenic
QAs both in cow (Panter and James, 1990) and goat milk (reviewed in Molyneux and Panter, 2009), no
information could be retrieved about the mammary excretion of lupanine, 5,6-dehydrolupanine or
other non-teratogenic QAs. It is not known whether feeding of lactating farm animals with lupins from
L. albus or L. angustifolius results in occurrence of lupin alkaloids or their metabolites in cow’s, sheep’s
or goat’s milk.
In the study by Vogt et al. (1987; see Section 3.1.4), there was no measurable transfer of alkaloids
into meat or eggs of laying hens fed for 168 days a diet containing 16% of three different debittered
lupin grists, namely L. albus24 P., L. albus24 G. or L. mutabilis, with a QA concentration ranging from
8 to 60 mg total alkaloids/kg grists, corresponding to 1.1–9.6 mg total alkaloids/kg diet. However, the
Panel noted that the animal QA exposure via feed in this study is low and does not allow to assess
possible transfer rates.
3.1.1.4. Main biotransformation pathways of quinolizidine alkaloids
Figure 4 summarises information on the biotransformation of sparteine and lupanine (mainly
oxidative) in humans, pigs, rats and rabbits. There is no information on whether conjugated
metabolites might be formed from sparteine and lupanine and their metabolites. For other QAs, a
general picture of their biotransformation is lacking.
3.1.1.5. Summary remarks on toxicokinetics
Humans and experimental animals
There is scant information on QA toxicokinetics in rats and humans except for sparteine and
lupanine. In humans and rats, sparteine and lupanine are rapidly absorbed, widely distributed and
rapidly eliminated in urine mainly unchanged and as oxidised metabolites. Sparteine undergoes a
CYP2D-mediated oxidation to 2,3-dehydrosparteine in rats, which are also able to oxidise sparteine
into lupanine. In humans, the CYP2D6-mediated production of both 2,3-dehydrosparteine (major) and
Figure 4: Biotransformation of sparteine and lupanine in human, rat, pig and rabbit
24 Referred to as L. alba by the authors.
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5,6-dehydrosparteine (minor) is reported. About 5–10% of Caucasians are PMs, as they are defective
in CYP2D6 activity due to genetic polymorphisms, and these individuals eliminate sparteine more
slowly. Lupanine is partly biotransformed to a hydroxyl derivative, presumably 13-OH-lupanine in rats
through an unknown pathway. Lupanine is mainly excreted unchanged in humans with some formation
of 13-OH-lupanine with no apparent involvement of CYP2D6. The de-hydroxylation of 13-OH-lupanine
to lupanine is reported to occur in some individuals. There is no evidence of the formation of
conjugated metabolites of sparteine, lupanine or their metabolites in rats and humans.
Farm animals, horses and companion animals
Little is known on QA ADME in farm animals, horses and companion animals; most of the published
studies are concerned with teratogenic lupins also containing lupanine and 5,6-dehydrolupanine and
just one in vivo study has been performed with the pure compounds (i.e. lupanine in pigs). Very
limited information is available for other QAs, including sparteine.
No metabolic degradation of sparteine was found to occur upon the incubation with bovine and ovine
ruminal ﬂuid. By contrast, sparteine undergoes a CYP-mediated oxidation to 2,3-dehydrosparteine in
rabbit liver microsomes.
As regards ruminants, in the majority of the reported studies blood levels recorded in cattle after a
single exposure to different lupin species indicate, contrary to humans and experimental animals, a
slow but extensive absorption and a slow elimination of lupanine and 5,6-dehydrolupanine, with
possible breed-related differences. Under similar exposure conditions, a comparable kinetic behaviour
was observed for both alkaloids in sheep and goats, the former exhibiting comparably higher and more
sustained levels than cows and goats. In pigs, lupanine seems to be extensively absorbed and
excreted in urine mainly unmodiﬁed together with the metabolites isolupanine and OH-lupanine. There
is no evidence of the formation of conjugated QA metabolites in ruminants, pigs and rabbits.
No adequate data on the toxicokinetics of QAs for poultry, ﬁsh, horses, cats and dogs were
identiﬁed.
Possible transfer to milk should be considered and no information is available to assess possible
transfer rates of QAs in food of animal origin.
3.1.2. Toxicity in experimental animals
For studies reporting only concentrations of the toxin in the feed, doses have been calculated to
mg or lg/kg bw per day following the respective EFSA guidance (EFSA FEEDAP Panel, 2012).
3.1.2.1. Acute toxicity
An overview of the acute toxicity studies with QAs is presented in Appendix H.1.
D-lupanine, isolated from L. angustifolius seeds and puriﬁed by recrystallisation (identiﬁcation by
refractive index; ﬁnal purity not reported), was injected i.p. in mice, rats and guinea pigs at
concentrations of 15 and 100 mg/mL. Minimal lethal dose (MLD) values were 75–85, 180–192 and
210–225 mg/kg bw in mice, rats and guinea pigs, respectively. The dose killing 50% of the animals
(LD50) for mice was 80 mg/kg bw. Fatally dosed animals suffered from paralysis, with intermittent
convulsive movements, then complete exhaustion. Necropsy revealed that death resulted from
asphyxiation (no apparent liver damage or other pathological lesions were noticed) and all animals
seemed to die from respiratory failure (Gordon and Henderson, 1951).
Lupanine isolated from L. albus seeds and puriﬁed by column chromatography and recrystallisation
(identiﬁcation by 2D-TLC and IR; ﬁnal purity not reported) and commercial sparteine were
administered orally or i.p. to male Swiss mice. Oral LD50s were 410 and 220 mg/kg bw for lupanine
and sparteine, respectively, while i.p. administration led to LD50s of 175 and 36 mg/kg bw,
respectively. Identical symptoms (trembling, tonic-clonic seizures) were observed for both alkaloids and
death was caused by breathing arrest. The lower toxicity of lupanine vs sparteine was conﬁrmed in
guinea pigs (intravenous (i.v.) administration), in which a MLD of 78 and 27 mg/kg bw was identiﬁed
for lupanine and sparteine, respectively. In view of the similarity of the pharmacological properties of
sparteine and lupanine, the authors conclude that the lower toxicity of lupanine is probably due to
differences in bioavailability and/or pharmacokinetics (Yovo et al., 1984).
Oral LD50 of alkaloid extracts from L. angustifolius (cv. Fest) seeds (alkaloid proﬁle: 49% lupanine,
39% 13a-OH-lupanine, 10% angustifoline, 0.7% a-isolupanine) was 2,279 mg/kg bw for fed rats and
2,401 mg/kg bw for rats fasted for 16–18 h before dosing. Lupanine and 13a-OH-lupanine were
further puriﬁed from the alkaloid extracts by recrystallisation and column chromatography (purity by
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GC: > 99.5%). For lupanine, the LD50 by oral administration to fasted male Wistar rats was 1,664 mg/kg
bw. Administration of lupanine and 13a-OH-lupanine i.p. to rats identiﬁed LD50s of 177 mg/kg and
199 mg/kg, respectively. After administration of a lethal oral dose of alkaloids, rats displayed nervous
signs within 2–16 min and died within 2–23 min. Signs included tremor, followed by convulsions, cyanosis,
collapse and death irrespective of the route of administration. Post-mortem analyses identiﬁed congestion
of the liver and lungs in some animals. Surviving rats from all treatments showed no signs of clinical
toxicity (Petterson et al., 1987).
Stobiecki et al. (1993) extracted seeds of L. angustifolius and L. albus and these extracts
(containing 10% alkaloids in the dry extract) were administered by gavage to male and female mice
(inbred strain 129/AoBoy/Iiw, unspeciﬁed number of animals). No deaths were recorded and an LD50
of > 4,000 mg lupin extract/kg bw (corresponding to > 400 mg alkaloids/kg bw) was established. The
CONTAM Panel noted that it is not clear from the study how alkaloids were measured in these
extracts.
A comparative study was conducted of the effects of extracts from L. mutabilis Sweet seeds
(alkaloid proﬁle: 20% sparteine, 59% lupanine and 21% 13a-OH-lupanine), lupanine isolated from
L. mutabilis seeds and puriﬁed by column chromatography (purity checked by TLC and GC–MS) and
sparteine sulfate pentahydrate. Five doses (50, 100, 125, 250 or 500 mg/kg) were i.p. injected in male
Swiss mice and acute toxicity and maximum non-lethal dose (LD0) were determined 8 days later
(Pothier et al., 1998). LD0s for i.p. administration were 25 mg/kg for sparteine and 64 mg/kg for
lupanine and lupin extracts. Lethal i.p. doses (LD100) were 100 mg/kg for sparteine and 250 mg/kg for
lupanine and lupin extracts. The clinical signs of poisoning (shaking, excitation and convulsions) were
the same for the three compounds.
Summary remarks on acute toxicity
Mice appear to be more sensitive than rats to acute toxicity (by i.p. and oral administration) of
lupanine. A comparison of the acute toxicity of lupanine and 13a-OH-lupanine in rats (by i.p.
administration) showed similar LD50 values. In contrast, when comparing results from the same route
of administration, several reports on mice and guinea pigs indicate that sparteine is approximately
two- to three-fold more acutely toxic than lupanine, regardless of the way the acute toxicity is
expressed. Finally, acute symptoms following oral administration of these QAs are similar in rats, mice
and guinea pigs, with death resulting from respiratory failure and toxic effects affecting the central
nervous system (CNS).
3.1.2.2. Repeated dose toxicity studies
The CONTAM Panel identiﬁed ﬁve repeated dose toxicity studies in which rats received a lupin-
based diet. No studies in other experimental animals were identiﬁed. These studies are described
below in detail and are summarised in Appendix H.2. No repeated dose toxicity studies on individual
QAs were found. In addition to the papers described below, several other papers were identiﬁed which
were considered of low relevance for the risk assessment due to a lack of information on the alkaloid
concentration in the feed, poor reporting or unsuitable experimental design which focused on studying
nutritional beneﬁts of lupin seeds or mechanistic insights in experimental models of human disease. A
description of these studies is provided in Appendix H.3.
In a 112-day feeding study, three groups of Charles River rats (21–23 day old) were given a diet
containing casein (control group), ground seeds (58%) of L. albus (510 mg lupin alkaloids/kg,
equivalent to 45 mg/kg bw per day) and ground seeds (51%) of L. luteus (910 mg lupin alkaloids/kg,
equivalent to 81 mg/kg bw per day, no speciﬁcation of QAs; total lupin alkaloid content measured by
titration) (Ballester et al., 1980). Food and water were available ad libitum and dietary intake and body
weights were recorded weekly. Animals fed either lupin seeds at 10% protein diets without DL-
methionine performed poorly (low growth and protein efﬁciency ratio). In contrast when 20% protein
diets supplemented with 0.3% DL-methionine were compared L. luteus-fed animals gained weight at
rates similar to those fed with casein and a slight, but not statistically signiﬁcant decrease was
observed for L. albus-fed animals. At the end of the 112-day feeding period, no differences among the
three groups were found in organ-to-body weight ratios of liver, kidneys, spleen, heart and adrenals.
Histopathological examinations of liver, kidneys and lungs did not reveal any signiﬁcant differences
with the control group. The CONTAM Panel noted that no effects were observed at the only tested
dose levels of 45 and 81 mg lupin alkaloids/kg bw per day, for L. albus and L. luteus, respectively.
A diet based on ﬂour (33.6%) prepared from water-debittered grains of L. mutabilis and containing
trace amounts of lupin alkaloids (160 mg/kg, equivalent to 14.4 mg/kg bw per day as determined by
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GC-NPD, no speciﬁcation of QAs) was tested in Sprague–Dawley rats (21 days old) for 12 weeks
(Schoeneberger et al., 1987). The protein content was 15% and the diet was supplemented with 0.2%
DL-methionine. The control group was fed a 15% protein casein diet. Rats fed on lupin diet did not
show any statistically different growth performances (body weight, food consumption) in comparison
to the control group. No consistent indications of signiﬁcant physiological differences (haematological
and biochemical parameters) were recorded. Similarly, absolute and relative weights and
histopathological examinations of some organs (liver, kidney, heart, spleen and brain) were unaffected
by the alkaloids. The CONTAM Panel noted that no effects were observed at the only tested dose level
of 14.4 mg lupin alkaloids/kg bw per day for L. mutabilis.
Diets based on L. angustifolius (cv. Fest) ﬂour (554 g/kg diet) which had been spiked with extracts
from L. angustifolius seeds to provide dietary concentrations of 250, 1,050 and 5,050 mg lupin
alkaloids/kg diet (equivalent to 25, 105 and 505 mg/kg bw per day) was fed to three groups of
Sprague–Dawley rats (3 weeks old) for 90–98 days (Butler et al., 1996). No control group was
included but a reference group receiving the same lupin ﬂour-based diet containing background levels
of alkaloids (50 mg lupin alkaloid/kg diet, corresponding to 4.5 mg/kg bw per day) derived from the
background level of alkaloids in lupin ﬂour. The alkaloid proﬁle of the ﬂour was lupanine (44.2–44.6%),
13a-OH-lupanine (41.9–42.4%), angustifoline (9.9–10.9%) and a-isolupanine (1.0%) (analytical
method not reported). The diets were supplemented with 0.6% methionine. No mortality was
recorded during the study. A slight transient reduction in body weight was recorded in the male group
treated with 250 mg/kg diet. Food intakes were generally equivalent to those of the reference group.
Haematological investigations gave little evidence of consistent effects (changes were small, often of
transient nature and characterised by lack of dose response). Clinical chemistry measurements
revealed no differences between lupin-fed rats and the reference group. Relative liver weights were
increased in female rats at all doses (4% increase and no dose response). Altered foci of liver
parenchymal cells were seen in 1/20 females and 1/20 males in the lowest dose group, 1/20 males in
the mid-dose group, 5/20 females in the highest dose group and none in the reference group. Cells
comprising these foci were basophilic or large pale-staining cells, characterised by nuclei with
prominent nucleoli and occasional mitotic ﬁgures (usually called altered hepatic foci). However, the
Panel noted that these effects were not observed in a follow-up study described below.
Diets mixed with extracts from L. angustifolius (cv. Fest) containing lupin alkaloids at dose levels of
0, 100, 330, 1,000 or 5,000 mg/kg (equivalent to 0, 10, 33, 100 and 500 mg/kg bw per day) were fed
to groups of Sprague–Dawley rats (4 weeks old) for 90 days (Robbins et al., 1996). The alkaloid proﬁle
consisted of lupanine (49.5–50.7%), 13a-OH-lupanine (38.4–39.2%), angustifoline (8.8–10.7%) and a-
isolupanine (1.3–1.4%) (analytical method not reported). The diets were supplemented with 0.3%
methionine. The control basal diets were commercial preparations with and without 4.5%
maltodextrin. A statistically signiﬁcant decrease in body weights was observed in both male and female
rats fed a diet containing 500 mg/kg bw per day lupin alkaloids in comparison to the control diet
groups. The body weights of both male and female rats fed 100 mg/kg bw per day were also lower,
although the difference was statically signiﬁcant only on a few time points. Feed intakes of both sexes
given 100 or 500 mg/kg bw per day were consistently lower than the control groups. Some changes
(with no dose response) were observed in haematological parameters and in clinical chemistry
ﬁndings. The authors noted that these fell within the normal range according to age and sex of the
animals. Relative liver weights at 500 mg/kg bw per day in both males and females were signiﬁcantly
higher (8–9%) than in control groups. Kidney weights showed some inconsistent and dose-unrelated
differences between sexes. The histopathological examination of liver, heart and bone marrow was
unremarkable and none of the altered foci of liver cells reported by Butler et al. (1996) were
reproduced in this study. The CONTAM Panel noted that the reduced body weight gain already
recorded at 100 mg/kg bw per day might be due to reduced palatability and feed intake. Based on the
increased relative liver weight observed at 500 mg lupin alkaloids/kg bw per day, the CONTAM
Panel identiﬁed 100 mg lupin alkaloids/kg bw per day as a dose of lupin alkaloids present in the
studied L. angustifolius cultivar that is not associated with effects is rats.
Diets containing seeds of L. angustifolius were administered to male Wistar rats (3 weeks old, 81 g
initial body weight, 8 animals/group) for 28 days. Diet materials were prepared from three
L. angustifolius cultivars (25.8–27.1%), i.e. Baron, Zeus and Wersal, with different lupin alkaloid
concentrations (360, 410 and 560 mg/kg, respectively) (Stanek et al., 2015). The composition of
QAs (measured by GC–MS) was lupanine (62.4–70.2%), 13a-OH-lupanine (9.5–14.4%), angustifoline
(8.7–10.6%), a-isolupanine (6.6-8.1%), tetrahydrorhombifoline (2.5–4.1%) and isoangustifoline
(1.0–1.9%). The composition of the experimental diet was 10% protein and an alkaloid concentration
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of 90, 110 and 150 mg/kg feed (equivalent to 8.1, 9.9 and 13.5 mg/kg bw per day for Baron, Zeus
and Wersal feed), respectively. The CONTAM Panel noted that previous experiments with 10% protein
without DL-methionine supplementation showed that animals performed poorly (see Ballester et al.,
1980). The control group received soybean meal. Diets containing the seeds of all L. angustifolius
cultivars reduced the feed intake by 50% and the growth rate of experimental rats in comparison to
the control group. Baron-, Zeus- and Wersal-based diets increased serum triacylglycerol (TG) levels,
while decreased alanine transaminase (ALT) activity was observed only in Zeus- and Wersal-based
ones. The liver weight of rats fed diets with L. angustifolius seeds decreased with increasing dietary
alkaloid concentrations. Liver histopathology revealed parenchymatous degeneration of hepatocytes
(more pronounced in rats fed Zeus and Wersal diets), and congestion of portal vessels and central
veins (more severe in rats fed Baron and Zeus diets). The CONTAM Panel disregarded this study
because of the nutritional imbalance and the large effects on feed intake and growth rate induced by
relatively low levels of alkaloids from L. angustifolius.
Summary remarks on repeated dose toxicity studies
All the repeated dose studies with laboratory animals on QAs were carried out in rats. The CONTAM
Panel identiﬁed two key 90- to 98-day studies performed in the same laboratory using L. angustifolius-
based ﬂour. The major QAs of the diet were lupanine and 13a-OH-lupanine (about 40% each). Both
studies reported an increase in relative liver weights. However, the induction of altered liver foci
observed in the ﬁrst study was not conﬁrmed in the second one. Conﬂicting results were also obtained
in the two studies on weight gains. Based on increased relative liver weight a NOEL of 100 mg
alkaloids/kg bw per day was proposed in the second study.
No signiﬁcant toxicological effects were reported in sub-chronic studies on L. albus-, L. luteus-and
L. mutabilis-based diets at doses of 45, 81 and 14.4 mg alkaloids/kg bw per day, respectively, which
were the only doses tested. It should be noted that lupanine is the major alkaloid contained in L. albus
and L. angustifolius, while the more toxic sparteine is a major alkaloid present in L. luteus and
L. mutabilis (see Table 1).
The PANEL noted that the only available studies on QAs repeated dose toxicity are in rats, the less
sensitive species among experimental animals (see acute toxicity section). In addition, it is difﬁcult to
compare these studies because of differences in the sources of QAs (seed extracts vs ﬂour), cultivars,
presence of alkaloids other than QAs relevant for this opinion, and the control diets (commercial, lupin-
based) used for comparison. Because of these reasons and some conﬂicting results reported in
different publications from the same laboratory, the CONTAM Panel considered that these studies have
a limited value for the evaluation of QA toxicity.
3.1.2.3. Neurotoxicity
In an acute toxicity study in mice by Pothier et al. (1998), the effects of i.p. administration of
lupanine and sparteine (64 and 25 mg/kg, respectively, representing the maximum non-lethal i.p.
doses) on behaviour (i.e. psychomotor activity and exploration test), were investigated. Both alkaloids
elicited a weak decrease in spontaneous activity and reduced locomotor activity indicating a slight
sedative action on the CNS. Also, the interaction with drugs acting on the CNS and analgesic effects
were studied. No effects were seen on the interactions with drugs such as stimulating (amphetamine,
pentetrazol) or depressant (pentobarbital, chlorpromazine) drugs. Similarly, these alkaloids did not
show any analgesic activity (on abdominal constrictions induced by acetic acid).
The effects of the intracerebroventricular (ICV) administration of QAs extracted from L. exaltatus
and L. montanus seeds were studied in adult Swiss-Wistar rats (10 animals/group) receiving a daily
ICV injection (10 lL) of sesame oil (control group) or QA extract on ﬁve consecutive days (Banuelos
Pineda et al., 2005). Principal QAs present in L. montanus extracts were sparteine (35,000 mg/kg),
lupanine (17,700 mg/kg), 3b-OH-lupanine (3,800 mg/kg) and 13a-OH-lupanine (3,200 mg/kg).
Extracts from L. exaltatus contained lupanine (5,800 mg/kg), 3b-OH-lupanine (1,500 mg/kg) and only
a small amount of sparteine (284 mg/kg). Clinical symptoms immediately after QA administration
included tachycardia, tachypnoea, piloerection, tail erection, muscular contractions, loss of equilibrium,
excitation, and unsteady walk. The contralateral unlesioned left hemisphere of the brain was analysed
at the end of the treatment. A high number of neurons with degenerative alterations (30–40% vs
~ 10% in the control group) were observed in the brains of QA–treated animals, thalamus,
hypothalamus, and hippocampus being the most susceptible brain areas. These structures contain
cholinergic neurons, structures related to cholinergic paths and structures of the basal ganglion that
possess cholinergic receptors (muscarinic or nicotinic type). These neurotoxic ﬁndings support the
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mode of action of QAs in the CNS proposed by Kinghorn and Balandrin (1984) and Schmeller et al.
(1994). The authors conclude that neuronal damage induced by QAs from L. montanus was more
severe than that of L. exaltatus (no quantiﬁcation reported) in all the examined areas. These results
are in agreement with the high content of sparteine present in QA extracts from L. montanus.
Following sparteine administration either ICV or i.p. in Wistar rats (8 animals/group) for 5 days,
Meraz Medina et al. (2017) found that brain structures of the CNS showing toxic effects were those
mainly related to cholinergic pathways (frontal, frontoparietal and striate cortex, olfactory and
amygdaloid area, ventromedial hypothalamic nucleus, cerebellar Purkinje cells and the Cornus
Ammonis area 1 and 3 dentate gyrus regions of the hippocampus).
Sparteine-induced brain damage was investigated in neonatal Wistar rats (8 animals/group)
receiving a single dose of 25 mg/kg bw by subcutaneous injections at postnatal day 1 and 3.
Sparteine-induced damage to neurons in the cerebral motor cortex (analysed at 7, 14, 21 and 60 days)
was visible at 7 days and persisted up to 21 days. Neuronal death was due to necrosis and was
signiﬁcantly reduced by pretreatment with atropine suggesting that cytotoxicity of sparteine is
mediated by muscarinic acetylcholine receptors (mAChRs). Transient decreases in the expression of
m1–m4 subunits mAChR both at RNA and protein levels were indeed demonstrated (Flores-Soto et al.,
2006).
Yovo et al. (1984) investigated comparatively the toxicodynamics of sparteine and lupanine. Cats
(n = 4) and dogs (n = 4) were injected i.v. with sparteine (cats: 0.5, 1.0, 1.5, 2.0 and 4.0 mg/kg bw;
dogs: 5.0 and 7.5 mg/kg bw) and lupanine (cats: 1.0, 2.0, 3.0, 4.0 and 5.0 mg/kg bw; dogs: 5.0 and
7.5 mg/kg bw). Sparteine is more efﬁcient than lupanine in antagonising secondary reﬂex hypertension
caused by carotid occlusion and hypotension induced by electrical stimulation of pneumogastric nerve
both in the cat and in the dog. Lupanine and sparteine show identical inhibitory action on nicotinic
type hypertension induced by injection of acetylcholine (ACh) in atropine-treated dogs.
The CONTAM Panel noted that the method of application in the above described studies (in
particular ICV administration) might be of limited relevance for assessment of the toxicity of QAs via
the diet. However, they give an indication of the neurotoxic effects that QAs may cause and the
related mode of action.
3.1.2.4. Genotoxicity
No binding or intercalation with DNA (as measured by DNA methylgreen release from DNA and
inhibition of DNA polymerase I) was identiﬁed for several QAs (anagyrine, angustifoline, cytisine, 3b-
OH-lupanine, 13a-OH-lupanine, lupanine, lupinine, 17-oxosparteine, sparteine, 13a-tigloyloxylupanine)
(Wink et al., 1998).
At variance with alkaloids belonging to other chemical classes (e.g. indole and quinoline alkaloids)
which bind/intercalate in DNA, cytisine, lupanine and sparteine were unable to induce apoptosis as
identiﬁed by DNA fragmentation, in HL60 cells (Rosenkranz and Wink, 2007).
Lupanine did not induce gene mutations in Salmonella Typhimurium strains TA97, TA98, TA100,
TA102, TA1535, TA1538 in the presence or absence of exogenous metabolic activation (S9) (Santiago
Quiles et al., 2010).
In the same study, negative results were also reported in these S. Typhimurium strains with ethanol
extracts of L. termis seeds (the authors state that lupanine is the main alkaloid present in L. termis).
Ethanol extracts of L. termis were also negative for mutation induction in L5178Y tk+/ mouse
lymphoma cells and for micronuclei formation in the bone marrow of BalbC mice administered a single
i.p. dose of L. termis extracts (635 mg/kg bw corresponding to 50% of the LD50) (Santiago Quiles
et al., 2010).
Sparteine ability to induce single-strand breaks (SSBs) was measured by Comet assays in a non-
standard assay based on cultures of Tradescantia staminal nuclei. A small increase in breaks was
observed at a single dose. In the same study, ethanol extracts from L. mexicanus and L. montanus
increased SSBs in the same cells at all tested concentrations, but with no dose dependency (Silva
et al., 2014). The CONTAM Panel noted the limitations of the study, i.e. lack of dose response, no
information on toxic effects and the use of a non-standard assay.
Unpublished data (BIBRA, 1986) showing negative mutagenic effects in S. Typhimurium of alkaloid
preparations from L. angustifolius have been mentioned in reviews (Petterson, 1998; Pilegaard and
Gry, 2008) (the original report of BIBRA was however not available and thus the information could not
be veriﬁed by the CONTAM Panel).
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Summary remarks on genotoxicity
Very limited information is available on the genotoxicity of QAs, which is summarised in
Appendix H.4. None of several QAs (anagyrine, angustifoline, cytisine, 3b-OH-lupanine, 13a-OH-
lupanine, lupanine, lupinine, 17-oxosparteine, sparteine, 13a-tigloyloxylupanine) were able to bind or
intercalate into DNA. Lupanine and extracts of L. termis (main alkaloid being lupanine) were unable to
induce gene mutations in bacteria and in mammalian cells in vitro or micronuclei in vivo. The data on
sparteine are too limited to conclude regarding genotoxicity.
3.1.2.5. Developmental and teratogenicity studies
Ballester et al. (1984) studied the effects of lupin feeding for 9 months in a multigeneration study
in Wistar rats. The lupin diet containing 51.8 g ﬂour from L. albus per 100 g diet (supplemented with
0.2% DL-methionine) was compared to a control diet containing the same protein levels (20%)
obtained by defatted soybean ﬂour, ﬁshmeal and dried skimmed milk. The total alkaloid level of the
test diet was 250 mg/kg (corresponding to 12.5 mg/kg bw per day). The results for the F0 generations
have been reported in a previous study (Ballester et al., 1982; see Appendix H.3). F1 and F2
generations (descendants of the parent F0 generation mated at 12 weeks of age) were given the
same diet as their parents. The growth rate of males fed the lupin diet both at the F1 and F2
generations was higher than that of the control group. No differences were observed in females. No
signiﬁcant changes in the relative weights of heart, spleen, kidneys, brain and gonads were observed
with the exception of relative liver weights of both lupin-fed male and female rats being signiﬁcantly
lower than control animals. The histology of the liver, as well as that of the other organs, was,
however, normal. There were no treatment-related haematological changes or changes in ALT and
aspartate transaminase (AST) at any stage in either generation. Reproductive performance was also
unaffected by a lupin-containing diet. The authors proposed that the difference in relative liver weights
between lupin-fed male rats and control groups is due to the unusually high liver weights of the
control group (not observed in previous studies from the same group using a casein diet as control
group).
Kennelly et al. (1999) tested QAs extracted from rhizomes of blue cohosh (Caulophyllum
thalictroides) in in vitro rat embryo cultures. Following methanol extraction and puriﬁcation of the
extracts, QAs were analysed by GC–MS. The assay is an assessment of the overall growth and
morphogenesis of organogenesis-staged rodent embryos. In this assay, rat embryos are dissected
from the dams at gestation day 9.5 and cultured in medium together with test compounds for 45
h. a-Isolupanine and N-methylcytisine isolated from the extract were tested (purity not speciﬁed).
a-Isolupanine was negative at all concentrations tested (0, 5, 20 and 80 lg/mL). In contrast,
N-methylcytisine (tested at 5, 20, 50, 80 and 250 lg/mL) caused major malformations (open
anterior neural tube, disturbed eye development and twisted tail) from 20 lg/mL onwards. Anagyrine
(tested at 5, 20, 80 and 250 lg/mL) inhibited overall morphogenesis at the highest concentration
tested but did not cause teratogenic effects (it should be noted however that skeletal development is
not scored in this assay).
In conclusion, a two-generation study in rats indicate that a diet based on L. albus seeds did not
affect the reproductive performance. In addition, an in vitro study in rat embryos assessing overall
growth and teratogenic potential of puriﬁed a-isolupanine did not cause major malformations. No
information is available on the effects on development and the teratogenic potential of other QAs.
3.1.2.6. Carcinogenicity
The CONTAM Panel did not identify carcinogenicity studies.
3.1.3. Observations in humans
The data presented here reﬂect the existing knowledge on effects observed in humans after
exposure to lupin alkaloids or lupin seeds which results from intake for medicinal purposes, human
studies in healthy volunteers or from case reports on accidental intake leading to intoxication.
The Panel noted that QAs, including sparteine and lupanine, are also known as components of the
aerial parts of Cytisus scoparius (L.) Link (synonym: Sarothamnus scoparius (L.) W.D.J. Koch;
vernacular name: Scotch broom; family: Fabaceae), for which medicinal uses have been reported (e.g.
Thies, 1986). However, data obtained for C. scoparius are not considered relevant for this assessment
due to differences in the pattern of QAs occurring in parts of C. scoparius compared to that of lupin
seeds.
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3.1.3.1. Pharmacodynamics
Among the QAs, sparteine is the only one for which human data from previous medicinal uses as
an antiarrhythmic or oxytocic drug are available (Thies, 1986). However, existing data are limited.
Sparteine19
Knowledge from use as an antiarrhythmic agent
Sparteine has been shown to diminish irritability and conductivity of the heart muscle as a sodium
channel blocker in a comparable manner to quinidine and has been used therapeutically since 1873 for
the treatment of cardiac arrhythmias (Thies, 1986; Blaschek et al., 2006). Thies (1986) describes that
single doses of 15 to 20 mg sparteine (equivalent to 0.21 to 0.29 mg sparteine/kg bw for a person
with a body weight of 70 kg) were introduced in the 1920s in the treatment of cardiac arrhythmias in
France. However, Thies (1986) describes this dosage as below the threshold of pharmacological
activity. According to Blaschek et al. (2006), antiarrhythmic properties have been reported for
sparteine sulfate in an oral dose of as low as 20 mg (equivalent to 0.29 mg sparteine sulfate/kg bw
for a person with a body weight of 70 kg)25 without clinical studies being available. In later years,
(-)-sparteine sulfate was used in the treatment of tachycardia in single doses of 100 mg/tablet or
200 mg/tablet as a Class I antiarrhythmic (Rote Liste, 1983; Thies, 1986; Blaschek et al., 2006). The
maximum single therapeutic dose was indicated to be at 4 mg/kg bw (Thies, 1986; Blaschek et al.,
2006). According to clinical experiences, a single dose of 100 mg (equivalent to 1.4 mg/kg bw for a
person with a body weight of 70 kg)26 still could not ensure a reliable antiarrhythmic effect. However,
this could be achieved with a single oral dose of 150–200 mg (equivalent to 2.1–2.9 mg/kg bw for a
person with a body weight of 70 kg). The recommended daily dosage for (-)-sparteine sulfate ranged
from 800 to 1,000 mg per day for short-term use and from 400 to 500 mg per day for long-term
therapy, the daily doses always being divided into 4–5 single doses (Rote Liste, 1983). Individual
variations in sensitivity to sparteine sulfate are explained by the genetic polymorphism, which the
isoenzyme CYP2D6 underlies. This isoenzyme is responsible for the metabolic oxidation of sparteine to
2,3-dehydro- and 5,6-dehydrosparteine (Eichelbaum et al., 1986; Thies, 1986; see also
Section 3.1.1.1). Due to the existing genetic polymorphism, these two metabolites cannot be formed
by 5% of the population who thus have higher sparteine plasma levels than the normal population and
who excrete more than 95% of the perorally administered dose as unchanged sparteine with the
urine. These PMs were considered as a group at higher risk to develop adverse effects, which include
gastrointestinal disturbances, central nervous disorders, dizziness, head pressure, accommodation
disturbances in the eye, bradycardia, negative inotropy, hypertonia, changes in haemogram and liver
enzymes. Use during pregnancy is considered as contraindication (Rote Liste, 1983; Thies, 1986;
Blaschek et al., 2006; Aktories et al., 2009).
From the interindividual differences in sensitivity between PMs and EMs, the Panel concludes that
the pharmacological activity is expected to be associated with the parent compound (-)-sparteine and
lost upon biotransformation.
Knowledge from use as an oxytocic agent
Sparteine exhibits oxytocic properties, leading to a muscular stimulation in the virginal, puerperal
and gravid uterus. During the expulsive phase of birth, sparteine induces rhythmic contractions of the
uterus (Thies, 1986).
Dipont investigated the effect of orally administered sparteine sulfate on uterine contractility and if
the treatment reduces the duration of labour during childbirth (Dipont, 1971). Sparteine sulfate was
given to 427 women in the ﬁrst stage of labour in the form of a 20% solution in drops in single doses
of 100–150 mg by repeating dosage every hour if needed, up to a total dose of 600 mg. Compared to
the control group, which comprised 98 labouring women, a statistically signiﬁcant shortening of the
duration of the ﬁrst stage of labour was achieved by the treatment. The shortening amounted on
average to 2 h and 8 min and was due to pronounced oxytocic activity. The average dose of sparteine
25 According to Milne (2018) and The Merck Index (2006), it is assumed that sparteine sulfate is used in the form of the
pentahydrate (MW: 422.54). A single dose of 20 mg sparteine sulfate pentahydrate (equivalent to 0.29 mg/kg bw for a person
with a bw of 70 kg) would then correspond to a single dose of 11.09 mg sparteine (MW: 234.38) (equivalent to 0.16 mg/kg
bw for a person with a bw of 70 kg).
26 A single dose of 100 mg sparteine sulfate pentahydrate (equivalent to 1.4 mg/kg bw for a person with a bw of 70 kg) would
then correspond to a single dose of 55.47 mg sparteine (MW: 234.38) (equivalent to 0.78 mg/kg bw for a person with a bw
of 70 kg).
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sulfate administered was 402.5 mg. In this study the use of sparteine sulfate did lead neither to an
increase of operative deliveries, nor to an increase in the number of perinatal complications, nor did it
have a negative effect on the fetus. An adverse effect reported for the pregnant women was vomiting,
which was associated by the author with the bitter taste of the sparteine sulfate (Dipont, 1971).
Sparteine sulfate was administered by intramuscular injection in repeated doses of 100–150 mg
(equivalent to 1.4–2.1 mg/kg for a body weight of 70 kg) to intensify labour (Gessner and
Orzechowski, 1974). However, due to the unpredictable occurrence of ‘tetanic’ uterine contractions,
the use of sparteine sulfate as an oxytocic was banned by the FDA (1979).
Intoxication
The symptoms of intoxication with sparteine, for which PMs are at higher risks, are dizziness,
drowsiness, headache, sweating, mydriasis and myasthenia. Via the paralysis of the phrenic nerve
endings, sparteine produces in oral doses from 40 mg/kg bw onwards peripherally a curare-like effect
which may lead to respiratory arrest and death. In cases of intoxication, where peripheral respiratory
paralysis has been overcome by artiﬁcial ventilation, higher oral doses from 90 mg sparteine/kg bw
onwards, induce bradycardia with the risks of fatal outcome due to cardiac arrest (Thies, 1986;
Blaschek et al., 2006; Aktories et al., 2009).
A child of the age of 2 years and 4 months died 3 h after accidental ingestion of 413 mg of
sparteine (according to the author equivalent to approximately 30 mg of sparteine/kg bw) in the form
of a medicinal product. After 2 h, the child became conspicuously tired. Respiratory paralysis was
observed followed by intense pulse acceleration. Tonic seizures occurred repeatedly before death set in
(Schmidt, 1961).
A 4-year-old boy with a body weight of 15 kg was intoxicated after accidental ingestion of 100 mg
sparteine sulfate/kg bw27 in the form of tablets. A 4-year-old boy with a body weight of 15 kg was
intoxicated after accidental ingestion of 100 mg sparteine sulfate/kg bw (28) in the form of tablets.
Three hours later and after admission to the hospital, extrasystoles, a heart rate of 95 per min and
gasping were observed, followed by vomiting and cardiorespiratory arrest. The boy survived after
cardiopulmonary resuscitation was delivered (Landes and Robl, 1967).
3.1.3.2. Human studies
Lupanine, 13a-OH-lupanine
In a randomised kinetic study with a cross-over design described in detail in Section 3.1.1.1, oral
doses of 10 mg of lupanine or 10 mg 13a-OH-lupanine (each equivalent to 0.143 mg/kg bw for a
person with a body weight of 70 kg) were administered with a two-week wash-out phase to eleven
volunteers. With respect to the expression of CYP2D6, seven of them were classed as EMs and four as
PMs. No adverse effects were observed in any of the test subjects, blood pressure and heart rate
remaining unaffected (Petterson et al., 1994).
3.1.3.3. Case reports on intoxication with lupin seeds
From the standard literature, it is known that symptoms of lupin seed intoxication set in 20 min
after consumption with maximum effects being observed after 4–5 h. Typical symptoms are of
neurological nature and may additionally manifest in the digestive and/or cardiovascular systems.
Moderate cases of intoxication represent themselves by mydriasis, dizziness, nausea, dryness of the
mouth, stomach aches, vomiting, diarrhoea and/or cardiac complaints. For severe cases of intoxication
prominent tiredness accompanied by curare-like paralysis and convulsions 2–3 h after intake have
been described. Death can occur by respiratory paralysis or cardiac arrest and also by choking
(Schmidlin-Meszaros, 1973; Blaschek et al., 2006; Forrester, 2006).
In general, the alkaloid pattern of the lupin seeds, which were reported to induce the intoxication,
is unknown and often the botanical origin of the seeds (e.g. lupin species and variety) is not indicated.
According to the available literature, including review articles and risk assessment monographs
published by Food Authorities, the number of known cases of intoxication associated with the intake of
lupin seed-based food is limited (e.g. Schmidlin-Meszaros, 1973; ANZFA, 2001; Pilegaard and Gry,
2008; BfR, 2017a).
27 Assuming the intake of sparteine sulfate in the form of the pentahydrate, 100 mg sparteine sulphate pentahydrate/kg bw
would correspond to 55.47 mg sparteine/kg bw.
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In the following, focus is put on case reports on poisonings with relevance for the risk assessment
of the intake of QAs with lupin seed-based food, e.g. giving information on dose effect relationships.
More than 10 published reports on poisoning cases in humans with seeds of the genus Lupinus or
preparations thereof have been identiﬁed during the literature search (see Section 2.1). However, the
CONTAM Panel is aware that this list may not be complete. The few cases which allow for estimation
of alkaloid doses, to which subjects have been exposed, are summarised in Table 2. Other cases for
which a quantiﬁcation of alkaloid exposure was not possible (Smith, 1987; Marquez et al., 1991;
Lowen et al., 1995; Tsiodras et al., 1999; Di Grande et al., 2004; Sarikaya and Tettenborn, 2006;
Litkey and Dailey, 2007; Kurzbaum et al., 2008; Pingault et al., 2009; Awada et al., 2011; Jamali,
2011; Daverio et al., 2014) are not dealt with here in detail. In some of the case reports, authors
report on inadequate debittering of lupin seeds before consumption (Smith, 1987; Lowen et al., 1995;
Litkey and Dailey, 2007; Kurzbaum et al., 2008; Awada et al., 2011; Jamali, 2011; Daverio et al.,
2014). One case of intoxication was even associated with the drinking of 0.5 L water from debittering
of lupin seeds (Marquez et al., 1991). Schmidlin-Meszaros (1973) and Schmidt (1961) summarise three
cases from older literature of lethal intoxication of children after the intake of lupin seeds (see
Table 2). Furthermore, three cases of poisoning with higher alkaloid dose estimates per kg bw are
described in adults, who survived. This suggests that children may be more susceptible to intoxication
with lupin alkaloids than adults and that doses from 10 mg/kg bw onwards have to be considered to
be lethal in children (Schmidt, 1961; Schmidlin-Meszaros, 1973; Malmgren et al., 2016).
The available data do not allow drawing conclusions on the botanical origin of the lupin seeds
involved in intoxication. However, Schmidlin-Meszaros (1973) and Awada et al. (2011) name L. albus
or L. luteus, respectively, as species whose seeds have led to cases of poisoning.
Table 2: Summary of published reports on lupin seeds intoxication in humans which allow for
quantitation of alkaloid intake
Affected
subject
Intake of seeds
(Lupin species and
alkaloid level of
seeds)(a)
Estimated dose of
total alkaloids(b)
Symptoms and
outcome
Reference
17-month-old
toddler, bw:
about 8 kg
5–10 g; (seeds of
unknown botanical
origin contained more
than 1% sparteine and
lupinine)
12–25 mg/kg bw Paralysis Death Petraroia (1926) (as
cited by Schmidlin-
Meszaros, 1973)
10-year-old boy,
bw: about 30
kg
About 25–30 g;
(Lupinus albus)
About 17–20 mg/kg
bw
Gastric symptoms,
mydriasis, clonic
seizures, dyspnoea,
cyanosis;
Death after 3 h
Fischer (1940) (as
cited by Schmidlin-
Meszaros, 1973 and
Schmidt, 1961)
18-month-old
toddler,bw:
about 9 kg
5—10 g 11–22 mg/kg bw No symptoms reported
Death
Fischer (1940) (as
cited by Schmidlin-
Meszaros, 1973)
Adult (female),
bw: about 55
kg
70–80 g dry seeds
(Lupinus albus)
25–29 mg/kg bw Strong gastric pain,
vomiting, disturbed
vision, strong
mydriasis, dry throat,
imperceptible pulse,
agitation, dyspnoea
Abbozzo (1952) (as
cited by Schmidlin-
Meszaros, 1973)
Adult (male),
bw: about 65
kg
100–(150) g dry seeds
(total alkaloid level:
2%; lupanine
concentration of total
alkaloids: 75–80%)
About 31–46 mg/kg
bw
Nausea, mydriasis,
coma;
Recovery
Schmidlin-Meszaros
(1973)
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Overall, it can be concluded that intoxication with lupin seeds do not occur frequently and rarely
lead to a fatal outcome. In poisoning cases, the estimated total alkaloid intakes range from about
10–50 mg/kg bw. For children, lethal cases of poisoning have been described from 10 mg/kg bw
onwards. In several publications, intoxication have been associated with inadequate debittering of
lupin seeds by consumers (Smith, 1987; Lowen et al., 1995; Litkey and Dailey, 2007; Kurzbaum et al.,
2008; Awada et al., 2011; Jamali, 2011; Daverio et al., 2014; Malmgren et al., 2016). No case of
poisoning has been identiﬁed which was attributed to consumption of industrially produced lupin seed-
based food. The botanical origin of the lupin seeds involved in intoxication remains unclear in most
case reports. However, Schmidlin-Meszaros (1973) and Awada et al. (2011) indicate that seeds of
L. albus and L. luteus, respectively, have led to cases of poisoning.
3.1.4. Adverse effects in farm animals, horses and companion animals
Little is known about the effects of QAs in farm animals, horses and companion animals. As
mentioned above (see Section 3.1.1.2) wild lupins contain teratogenic alkaloids including QAs (e.g.
anagyrine) which may be ingested upon grazing by ruminants. Most of the available literature deals
with such effects (for a review, see Panter et al., 1999). However, since lupins used in European
countries as feed do not contain teratogenic compounds, such effects will not be considered further.
The CONTAM Panel identiﬁed ﬁve papers studying the effect of single oral dosing of plant material
from L. caudatus or L. argenteus in ruminants (see Appendix H.5). In these studies, the animals were
exposed to a mixture of lupin alkaloids that consisted of less than 50% of QAs that are the subject of
this opinion. These studies are therefore considered to be of limited relevance for the opinion. In
addition, several other studies showing a poor experimental design were identiﬁed, which are also
reported in Appendix H.5.
3.1.4.1. Ruminants
Cattle
A study (Johnson et al., 1986) was conducted on 12 Jersey heifers (average weight 107 kg), which
were randomly allocated to two groups receiving either a diet containing soybean (control) or a diet
containing Tifwhite-78 lupin seeds (19.3%), a low alkaloid cultivar of L. albus, for 70 days. The seeds
contained 680 mg lupin alkaloids/kg (dry matter (DM)) (measured by a GC method) and the resulting
dietary concentration was 131 mg lupin alkaloids/kg feed (DM). Based on the reported dietary intake
and weight, the CONTAM Panel calculated a corresponding dose of 4.5 mg/kg bw per day. Blood
sampling was performed after 35 and 70 days of feeding. Feed consumption and body weight were
measured daily. No statistically signiﬁcant differences were observed in dietary intake, weight gain and
feed efﬁciency. In addition, the lupin diet did not induce signiﬁcant changes in serum biochemistry (Ca,
P, Mg, total protein, albumin, BUN, total bilirubin, AP, AST, GGT, LDH). The CONTAM Panel concluded
that heifers can tolerate lupin alkaloids present in the studied L. albus cultivar at a dietary
concentration of 131 mg/kg, corresponding to a dose of 4.5 mg/kg bw per day. The CONTAM
Panel noted that this was the only dose tested.
Affected
subject
Intake of seeds
(Lupin species and
alkaloid level of
seeds)(a)
Estimated dose of
total alkaloids(b)
Symptoms and
outcome
Reference
Adult (male),
bw not reported
80–100 g soaked
seeds (Lupinus albus),
contained 2%
lupanine. The
analytical method
allowed only for
quantiﬁcation of
lupanine and not of
other alkaloids
= 25 mg/kg bw (only
lupanine measured)
Nausea, dizziness,
mydriasis, dry mouth,
abdominal pain,
confusion
Recovery
Malmgren et al.
(2016)
bw: body weight.
(a): If provided by the authors.
(b): As provided by the authors.
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According to a randomised complete-block design, 25 Friesian dairy cows were offered one of the
following diets with seeds from L. albus for 70 days: control, intact crushed lupin seeds (ICL) at 150
(ICL-15) or 300 (ICL-30) g/kg diet, and heat detoxiﬁed crushed lupin seeds (DCL) at 150 (DCL-15) or
300 (DCL-30) g/kg diet. Total alkaloids were extracted,28 but only the sum of the lupanine and 13a-
OH-lupanine was measured (GC–MS); in ICL-15 and ICL-30 it was 3,800 and 8,000 mg/kg diet DM,
respectively, while that of DCL-15 and DCL-30 was 2,100 and 5,200 mg/kg diet DM, respectively. Based
on the reported dietary intake and assuming a body weight of 650 kg, the CONTAM Panel calculated
corresponding doses of 72, 123, 52 and 111 mg/kg bw per day. Irrespective of the nature of the seeds
(intact vs heat inactivated), cows exposed to the higher lupanine and 13a-OH-lupanine dosages (72,
111, and 123 mg QA/kg bw/day) had a lower feed intake (12.3, 13.9 and 10.0 kg/day), respectively.
In addition, feed intake and milk yield were signiﬁcantly depressed in cows on intact lupins as
compared to those on detoxiﬁed lupins (Mukisira et al., 1995). The authors concluded that the
reduction in feed intake could be attributed to lupanine and 13a-OH-lupanine. Based on this endpoint,
it may be concluded that dairy cows tolerate a diet containing lupin seeds from L. albus at a
concentration of 2,100 mg lupanine and 13a-OH-lupanine/kg, corresponding to a dose of 52 mg/kg bw
per day.
Sheep
In the in vitro experiments cited above (Lanca et al., 1994), rumen microbial activity was not
affected by the incubation for 24 h of either sparteine up to 5.4 mM or of ﬁnely ground L. luteus seeds
(cv. Brava (bitter) or Topaz (sweet)) at three levels of incorporation (5, 10 or 15 g DM basis).
No relevant studies could be identiﬁed concerning the exposure to cultivated lupins.
Goats
No relevant studies could be identiﬁed concerning the exposure to cultivated lupins.
3.1.4.2. Pigs
Based on a review of the scientiﬁc literature, Cheeke and Kelly, 1989 concluded in that pigs are
reported to be more susceptible than other species to QAs contained in SLs.
Case reports of lupin toxicosis have been described in pigs. Feed refusal, unthriftiness, lethargy,
sporadic deaths, reduced litter size, stillbirth, increased postnatal death losses, poor performances and
intestinal stasis were reported by three different pork producers feeding growing piglets or sows with
dehulled hexane-extracted lupin seeds (most likely L. albus cv. Ultra, alkaloid content not reported) at
dietary concentrations from 10% to 30% (Casper et al., 1991).
More recently (2016), a ﬁeld case of lupin toxicosis has been described in northern Italy, affecting
about 2,170 pigs of different categories (pregnant or lactating sows, gilts, fattening pigs) and involving
several breeding farms. Poisoning was due to accidental contamination of grain legumes (peas) by
bitter lupins (BLs) (L. albus). Total QA content of feed was determined by the University of Milan with
a GC–MS method. There was a clear relationship between the QA concentration in the feed and the
severity of clinical signs. A decrease in feed consumption was already noted after the exposure to
dietary QA concentrations of 194 mg/kg; a more marked decline in feed intake was observed in
animals offered diets containing 373 or 450 mg QA/kg. Some of the latter (fattening pigs, about 5%)
also showed depression, recumbency, hypersalivation and vomiting along with a low mortality (about
1%) that was characterised at necropsy by torsion of the stomach and gastroenteric bloat. A
remarkable reduction in feed intake, a higher incidence of clinically affected individuals (up to 50%)
and a more severe clinical picture was instead reported in animals exposed to dietary QA levels of 866,
946 and 1,180 mg QA/kg feed, respectively. Mortality rose up to 20% in animals (lactating sows) fed
with the highest QA levels (Boschin and Tesio, 2019, personal communication).
The tolerance of growing pigs to lupin alkaloids was tested in two different trials (Godfrey et al.,
1985) in terms of changes in growth rate, feed intake, and feed conversion ratio. Total alkaloid
concentration was measured by GC (method according to Priddis, 1983). In experiment 1, 9-week-old
crossbred (Large White x Landrace) piglets (average weight 23 kg) were allocated to six groups
receiving diets containing increasing amounts of lupin seeds (a mixture of L. angustifolius sweet
cultivars) and consequently increasing total alkaloid concentrations (i.e. 120, 200, 280, 360, 440, 520
mg total alkaloids/kg feed, respectively) for 9 weeks. The corresponding doses calculated by the
CONTAM Panel are 5, 8, 11, 14, 16 and 19 mg/kg bw per day, respectively. In experiment 2, piglets of
28 Method published in the Proceedings of a congress.
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the same breed (average weight 31 kg) were allocated to 3 groups receiving diets containing
increasing amounts of BL seeds (L. angustifolius bitter cultivars) and consequently increasing total
alkaloid concentrations (i.e. 50, 200, 350 mg total alkaloids/kg feed, respectively) for 7 weeks. The
corresponding doses calculated by the CONTAM Panel are 2, 9 and 14 mg/kg bw per day, respectively.
At the end of the treatment, 10 animals/group were killed and liver and kidneys were removed and
subjected to gross and microscopic examination. No deaths or clinical signs of illness were detected in
both trials irrespective of the alkaloid dietary intake. In experiment 1, a dose-related linear decrease in
body weight gain and feed intake was detected, starting from 14 mg/kg bw per day. In experiment 2,
growth rate and feed intake were depressed only at the highest dose tested (14 mg/kg bw per day);
neither macroscopic nor microscopic changes were detected in liver and kidney from all treated piglets.
Although no control group was included, the authors concluded that growing pigs can tolerate lupin
alkaloids present in the studied L. angustifolius bitter cultivars at a dietary concentration up to 200
mg/kg. This concentration corresponds to a dose of 9 mg/kg bw per day.
A further study was conducted in Polish Large White 9 Pietrain barrows (average weight 53 kg)
(Rotkiewicz et al., 2007). Animals were fed 62 days with diets in which the soybean meal (control diet)
was replaced by lupin seeds of three L. angustifolius varieties, namely Baron, Zeus and Wersal, with
slightly different total alkaloid concentrations (360, 410 and 560 mg/kg DM, respectively; analytical
method not reported). The corresponding concentrations in the diet were 97, 119, 156 mg/kg diet
(DM). Only in barrows offered the diet containing the lupin variety Wersal with the highest alkaloid
concentration, daily weight gain was statistically signiﬁcantly lower than controls (680 g vs. 740 g). In
lupin-fed pigs, histopathological examinations revealed some degree of atrophy and deformation of
intestinal villi and an increase in eosinophils and lymphocytes in the enteric wall. In addition,
‘proliferation of glandular and hepatic cells’ was recorded. Due to the lack of a statistical evaluation of
the histopathological lesions, these ﬁndings cannot be used for hazard characterisation. Based on the
reduced weight gain observed for the diet containing the highest alkaloid concentration, the CONTAM
Panel concluded that pigs can tolerate lupin alkaloids present in the studied L. angustifolius varieties at
a dietary concentration of 119 mg/kg. In the absence of reported feed intakes, the corresponding dose
could not be calculated.
A study was designed to examine the effects of feeding two different levels of raw or germinated
seeds of L. luteus (yellow lupin) or L. angustifolius (blue lupin) on zootechnical performances in
growing pigs (Kasprowicz-Potocka et al., 2013). Total alkaloid content of the Raw Yellow Lupin (RYL)
seeds was 1,000 mg/kg, with sparteine and lupinine amounting to approximately 58% and 27% and
low levels of lupanine (3%) and 13a-OH-lupanine (6%). Germinated Yellow Lupin (GYL) seeds had a
lower total alkaloid content (700 mg/kg) with limited variation (about 10% less) in the percentages of
the mentioned QAs. Total alkaloid content of the Raw Blue Lupin (RBL) seeds (1,500 mg/kg) was
higher than that measured in RYL. As expected, RBL also showed a different QA composition, in that
lupanine (69%) and 13a-OH-lupanine (24%) accounted for more than 90% of total QAs. Germinated
Blue Lupin (GBL) seeds had a lower total alkaloid content (1,000 mg/kg) with lupanine (52%) and
13a-OH-lupanine (18%) accounting for only 70% of total QAs. Two experiments were performed, both
lasting 33 days. In Experiment I, 50 crossbred piglets (initial bw 10 kg) were randomly allocated to
one of the following treatment groups (N = 5 per sex and per group), namely control (no lupins), RYL,
GYL, RBL and GBL. In experimental diets, 50% of the soybean meal protein content of the control
group was replaced by the protein of RYL, GYL, RBL or GBL lupins. The same protocol was adopted
for Experiment II, but the protein replacement rose to 75%. The resulting total alkaloid content
(mg/kg diet) in Experiment I and Experiment II, was the following: RYL 17 and 24, GYL 10 and 15,
RBL 31 and 47, GBL 18 and 27. Zootechnical performances (ﬁnal body weight, feed intake, average
daily gain and feed conversion ratio) and health status were monitored in both experiments. Blood
samples were collected from 6 animals/group at the end of Experiment II only. Zootechnical
performances were not affected in animals from Experiment 1 (50% soy protein replacement)
irrespective of the lupin species (L. luteus or angustifolius) or status (raw or germinated). In
Experiment II (75% soya protein replacement), feed intake was signiﬁcantly depressed in RBL- or GBL
fed piglets and a signiﬁcant rise in serum alkaline phosphatase (~ 50%) of uncertain biological
relevance was observed in RYL-fed animals. However, the CONTAM Panel noted that no signiﬁcant
changes were observed in ALT or AST in Experiment II for all diets tested and blood enzymes were not
tested in Experiment I. Therefore, the CONTAM Panel took only the zootechnical performance into
account for a conclusion regarding the tolerated concentration of QAs in feed. It is concluded that
piglets tolerate lupin alkaloids present in the studied L. luteus cultivar up to a dietary concentration of
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24 mg/kg (1.5 mg/kg bw per day) and lupin alkaloids present in the studied L. angustifolius cultivar up
to 18 mg/kg (1.0 mg/kg bw per day).
3.1.4.3. Poultry
Laying hens and broiler chicks
A study was designed to determine the lethality of total and selected QAs from a bitter variety of
L. albus (cv. not mentioned) in two breeds of 10-day-old laying hens (ISAbrown and SHAVERcross)
(Cubillos et al., 1999). Total alkaloids were extracted from seeds to obtain aqueous solutions
(analytical technique not mentioned). Lupanine (71%) and 13a-OH-lupanine (13%) were by far the
most abundant QAs in the extract, which contained less than 1% sparteine. Lupanine was puriﬁed
from the total alkaloid extract and sparteine sulfate (192 mg/mL) was commercially obtained. Animals
were gavaged and mortality recorded over 48 h. In ISAbrown poults, calculated LD50 (mean and 95%
conﬁdence interval) were 958 mg/kg bw (854–1,070) for total alkaloids, 1,131 mg/kg bw (929–1,378)
for lupanine, and 655 mg/kg bw (509–856) for sparteine base. In SHAVERcross poults, similar LD50
values were found for total alkaloids and lupanine, being, respectively, 961 mg/kg bw (890–1,035) and
1,271 mg/kg bw (1,027–1,573), while much lower values were calculated for sparteine, i.e. 425 mg/kg
bw (303–544), pointing to the occurrence of breed-related differences in the sensitivity to certain QAs.
Results from this study also conﬁrm the higher toxicity of sparteine compared to lupanine (two- to
three-fold) observed in mammals.
Vogt et al. (1987) fed laying hens (age 24 weeks) with diets containing no lupins or diets
containing 16% debittered lupin grist (from either L. albus24 P, or L. albus24 G or L. mutabilis) that
contained 1.1, 6.2, 9.6 or 1.2 mg total alkaloids/kg diet, respectively, for 168 days. Total alkaloid
concentration was determined with GC (no details given); according to the authors, almost 90% of the
measured total alkaloid was lupanine. Using a starting weight of 1.505 kg for the animals and a mean
feed intake of 116, 120, 121 and 109 g per day, respectively, a corresponding intake of 0.08, 0.49,
0.77 and 0.09 mg alkaloids/kg bw per day could be calculated. Feeding of lupin grist did not adversely
affect feed intake/efﬁciency, laying rate, egg weight, and egg fertility/hatchability. However, the
Panel noted that the applied doses are low and not expected to cause any effects.
The adverse effects of dietary lupins were assessed in 1-day-old broiler chicks (unspeciﬁed breed)
offered a diet including soybean meal (control) or raw (40%, group A), dehulled (40%, group B), or
autoclaved (35% group C) L. angustifolius (cv. Troll) seed meals, respectively, for 21 days. The total
alkaloid concentration, measured by a titration method according to Ruiz (1977), was less than
100 mg/kg in the lupin seeds, which approximately corresponded to less than 40, 40 and 35 mg
alkaloid/kg feed for group A, B, and C, respectively. During the ﬁrst week, two chicks from group A
died and further two were euthanatised in the remaining weeks showing bradycardia, twisting of the
neck, leg weakness and coma. Post-mortem examination did not reveal signiﬁcant gross changes.
Skeletal deformities (limb deformity, crooked sternum and scoliosis) affected a total of seven
individuals (3 from group A, 3 from group B, 1 from group C). In all treated groups, body weight gain,
feed consumption, and feed to gain ratio were remarkably depressed, while the liver CYP level
doubled. The authors concluded that in broilers the repeated dietary exposure to certain varieties of
lupins may entail severe systemic effects (including skeletal deformities) which were not counteracted
by dehulling or autoclaving (Olkowski et al., 2001). The CONTAM Panel noted the observed effects;
however, due to the uncertainty regarding the concentration of total alkaloids in the feed, this study
cannot be used for dose-response assessment.
A study was designed to investigate the effects on zootechnical performance of lupin seeds (Olver
and Jonker, 1997). A SL (L. albus cv. Hanti), a BL (L. angustifolius) and soaked micronised bitter lupin
(SMBL) seeds were analysed for alkaloids by titration (method according to Ruiz, 1977) and found to
contain < 100 mg alkaloids/kg for the SL, < 200 mg alkaloids/kg for the SMBL and > 900 mg/kg for the
BL. As a result, the soaking procedures reduced the alkaloid concentration to less than 200 mg/kg
lupin seeds. The trial was conducted on male Ross 1-day-old broilers chicks which were offered for 6
weeks a control (no lupin), a SL, a BL or a SMBL diet, containing 0, 50, 100, 200, 300 or 400 g/kg of
the lupin under test. In chicks fed SLs, body weight gain, feed consumption, and feed to gain ratio
were almost superimposable to control values irrespective of the added lupin amount. This was also
the case for carcass characteristics (moisture, fat, protein, and ash content). By contrast, all BL-fed
chicks (both BL and SMBL at all dosages) showed a depression in body weight gain, feed consumption
and feed to gain ratio. An increased moisture and carcass fat content were detected at the two
highest lupin concentrations for the BL group and at the highest lupin concentration for the SMBL
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group, respectively. The CONTAM Panel noted the observed effects; however, due to the uncertainty
regarding the concentration of total alkaloids in the feed, this study cannot be used for dose-response
assessment.
Feeding experiments with L. albus (cv. Ultra) seeds at several levels and different processing
methods were performed in Single Comb White Leghorn laying hens (Watkins and Mirosh, 1987). The
lupin alkaloid concentration (GC–MS) of the seeds was 80 mg/kg and only lupanine was quantiﬁed.
Raw, autoclaved (121°C for 30 min) or extruded (80°C for 20 sec) lupins29 were included in the diets
at different percentages (10, 15, 20, 25 or 30%) and administered for up to 32 weeks. A group fed
with a basal diet (no lupins) was always included. The tested parameters were mortality, feed
consumption, egg production and egg weight. No differences were observed between hens offered the
basal diet or diets containing autoclaved lupins (up to 20% for 12 weeks) or extruded lupins (up to
25% for 16 weeks). Only hens administered with 25 or 30% raw lupins and for the longest duration
(32 weeks) showed signiﬁcant reduction in egg weight and/or egg production. The authors concluded
that the L. albus (cv. Ultra) may be fed to laying hens as a protein source at levels of up to 20%
(corresponding to a lupanine concentration of 16 mg/kg feed and a daily dose of 0.9 mg/kg bw based
on a body weight of 2 kg and a daily feed intake of 0.113 kg/hen).
Turkeys
The tolerance to the dietary inclusion of different levels of seeds of white lupins (L. albus cv. Ultra)
was investigated in growing male and female Large White (Nicholas) turkeys (Halvorson et al., 1988).
The control diet consisted of corn and soybean; in lupin-treated animals, the control diets were partially
replaced by ground whole (WL) or ground dehulled (DWL) seeds. Total alkaloid content (analytical
method: GC-FID) amounted to 960 mg/kg (including 740 mg/kg ‘OH-lupanine’30 and 150 mg/kg
lupanine) in WL seeds and to 430 mg/kg (including 190 mg/kg ‘OH-lupanine’ and 130 mg/kg lupanine)
in DWL seeds used in Experiment 1, and 430 mg/kg (including 180 mg/kg ‘OH-lupanine’ and 140 mg/kg
lupanine) for WL seeds used in Experiment 2. In Experiment 1, one-day old males were offered one of
the following diets for 21 days: control, WL at 20% or 40% inclusion or DWL at 20% or 40% inclusion.
The CONTAM Panel calculated the corresponding doses of 29, 61, 13 and 26 mg lupin alkaloids/kg bw.
Tested parameters were body weight, average daily gain, average feed intake, and feed efﬁciency. In
Experiment 2, one-day old females were assigned to one of the following groups: control diet, control
diet + WL (2:1, ~ 33% lupins), control diet + WL (1:1, 50% lupins), control diet + WL (0.6:1, ~ 43%
lupins). At the end of the study (17 weeks), animals were killed and organs (liver, heart, pancreas,
kidney, gizzard, intestine) were removed and weighed.
In Experiment 1 (3-week feeding), there was a very similar daily feed intake in controls and all
treated animals; body weight and daily weight gain were depressed only in male turkeys administered
with the 40% WL diet, corresponding to a total alkaloid dose of 61 mg/kg bw per day. In Experiment 2
(17-week feeding), mortality was not affected by the treatment and the macroscopic examination of
the organs did not reveal any alteration; a very slight (up to 5%) but statistically signiﬁcant reduction
in body weight and average daily gain was detected in turkey hens from all treated groups along with
an increase in gizzard and pancreas weight. The treated groups were exposed to concentrations
ranging from 61 to 215 mg/kg feed and the corresponding doses ranged from 2.7 to 9 mg/kg bw per
day. According to the authors it is doubtful that the observed effects could be related to the alkaloid
contents. Based on the obtained results, the CONTAM Panel could not identify a tolerated dose from
this study since effects were observed at all doses tested in the experiment with the longest and
lowest exposure.
Ducks
A study was designed in Peking ducklings (Olver and Jonker, 1998) using the same experimental
design of a study performed in broilers, as described above (Olver and Jonker, 1997). The tested lupin
seeds included SL (L. albus cv. Hanti), a BL (L. angustifolius) and SMBLs, with an alkaloid
concentration (measured by titration) of < 100 mg alkaloids/kg for the SL, > 900 mg/kg for the BL and
< 200 mg/kg for the SMBL. Two hundred and forty ducklings were allocated to 16 groups and offered
for 6 weeks one of the following diets containing 0, 50, 100, 200, 300, 400 g/kg of the lupins under
test. Three animals per group were killed at the end of the treatment for carcass traits analysis
(moisture, fat, protein, and ash content). Productive parameters (body weight gain, feed consumption,
29 The effect of processing on the lupin alkaloid concentration was not reported.
30 Position not indicated in the paper, but likely to be 13a-OH-lupanine.
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and feed to gain ratio) were recorded after 3 and 6 weeks. Animals fed either with the SL variety or
with the SMBL, did not show statistically signiﬁcant differences with controls in any of the tested
parameters irrespective of the amount added to the diet. By contrast, BL did not affect productive
traits only at inclusion levels up to 100 g/kg diet and carcass characteristics up to 300 g/kg. According
to the authors, the apparent higher sensitivity of ducklings to BLs compared to broilers might be due
to a more developed sense of taste in ducks, as assessed by a higher number of taste buds (200) with
respect to broilers (20) (Kare and Ficken, 1963 as cited in Olver and Jonker, 1998). The CONTAM
Panel noted the observed effects; however, due to the uncertainty regarding the concentration of total
alkaloids in the feed, this study cannot be used for dose-response assessment.
Japanese quails
One-day-old quail chicks (average weight 7 g, breed not reported) were randomly divided into four
groups, namely a control group I and three further groups fed 15% L. albus seeds as follows: raw I,
processed (debittered) according to a traditional Turkish method (TTM) or subjected to extrusion I.
The lupin alkaloid concentration was determined by GC-FID. The trial lasted 6 weeks and feed
consumption, live weight, and feed conversion efﬁciency were monitored weekly. Lupanine
(28,000 mg/kg) accounted for more than 80% of the lupin alkaloid content in raw lupin seeds
(29,000 mg/kg) and low levels of sparteine (210 mg/kg), lupinine (15 mg/kg), cytisine (185 mg/kg)
and anagyrine (115 mg/kg) were also reported. While TTM proved extremely efﬁcacious in reducing
the alkaloid concentration (lupanine concentration around 400 mg/kg, all other alkaloids not
detectable), the extrusion method brought about only a negligible reduction (10%) of alkaloids. While
live weight and feed conversion efﬁciency were lower in both R and E groups up to the fourth week of
treatment, at the end of the trial there were no statistically signiﬁcant differences in any of the tested
parameters. It was concluded that growing performances of Japanese quails are not affected by the
dietary inclusion of 15% lupin seeds from L. albus containing up to 29,000 mg alkaloids/kg seed
(corresponding to 4,771 mg lupin alkaloids/kg feed DM or 826 mg/kg bw per day) (Arslan and Seker,
2002).
3.1.4.4. Rabbits
New Zealand White rabbits (initial average weight ~ 1 kg) were allocated to three experimental
groups (Battaglini et al., 1991). Each group was offered a diet containing three different levels (0, 8 or
16%) of three different cultivars of L. albus seeds, namely Italian (I), Australian (A) or Australian
extruded (AE) cultivars, for 80 days. Total alkaloid content was measured with an ‘ofﬁcial EC method’
and amounted to 5.8 (I), 5.4 (A), and 1.6 (AE) g/kg DM; the three inclusion levels resulted in the
following total alkaloid content in the feed (mg/kg DM): 0, 460, 930 (I), 0,430, 860 (A) and 0, 130,
260 (AE). The corresponding doses for group I were 0, 30 and 60 mg/kg bw per day, for group A 0,
30 and 55 and for group AE 0, 10 and 19. The trial lasted 80 days, but zootechnical performances
were recorded from day 45 until day 80 only. As compared to controls, in the I group, only the highest
inclusion level (16%) negatively affected feed consumption, ﬁnal weight and daily weight gain. In
rabbits of the A group exposed to the same level (16%, same total alkaloid content) a reduced feed
consumption was observed. Zootechnical parameters were not affected in rabbits receiving extruded
lupins (AE). From this study, it is concluded that rabbits tolerate lupin alkaloids present in the studied
L. albus cultivars at a dose of 30 mg/kg bw per day.
3.1.4.5. Fish
Rainbow trout (Oncorhynchus mykiss)
A feeding study (Serrano et al., 2011) was carried out in rainbow trout to investigate the effects of
lupinine, the main QA in European L. luteus cultivars (Wink et al., 1995), accounting for almost 60% to
the total alkaloid concentration in the plant. Rainbow trout (average weight 330  20 g) were allocated
to 8 groups receiving a diet containing 0, 50, 75, 100, 250, 500, 1,000 or 5,000 mg lupinine/kg,
respectively, for 60 days. From the data provided by the authors regarding feed intake and body
weight, the CONTAM Panel calculated the corresponding doses (0, 0.5, 0.8, 1.1, 2.5, 4.5 and 7.2 mg/kg
bw). A 20% and 33% reduction in feed intake was detected at 500 and 1,000 mg/kg inclusion levels,
respectively; the same dosages resulted in a 30% and 50% fall in weight gain, respectively. After 40
days, the treatment with the highest concentration (5,000 mg lupinine/kg) was stopped for animal
welfare reasons (extremely low feed intake and weight gain). At the end of the experimental period, 9
individuals/group were sacriﬁced. Body, liver and spleen were weighed. Treatment effects on productive
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parameters, whole body composition analysis and tissue histopathology were also investigated. There
was a dose-related quadratic depression in both feed intake and growth rate, negative effects being
observed at doses greater than 1.1 mg/kg bw. Feed efﬁciency ratio was not affected. No relevant
histopathological changes were detected, except for a depletion of glycogen and lipid stores in the
7.2 mg/kg bw dose group. Splenosomatic index31 was not affected, whereas decrease in the
hepatosomatic index31 was noticed at lupinine doses higher than 1.1 mg/kg bw. It is concluded that
a dose of 1.1 mg lupinine/kg bw is tolerated by rainbow trout and can be considered as a NOAEL
for lupinine in rainbow trout, while 2.5 mg/kg bw can be considered as a lowest-observed-adverse-
effect level (LOAEL).
A further study was conducted in rainbow trout to investigate the effects of sparteine (Serrano
et al., 2012). Juvenile rainbow trout (average weight 61  7 g) were allocated to 8 groups receiving a
diet containing 0, 50, 100, 250, 500, 1,000, 2,500 or 5,000 mg sparteine/kg, respectively, for 62 days.
From the data provided by the authors regarding feed intake and body weight, the CONTAM
Panel calculated the corresponding doses (0, 0.7, 1.4, 3.5, 6.6, 11.9, 14.5 and 15.6 mg/kg bw). No
mortality occurred. Final body weight, weight gain, feed consumption and hepatosomatic index were
decreased in ﬁsh exposed to > 1.4 mg/kg bw. By contrast, treated ﬁsh did not display relevant
histopathological changes in liver, kidney, spleen, and intestine, suggesting that the adverse effects of
sparteine in rainbow trout are likely to reﬂect the decrease in feed intake. In conclusion, doses of
sparteine up to 1.4 mg/kg bw per day are safe in trout and this dose can be considered as a NOAEL
for sparteine in rainbow trout. The LOAEL identiﬁed from this study was 3.5 mg/kg bw.
3.1.4.6. Horses
No information about QA toxicity in horses was identiﬁed.
3.1.4.7. Companion animals
One study in cats and dogs was identiﬁed, which is described in Section 3.1.2.3.
3.1.4.8. Summary remarks
Limited data are available regarding the adverse effects caused by QAs in farm animals, horses and
companion animals. Most studies used lupin seeds as source of QAs in the diet and do not report the
QAs present in the diet or their relative contribution to the total QA concentration. Such studies do not
allow identiﬁcation of NOAEL/LOAELs. These studies, as well as studies that allowed the identiﬁcation
of NOAEL/LOAELs are summarised in Appendix H.6
In cattle, only studies on zootechnical performance were identiﬁed and from these, the CONTAM
Panel identiﬁed 50 mg/kg bw per day as a dose of lupanine and 13a-OH-lupanine present in seeds
from L. albus that can be tolerated. No relevant studies were identiﬁed for sheep and goats.
Case reports on lupin toxicosis are only reported for pigs, indicating that pigs are sensitive to QAs.
Based on zootechnical performance, the CONTAM Panel identiﬁed 1-10 mg/kg bw per day as a dose
range of lupin alkaloids present in seeds from L. angustifolius and 1.5 mg/kg bw per day as a dose of
lupin alkaloids present in seeds from L. luteus that can be tolerated by pigs. In addition to an effect on
zootechnical performance, gastro-intestinal lesions have been observed in pigs receiving a lupin seed-
based diet. However, due to the lack of a statistical evaluation, these ﬁndings could not be taken into
account for identifying tolerated doses.
An acute toxicity study in laying hens, conﬁrms the higher toxicity of sparteine compared to
lupanine observed in mammals. Based on zootechnical performance, 1 mg/kg bw per day was
identiﬁed as a dose of lupin alkaloids present in seeds from L. albus that can be tolerated by laying
hens. In a study with one-day-old broiler chicks (for which no dose calculation was possible), effects
on zootechnical performance, as well as severe systemic effects, were observed, however at
concentrations in the feed that were higher compared to the studies in laying hens. No tolerated dose
could be identiﬁed for turkeys since effects were observed on zootechnical performance at the lowest
dose tested of 2.7 mg/kg bw per day. In one-day-old quail chicks, 826 mg/kg bw was identiﬁed as a
dose of lupin alkaloids present in seeds from L. albus that can be tolerated (only dose tested).
For rabbits, the CONTAM Panel identiﬁed 30 mg/kg bw per day as a dose of lupin alkaloids present
in seeds from L. albus that can be tolerated.
31 The organ weight expressed as percentage of body weight.
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Pure lupinine and sparteine were tested in feeding studies with rainbow trout, and NOAELs of 1.1
and 1.4 mg/kg bw per day were identiﬁed for lupinine and sparteine, respectively, for the effect on
zootechnical performance and hepatosomatic index.
3.1.5. Mode of action
Typically, human acute poisoning cases involving intake of QAs from lupin seeds present symptoms
consistent with the so-called anticholinergic syndrome with symptoms associated with the central
nervous system, the gastro-intestinal system and the cardiovascular system. Classically these include
mydriasis, dry mucous membranes, reduced saliva production, tachycardia and/or arrhythmia, urine
retention, confusion and general malaise. Respiratory paralyses have also been reported. Suggested
modes of action for these effects are interaction with ACh receptors both in the CNS and in the peripheral
autonomic system, involving both nicotinic ACh receptors (nAChR) in ganglions and peripheral mAChR of
postganglionic parasympathetic nerve ﬁbres. The nAChR and mAChR are two classes of acetylcholine
receptors. There are two main subtype groups of the nicotinic receptors, N1 called peripheral or muscular
(motor endplates) receptor subtypes and the N2 subtypes known as the central or neuronal receptor. The
nAChRs consist of ﬁve subunits. In humans, there are 16 different subunits encoded be separate genes,
and the nAChRs are both homomeric and heteromeric. The nAChR is coupled to non-selective cation
channels and, dependent on subunit composition it transports sodium, potassium and in some instances
calcium (Colquhoun et al., 2003; Zoli et al., 2018). The mAChR form G protein-coupled receptor
complexes in the cell membranes of certain neurons, i.e. in postganglionic ﬁbres in the parasympathetic
nervous system. There are ﬁve subtypes of the muscarinic receptors (M1–5). Separate genes encode
these subtypes, which are expressed differently in the tissues (Carlson and Kraus, 2018). There are also
polymorphisms in both nAChR and mAChR (Michel and Teitsma, 2012; Deﬂorio et al., 2017).
Acute symptoms of lethal amounts of QAs given orally are similar in rats, mice and guinea pigs,
with clinical signs showing shaking, excitation and convulsions and death resulting from respiratory
failure. In cases with respiratory paralysis, also nAChR (subtype N1) of the motor endplates of the
muscles might have been affected. Mild intoxicated cows exhibited mild signs of uncoordinated gait,
muscle fasciculations or coarse muscle tremors, and increased sensitivity to external stimuli. The
effects in experimental animals and cattle as described above are also compatible with QAs interacting
with cholinergic receptors.
Yovo et al. (1984) examined sparteine and lupanine in an in vitro binding assay with ACh receptors
isolated from rat brain. Binding to the receptors was assayed using displacement of 3H–nicotine and
3H-quinuclidinyl benzilate. The authors concluded that sparteine and lupanine had a very weak afﬁnity
for the mAChR with Kis32 of 7 and 11 lM, respectively, whereas the respective values for the nAChR
were 0.4 and 0.5 lM. The authors noted the selectivity of both compounds for the nicotinic sites. This
accords with the ganglioplegic effects observed for both compounds in cats and dogs (Yovo et al.,
1984; see also Section 3.1.2.3 Neurotoxicity).
Voitenko and co-workers (1991) investigated the effect of (+)-sparteine on nAChR in neurons in rat
superior cervical ganglion of the sympathetic system. They found that (+)-sparteine (2 lM) reduced
ACh induced activation in a competitive manner. Also, an open-channel-blocking of (+)–sparteine was
observed, but this effect was relatively low, possible due to the larger size of the molecule relative to
channel proﬁle.
Cytisine has been tested in experimental systems and has been found to possess nAChR agonist
activity, being a partial agonist of a4/b2* nAChRs and a full agonist at a3/b4* nAChRs (Luetje and
Patrick, 1991; Picciotto et al., 1995; Mineur et al., 2007; Li et al., 2010).
Schmeller et al. (1994) further examined the inhibitory action of the major QAs present in L. albus,
L. mutabilis, L. luteus, L. angustifolius, Anagyris foetida and Laburnum anagyroides at the nAChR and
mAChR. They used ACh receptor preparations from porcine brain and measured QA induced
displacement of 3H-nicotine and 3H-quinuclidinyl benzilate. From the resulting displacement curves,
half maximal inhibitory concentration (IC50) values were calculated which are presented in Table 3.
The afﬁnities for the receptors differed from those found by Yovo et al. (1984) who used rat brain
instead of pig brain as source of receptor preparation.
32 The Ki (inhibitor constant) is an indication of how potent an inhibitor is. It is the concentration required to produce half
maximum inhibition.
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From the study of Schmeller et al. (1994), it can be concluded that various QAs bind to both ACh
receptors, but with different afﬁnity. For example, lupanine appears to have the strongest afﬁnity to
the nAChR. Hydroxylation of lupanine strongly reduces its afﬁnity to the nAChR. N-Methylcytisine and
cytisine seem to have the strongest afﬁnity to the nAChR and 13a-tigloyloxylupanine for the mAChR.
These binding studies represent the neuronal N2 nAChR subtypes and a mixture of all ﬁve mAChR
subtypes. Any impact of polymorphic variants of the receptors for the QAs is unknown. Contrary to
the ﬁnding of Yovo et al. (1984), Schmeller et al. (1994) found that sparteine preferentially binds to
the mAChR, however different species, rats and pigs were uses in these receptor binding studies. The
CONTAM Panel further noted that interaction with cholinergic receptors is in agreement with toxicity
observed in the CNS affecting cholinergic pathways following QA exposure (see Section 3.1.2.3
Neurotoxicity). While receptor afﬁnity could give an indication of relative toxic potencies of the
different QAs, it is not known how the QAs might affect different receptor subtypes and whether toxic
potency in vivo would also depend on kinetic differences, e.g. in peak plasma concentration and
elimination speed. Although both Yovo et al. (1984) and Schmeller et al. (1994) used receptor
preparations from brain, it is unclear whether the difference in relative afﬁnity to the receptors is
related to species differences or other assay conditions.
Green and co-workers examined whether sparteine, lupanine and anagyrine could bind to and
cause desensitisation of muscle-type nAChR and turning it into a state that closes the cation channel.
As this would ultimately result in inhibition of foetal movements, desensitisation has been suggested as
a mode of action for teratogenicity in cattle induced by lupin alkaloids containing anagyrine (Green
et al., 2017). Using cell culture models expressing either autonomic ganglion-type nAChR or fetal
human muscle-type nAChR, the authors found that lupanine or sparteine had no desensitising effects,
whereas anagyrine appeared to be a strong nAChR desensitiser. As anagyrine is not relevant for the
current Scientiﬁc Opinion, it is therefore not further discussed in this section.
In addition to the interaction of QAs with neuroreceptors, i.e. the ACh receptor, it has also been
assumed based on electrophysiological studies that QAs and in particular sparteine affects sodium
inward current thereby reducing excitability of muscles and nervous tissues and affecting cardiac
action potentials. It is well known that voltage dependent ion channels are responsible for the
excitability of nerve, heart smooth muscle and skeletal muscle cells.
Sparteine and lupanine inhibit both sodium and potassium channels (Galvan et al., 1984;
Honerj€ager et al., 1986) and there are several reports on the impact of QAs on such channels. Pugsley
et al. (1995) investigated the electrophysiological effects on rat heart and isolated rat myocard cells
with patch-clamp technique. Sparteine prolonged the P-R and WaT intervals and reduced the
Table 3: Afﬁnity of different quinolizidine alkaloids to nicotinic or muscarinic receptors (Schmeller
et al., 1994)
Compound IC50
(a) nAChR (lM) IC50 mAChR (lM)
Albine 193 33
Anagyrine 2,096 132
Angustifoline > 500 25
Cytisine 0.14 400
3b-OH-Lupanine(b) 190 74
13a-OH-Lupanine(b) 490 140
Lupanine 5 114
Lupinine > 500 190
N-Methylcytisine 0.05 417
Multiﬂorine > 500 47
17-Oxosparteine 155 118
Sparteine 331 21
Tetrahydrorhombifoline 310 129
13a-Tigloyloxylupanine 160 11
mAChR: muscarinic acetylcholine receptor; nAChR: nicotinic acetylcholine receptor.
(a): The concentration that displaces 50% of the speciﬁcally bound radiolabelled ligand.
(b): The CONTAM Panel noted inconsistency in the reporting of the stereochemistry by the authors. However, based on the
available reports on QA composition of lupin seeds, the CONTAM Panel assumed that the compounds tested are 3b-OH-
lupanine and 13a-OH-lupanine.
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thresholds for premature beats and myocytes reduced voltage evoked sodium currents
(EC50 = 0.11 mM) as well as potassium currents (EC50 = 0.15 mM). K€orper et al. (1998) investigated
the impact on the sodium currents in isolated muscle ﬁbres of the frog Xenopus laevis upon application
of the QAs sparteine and lupanine and other alkaloids using the loose patch clamp method. The results
showed that all compounds tested had inhibitory activity albeit with widely differing potencies. The
IC50 values for Na
+ channel inhibition were 1.2 mM for lupanine, 168.8 lM for sparteine, 6.6 lM for
ajmaline33 and 55.7 lM for quinidine.33 Sparteine had about 1/20 and lupanine about 1/100 of the
activity of ajmaline, the most potent Na+ channel inhibitor. Again, it is noted that the relative effects of
these compounds in vivo also depend on the kinetic properties.
Sparteine also causes blockade of the calcium-activated potassium channels (Omote et al., 1993).
In addition, other possible modes of action of QAs have been investigated.
Wink (2004) reviewed the biological functions and molecular modes of action of QA and, in addition
to the effects of QAs described above, found that minor cellular targets of QAs could be dopamine, c-
aminobutyric acid (GABA), N-methyl-D-aspartate (NMDA) and alpha 2 receptors.
In an attempt to identify new inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase
(BchE), sparteine and cytisine were tested in vitro. Cytisine was completely inactive against both
enzymes. The anti-AChE effect of sparteine was modest (< 50%) EC41.6 = 1 mg/mL), while an
appreciable inhibition towards BchE (> 70%) (EC73.9 = 1 mg/mL) was observed (Orhan et al., 2007).
Sparteine was introduced in the late 1930s to induce labour and the uterotonic effect of QAs has
been investigated in old studies using in vitro set-ups with uterine preparations from both experimental
animals and humans (Garg et al., 1973). Ligon (1941) used in vitro uterine segments from rabbits to
investigate the impact of sparteine sulfate, sparteine disulfate, lupinine base, d-lupanine
dihydrochloride and trilupine base.34 They found that the sparteine compounds were the most potent
followed by lupinine, which was ﬁve times less potent, and trilupine and d-lupanine, which were 10 to
15 times less potent than sparteine. Garg et al. (1973) treated strips of both non-pregnant and
pregnant human uterus in vitro (5–20 lg/mL of sparteine sulfate) and found that response on
contractions was dose-related with pregnant uterus about 10 times more sensitive than non-pregnant
uterus. Spasms were observed at the highest doses (20 lg/mL of sparteine sulfate). The uterotonic
effects of chemicals may be mediated by several mechanisms (Gruber and O’Brien, 2011). One such
mechanism is via the prostaglandin pathway, which was investigated in the rat by Abtahi et al. (1978).
In in vivo experiments, they found that sparteine (10 mg/kg bw) increased the prostaglandin F
concentration in plasma and uterine tissue of pregnant, but not of non-pregnant rats. Indomethacin, a
well-known inhibitor of prostaglandin synthesis abolished the effect of sparteine. Indomethacin
pretreatment (5–10 lg/mL) strongly reduced the effect of sparteine in in vitro experiments using
uterine segments from pregnant rats treated with sparteine (80–3,220 lg/mL) aiming to give between
80% and 90% of maximum contraction. Indomethacin did not have any effect of prostaglandin F2a or
Acetylcholine induced contractions.
Negative results were reported for the ability of several QAs to inhibit protein synthesis (13a-OH-
lupanine and sparteine), or bind RNA (anagyrine, angustifoline, cytisine, 3b-OH-lupanine, 13a-OH-
lupanine, lupanine, lupinine, 17-oxosparteine, sparteine, 13a-tigloyloxylupanine) (Korcz et al., 1987;
Wink et al., 1998; Merschjohann et al., 2001; Lin et al., 2011).
Summary remarks
Several modes of action have been identiﬁed for QAs, the most important in relation to acute
toxicity being their binding and inhibitory action on AChRs producing an anticholinergic syndrome of
toxicity with paralysis of respiratory muscles causing respiratory failure and death. The different QAs
appear to bind with different afﬁnity to these receptors and also their preference for nAChRs or
mAChRs seems to differ. QAs may also cause, with different potencies, inhibition of voltage dependent
ion channels, e.g. sodium and potassium channels, and calcium activated potassium channel, effects
possibly underlying their antiarrhythmic effect. The uterotonic effects of sparteine appears to be
mediated via an increased production of prostaglandin F. No studies investigating mode of action and
possible additive effect of QAs were identiﬁed. Most data are on sparteine. With regard to the other
QAs relevant in this opinion, afﬁnities to AChRs appear to be in the same range or lower than those of
sparteine. Scarce data on other modes of action of a few QAs might indicate that these QAs are
similarly or less active than sparteine.
33 An alkaloid (non-QA) that is a well-known sodium channel inhibitor and used as an antiarrhythmic agent.
34 Trilupine was shown to be d-lupanine monohydrochloride dihydrate (see Marion, 1952).
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3.1.6. Consideration of critical effects and dose–response analysis
3.1.6.1. Acute toxicity
Experimental animal data
The acute toxicity of lupanine was two- to fourfold higher in mice compared with rats when
delivered either by i.p. (LD50: 80 vs. 177 mg/kg bw, respectively) or orally (LD50: 410 vs. 1,664 mg/kg
bw, respectively). Studies in rats indicated that acute toxicity of lupanine and 13a-OH-lupanine is
similar (LD50: 177 and 199 mg/kg bw by i.p., respectively). Sparteine is two times more toxic than
lupanine in mice (oral LD50: 220 vs. 410 mg/kg bw, respectively) as well as in guinea pigs. Following
oral intakes of lupanine, 13a-OH-lupanine and sparteine, the clinical symptoms of poisoning were
similar in all species, with the cause of death being identiﬁed in respiratory failure and anticholinergic
symptoms. The similarity of the symptoms of intoxication supports the conclusion on a similar mode of
action of these QAs.
Human data
Lupin seeds
Typical symptoms of acute intoxication in human with lupin seeds are associated with their content
of bitter QAs and are usually described as anticholinergic syndrome, often also affecting the
cardiovascular and digestive systems. Death is usually due to respiratory failure (see Section 3.1.5). In
poisoning cases with lupin seeds, the estimated total alkaloid intakes range from about 10 to 50 mg/kg
bw. Reports suggest that children are more susceptible to intoxication with lupin alkaloids than adults
and that doses from 10 mg/kg bw onwards have to be considered to be lethal in children.
Sparteine
For sparteine sulfate,35 antiarrhythmic properties have been reported in a single oral dose of as low
as 20 mg (for a person with a body weight of 70 kg equivalent to 0.29 mg sparteine sulfate/kg bw or
0.16 mg sparteine/kg bw) (Thies, 1986; Blaschek et al., 2006). According to clinical experiences, only
higher single doses of 150–200 mg (equivalent to 2.1–2.9 mg/kg bw for a person with a body weight
of 70 kg) could ensure a reliable antiarrhythmic effect. For short-term use, the recommended daily
dosage for (-)-sparteine sulfate ranged from 800 to 1,000 mg per day (equivalent to 11.4–14.3 mg/kg
bw for a person with a body weight of 70 kg), being divided into 4–5 single doses of 200 mg
(equivalent to 2.9 mg/kg bw for a person with a body weight of 70 kg) (Rote Liste, 1983). Individual
variations in sensitivity to sparteine sulfate were due to the genetic polymorphism, which the
isoenzyme CYP2D6 underlies (Eichelbaum et al., 1986; Thies, 1986). At these dosages, PMs were
considered as a group at higher risk to develop adverse effects, which include gastrointestinal
disturbances, central nervous disorders, dizziness, head pressure, accommodation disturbances in the
eye, bradycardia, negative inotropy, hypertonia, changes in haemogram and liver enzymes. Use of
sparteine sulfate as an antiarrhythmic drug during pregnancy was, because of its uterotonic effect,
considered contraindicated (Rote Liste, 1983; Thies, 1986; Blaschek et al., 2006; Aktories et al., 2009).
Sparteine sulfate also showed oxytocic activity and was effective in reducing the ﬁrst stage of
labour when given in oral single doses of 100–150 mg (equivalent to 1.4–2.1 mg/kg bw for a person
with a body weight of 70 kg) by repeating dosage every hour if needed, up to a total dose of 600 mg
(equivalent to 8.6 mg/kg bw for a person with a body weight of 70 kg). An adverse effect reported for
the pregnant women was vomiting (Dipont, 1971).
At oral doses from 40 mg/kg bw onwards sparteine blocks the nAChR (N1 subtype) of the motoric
endplate of muscles, which may lead to respiratory failure and death. In cases of intoxication, where
peripheral respiratory paralysis has been overcome by artiﬁcial ventilation, higher oral doses from
90 mg sparteine/kg bw onwards, induce bradycardia with the risks of fatal outcome due to cardiac
arrest (Thies, 1986; Blaschek et al., 2006; Aktories et al., 2009). Accidental ingestion of approximately
30 mg of sparteine/kg bw was fatal to a young child (Schmidt, 1961).
35 According to Milne (2018) and The Merck Index (2006), it is assumed that sparteine sulfate is used in the form of the
pentahydrate (MW: 422.54). A single dose of 20 mg sparteine sulfate pentahydrate (equivalent to 0.29 mg/kg bw for a person
with a bw of 70 kg) would then correspond to a single dose of 11.09 mg sparteine (MW: 234.38) (equivalent to 0.16 mg/kg
bw for a person with a bw of 70 kg).
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Lupanine, 13a-OH-lupanine
In a kinetic study, no adverse effects were observed after administration of single oral doses of
10 mg of lupanine or 10 mg 13a-OH-lupanine (each equivalent to 0.14 mg/kg bw for a person with a
body weight of 70 kg) to volunteers (n = 11) either classed as EMs or PMs (Petterson et al., 1994).
Livestock and companion animal data
In the only relevant study, oral LD50 of total alkaloids from a bitter variety of L. albus, lupanine and
sparteine was determined in 10-day-old laying hens of two different breeds (ISAbrown and
SHAVERcross). In ISAbrown poults, calculated LD50 (mean and 95%) were 958 mg/kg bw (854–1,070)
for total alkaloids, 1,131 mg/kg bw (929–1,378) for lupanine, and 655 mg/kg bw (509–856) for
sparteine. In SHAVERcross LD50 for total alkaloids and lupanine were 961 mg/kg bw (890–1,035) and
1,271 mg/kg bw (1,027–1,573), respectively, for lupanine, while for sparteine an LD50 of 425 mg/kg
bw (303–544) was calculated. Results from this study conﬁrm the higher toxicity of sparteine
compared to lupanine observed in mice and guinea pigs and indicate possible breed-related differences
in the sensitivity to certain QAs.
Overall summary for acute toxicity
Comparison of doses reported from human intoxication with those resulting in acute toxicity in
experimental animals shows that humans are more sensitive to QAs than laboratory rodents. The
observed difference in acute toxicity might be linked to the differences in toxicokinetics between
humans and rats and particularly the biotransformation of sparteine to lupanine in the rat, which is not
reported to occur in humans. Therefore, the CONTAM Panel used the human data as a basis for
hazard characterisation in the assessment of human risks due to exposure with QAs via food.
Supported by human data on sparteine, the CONTAM Panel concluded that anticholinergic and
antiarrhythmic effects of QAs are the critical acute effects for the hazard characterisation. No human
studies are available describing the dose-response relationship for these effects of QAs.
Knowledge on dose -responses refers only to oral therapeutic doses of sparteine sulfate used in the
treatment of cardiac arrhythmia, which is mainly due to the effect on the voltage dependant sodium
channels. Adverse effects associated with this treatment belong to the spectrum of the anticholinergic
syndrome. A dose of 20 mg of sparteine sulfate (equivalent to 0.16 mg sparteine/kg bw assuming a
body weight of 70 kg) is described as the lowest single oral dose with antiarrhythmic properties, which
is one-ﬁfth of the lowest single oral dose of sparteine sulfate associated with oxytocic activity.
Only one study in poultry was identiﬁed that supports the conclusion from experimental animals
that sparteine is more toxic than lupanine. No other data in livestock or companion animals were
identiﬁed.
3.1.6.2. Repeated-dose toxicity
Experimental animal data
All the repeated dose studies with laboratory animals on QAs were carried out in rats. Single dose,
sub-chronic studies on diets containing L. albus-, L. luteus-, and L. mutabilis seeds did not identify
signiﬁcant toxicological effects. Two studies investigated a diet containing increasing concentrations of
L. angustifolius ﬂour. The major QAs in the ﬂour were lupanine and 13a-OH-lupanine. Both studies
reported a slight increase in relative liver weights. However, some conﬂicting results were reported in
different publications from the same laboratory.
Due to several reasons including differences in sources of QAs in feeds, control diets and types of
cultivars, the CONTAM Panel concluded that the repeated-dose studies in experimental animals have a
limited value for the evaluation of QA toxicity.
Human data
In the long-term therapy of cardiac arrhythmias the recommended daily dosage for (-)-sparteine
sulfate was half of that for short-term treatment and ranges from 400 to 500 mg (equivalent to 5.7 to
7.1 mg/kg bw for a person with a body weight of 70 kg), divided into 4–5 single doses of 100 mg
(equivalent to 1.4 mg/kg bw for a person with a body weight of 70 kg). Known adverse effects and
contraindications were the same as for short-term use indicated above (Rote Liste, 1983).
No other human data on adverse effects associated with long-term exposure to lupin seeds or QAs
occurring in lupin seeds are available. The CONTAM Panel concluded that the available data are too
limited to identify a reference point for the human risk assessment following repeated exposure.
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Livestock and companion animal data
The large majority of relevant repeated-dose studies in livestock species (except ﬁsh, see below)
were performed with the sole aim of identifying the lupin dietary inclusion levels not affecting
zootechnical performances (feed intake, weight gain, feed efﬁciency, milk yield, egg production). The
CONTAM Panel noted the considerable differences in both total and speciﬁc QA content among lupin
seeds from different species and even cultivars as well as the lack of speciﬁc toxicity studies.
Therefore, based on the available data, NOAEL/LOAEL for most food producing species could not be
identiﬁed and were replaced by suggested tolerated concentrations/doses speciﬁcally referring to
seeds from a single lupin species/cultivar. The only relevant studies performed with pure QAs (i.e.
lupinine and sparteine) were conducted in rainbow trout and allowed to identify similar NOAEL values
for lupinine and sparteine (1 mg/kg bw per day). In the absence of data on other QAs, the CONTAM
Panel used this NOAEL for a group approach to characterise the hazard of the QAs relevant for this
opinion and applied to all farmed salmonids. No relevant studies have been identiﬁed for companion
animals.
3.1.7. Possibilities for derivation of a human health-based guidance value
Based on the available information, the CONTAM Panel concluded that anticholinergic effects and
the electrical conductivity of the heart following acute exposure to QAs are the critical effects for the
human hazard characterisation. The mode of action of sparteine and its pharmacological proﬁle as an
anticholinergic substance are considered similar to those of other main alkaloids in lupin seeds, such as
lupanine, 13a-OH-lupanine and lupinine. Therefore, the CONTAM Panel considers it appropriate to use
a group approach and apply the principle of dose-additivity for the combined activity of these QAs
acting on the same target receptors. Based on the ﬁndings of studies on acute toxicity in experimental
animals, in vitro studies showing inhibition of ion channels, in particular sodium channels, and effects
on the isolated uterus, sparteine is assumed to have a higher potency than other QAs from lupin
seeds. Therefore, and in the absence of dose-response information for other QAs, the CONTAM
Panel decided to base the hazard characterisation on sparteine as a conservative approach. Although
sparteine is only described as one of the major alkaloids in the seeds of L. luteus and L. mutabilis (see
Table 1), the approach is also considered valid for seeds of L. albus and L. angustifolius.
The available data were considered insufﬁcient to propose HBGVs and instead an MOE approach
using the lowest single oral antiarrhythmic dose of 0.16 mg sparteine/kg bw as reference point (see
Section 3.1.6.1) was selected to characterise the risk following acute exposure since the CONTAM
Panel considers that an intended pharmacological effect following therapeutic use is an unwanted
effect in the context of risk assessment for food. No reference point could be identiﬁed to characterise
the risk following chronic exposure.
3.2. Occurrence data
3.2.1. Current occurrence data submitted to EFSA
Data were collected according to the procedure described in Section 2.2. Occurrence data on QAs
for the present assessment were provided by one national authority from the Netherlands and one
University from Italy.36
An initial number of 1,465 analytical results on 13a-OH-lupanine, 13a-angeloyloxylupanine, 13a-
tigloyloxylupanine, albine, angustifoline, a-isolupanine, lupanine, lupinine, multiﬂorine, sparteine,
tetrahydrorhombifoline in feed (n = 390) and food (n = 1,075) were present in the EFSA Chemical
Occurrence database.
After the validation processes (Section 2.2.2), data providers were invited to clarify possible
inconsistencies identiﬁed by EFSA’s DATA Unit. Where such a clariﬁcation was not received from the
data provider, the CONTAM Panel was required to apply certain assumptions.
It should be noted that when reference is made to lupins in this section, as well as in the Annexes,
this should be understood as lupin seeds.
The CONTAM Panel is aware that both whole and dehulled seeds are used for food and feed. The
proportion of seed coat to whole seed is variable depending on the variety but may account for up to
25% of the weight of the whole seed (Brand et al., 2004). However, no studies have been identiﬁed in
36 University of Milano – Dipartimento di Scienze Farmaceutiche – DISFARM.
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which the levels of QAs, and their proportions, have been determined separately in the seed coat and
in the kernel (dehulled seed). Therefore, in this exposure assessment it has been assumed that levels
and proportions are similar in the whole and dehulled seeds, but recognised that if the levels or
proportions are different this would result in an under- or overestimation of the exposure.
3.2.1.1. Occurrence data on food
A total of 1,035 analytical results on 99 food samples were retained after data cleaning. All samples
referred to lupin-based foods. Details of the data cleaning applied for food samples are presented in
Annex A (Table A.2).
Analytical results were submitted by the Netherlands (540 analytical results from 54 samples on
10 QAs) and by the University of Milan (495 analytical results from 45 samples on 11 QAs); detailed
information on the number of samples versus analysed substance, sampling year and reporting
country/institution can be retrieved in Table A.3 of Annex A. The sampling year spanned from 2005
until 2018, with most of the samples collected in 2016 (Annex A, Table A.3).
Table 4 provides an overview of the number of samples per food category according to different
levels of the FoodEx2 classiﬁcation system.
The vast majority of occurrence data were reported for samples (n = 65) classiﬁed as ‘Lupins (dry)
and similar’. This type of samples represents lupin seeds that are sold as dry seeds and that can be
consumed upon rehydration, debittering, boiling and brining or as ﬂour that can be used for home-
made dishes (such as pancakes/crepes or pasta). Information on the lupin species was reported in
some cases: 29 samples were classiﬁed as L. albus and 27 as L. angustifolius. Twenty-eight samples of
‘Lupins (dry) and similar-’ were reported to be processed (i.e. ‘grinding/milling/crushing’) and the results
therefore refer to lupin seeds in the form of ﬂour or grits. Samples reported in the category ‘canned or
jarred legumes’ referred to lupin seeds in water and salt or pickled (those are normally consumed as
such). In the category ‘canned or jarred legumes’, all samples were left-censored for lupinine,
tetrahydrorhombifoline and albine, while for lupanine, multiﬂorine and 13a-OH-lupanine only 13% of
the samples were left-censored. In the category ‘Lupins (dry) and similar-’, left-censored results were as
follows: lupanine 0%, 13a-OH-lupanine 13%, angustifoline 11% and a-isolupanine 18%. Details on the
percentage of left-censored data in food samples can be found in Table A.4 (Annex A).
Under the category ‘meat imitates’ different types of lupin morsels, steaks or cutlets were reported,
in few cases the % of lupin ﬂour was reported as 40%. For lupanine and 13a-angeloyloxylupanine, no
left-censored samples were present in this category.
In the category ‘Pasta-like products’, pasta to which isolated protein was added as ingredient was
reported, while in the category ‘Pasta, plain (not stuffed), uncooked’ lupin ﬂour was added as ingredient.
Fifty-four samples were analysed with LC–MS/MS and an LOQ of 0.1 mg/kg was reported for all
tested substances (i.e. 13a-OH-lupanine, 13a-angeloyloxylupanine, 13a-tigloyloxylupanine,
Table 4: Number of samples per food category for which analytical data on quinolizidine alkaloids
were reported
FoodEx2 Category (Level 4) FoodEx2 Category (Level 6) N
Almonds and similar- Almonds(a) 1
Bread and rolls with special ingredients added Bread and rolls with special ingredients added 1
Canned or jarred legumes Canned or jarred legumes 8
Coffee imitate ingredients Coffee imitate ingredients 4
Isolated proteins and other protein products Isolated proteins and other protein products 6
Lupins (dry) and similar- Blue lupin (dry) 27
Lupins (dry) 9
White lupin (dry) 29
Meat imitates Meat imitates 8
Pasta based dishes, cooked Pasta, plain (not stuffed), cooked 1
Pasta, plain (not stuffed), uncooked Dried durum pasta 3
Pasta-like products Pasta-like products 1
Rusk Rusk 1
N: number of samples.
(a): Almond ﬂour containing a certain amount of lupin ﬂour.
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angustifoline, a-isolupanine, lupanine, lupinine, multiﬂorine, sparteine, tetrahydrorhombifoline). The
other samples were analysed with GC-MS and an LOQ of 1.5 mg/kg was reported for all tested
substances (i.e. the substances analysed by LC-MS/MS plus albine).
In the category ‘canned or jarred legumes’, all samples were left-censored for lupinine,
tetrahydrorhombifoline and albine, while for lupanine, multiﬂorine and 13a-OH-lupanine only 13% of
the samples were left-censored. In the category ‘Lupins (dry) and similar’, left-censored results were as
follows: lupanine 0%, 13a-OH-lupanine 13%, angustifoline 11% and a-isolupanine 18%. Full details on
the percentage of left-censored data in food samples can be found in Table A.4 (Annex A).
Descriptive statistics by food category for lupanine and TotQA are presented in Table 5 while the
full descriptive statistics for all the QAs can be found in Table A.5 (Annex A). TotQA is calculated as the
sum of the 6 most abundant QAs in the data set available, namely lupanine, 13a-OH-lupanine,
angustifoline, multiﬂorine, 13a-tigloyloxylupanine and a-isolupanine.
Very high levels of lupanine (up to 5,395 mg/kg) and TotQAs were found in certain samples
belonging to the category ‘Lupins (dry) and similar-’. For this reason, a clariﬁcation request was sent to
the data provider. It was conﬁrmed that a part of the reported samples (n = 22) were not present on
the EU market but rather cultivated for research purposes. These research samples showed a higher
mean concentration of lupanine compared to the other samples of lupin seeds (768 vs 192 mg/kg
LB = UB), multiﬂorine (60 vs 11 mg/kg LB) and 13a-angeloyloxylupanine (27 vs 2.6 mg/kg LB), but
showed a lower mean concentration of 13a-OH-lupanine, 13a-tigloyloxylupanine and angustifoline.
Based on this information, the CONTAM Panel decided to exclude the research samples from the data
set used for dietary exposure assessment.
Table 5: Descriptive statistics of lupanine and total quinolizidine alkaloids concentrations (mg/kg) by
food category
FoodEx2 category (Level 4) N LB/UB
Lupanine TotQA(a)
Min Mean Max Min Mean Max
Almonds and similar-(b) 1 LB –(c) 24 – – 53 –
UB – 24 – – 53 –
Bread and rolls with special ingredients added 1 LB – 8.4 – – 21 –
UB – 8.4 – – 21 –
Canned or jarred legumes 8 LB 0.0 16 54 0.0 25 75
UB 1.5 16 54 4.2 26 75
Coffee imitate ingredients 4 LB 98 165 238 186 331 482
UB 98 165 238 186 331 482
Isolated proteins and other protein products 6 LB 8.5 29 67 8.5 29 67
UB 8.5 29 67 16 37 74
Lupins (dry) and similar- (research) 22 LB 26 768 5,395 26 922 6,100
UB 26 768 5,395 34 926 6,105
Lupins (dry) and similar- 43 LB 8.9 191 1,859 25 429 3,673
UB 8.9 191 1,859 25 429 3,676
Meat imitates 8 LB 7.9 22 40 15 28 46
UB 7.9 22 40 19 33 52
Pasta based dishes, cooked 1 LB – 3.0 – – 6.5 –
UB – 3.0 – – 6.8 –
Pasta, plain (not stuffed), uncooked 3 LB 0.0 3.9 11 0.0 9.0 26
UB 0.1 3.9 11 0.6 9.3 26
Pasta-like products 1 LB – 2.7 – – 2.7 –
UB – 2.7 – – 10 –
Rusk 1 LB – 4.2 – – 4.2 –
UB – 4.2 – – 12 –
LB: lower bound; Max: maximum; Min: minimum; N: number of samples; TotQA: total quinolizidine alkaloids; UB: upper bound.
(a): Calculated as the sum of lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine, a-isolupanine.
(b): Almond ﬂour containing a certain amount of lupin ﬂour.
(c): Only one sample available in the data set and the concentration of this sample is reported under the mean concentration.
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3.2.1.2. Occurrence data on feed
A total of 390 analytical results on QAs were reported on 37 feed samples. Details of data cleaning
are reported in Table B.1 (Annex B).
Analytical data on feed were submitted by the Netherlands (170 analytical results from 17 samples
on 10 QAs) and by the University of Milan (220 analytical results from 20 samples on 11 QAs); the
sampling year spanned from 2011 until 2018, with most of the analytical results from samples
collected in 2017. Detailed information can be retrieved in Table B.2 (Annex B).
The University of Milan submitted 5 samples coded as ‘Legume seeds and products derived thereof
(feed)’ and 15 as ‘Lupin middlings (feed)’. It should be noted that some of the samples reported in the
category ‘Legume seeds and products derived thereof (feed)’ were speciﬁed by the data provider as
‘mixtures of dry legume seeds containing also dry lupin seeds (from L. albus) although with % lupin
and composition unknown’. The category ‘Lupin middlings (feed)’ includes samples speciﬁed as ‘lupin
ﬂour for pig feed with percentage of lupin and composition unknown’. The Netherlands submitted
17 samples of ‘sweet lupins (feed)’, which were all L. angustifolius seeds.
Both data providers reported that several samples were suspect.37 All 20 samples of ‘Lupin
middlings (feed)’ and ‘Legume seeds and products derived thereof (feed)’ reported by the University of
Milan were collected from pig farms where intoxication had been reported. In the category named as
‘sweet lupins (feed)’, 6 suspect samples were reported as well. A description of the number of feed
samples and percentage of left-censored data per substance can be found in Table B.3 of Annex B.
The 17 samples reported by the Netherlands were analysed using LC–MS/MS for 13a-OH-lupanine,
13a-angeloyloxylupanine, 13a-tigloyloxylupanine, angustifoline, a-isolupanine, lupanine, lupinine,
multiﬂorine, sparteine, tetrahydrorhombifoline. The LOQ was 0.1 mg/kg for all QAs reported. The
20 samples reported by the University of Milan were analysed by GC–MS for the 10 substances
mentioned above plus albine; all were reported with an LOQ of 1.5 mg/kg.
Descriptive statistics of the occurrence data for feed samples reported in this opinion can be found
in Table 6. As for the food, the CONTAM Panel decided to focus on lupanine and TotQA as the sum of
lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine and a-isolupanine. More
detailed descriptive statistics for all the alkaloids can be found in Table B.4 (Annex B).
Due to the large differences in mean concentrations between suspect and non-suspect samples,
the CONTAM Panel decided not to use feed samples reported as suspect (Table 6) for the exposure
assessment for farm animals, horses and companion animals. Consequently, a very limited number of
samples (n = 11) were available for the exposure assessment. The CONTAM Panel therefore decided
to complement the data set with data on occurrence of QAs in ‘Lupin (dry) and similar-’ reported as
food samples for which the species was reported (13 of L. albus and 21 of L. angustifolius), plus
Table 6: Descriptive statistics of lupanine and total quinolizidine alkaloids concentrations (mg/kg) by
feed category
Category(a) N Suspect LB/UB
Lupanine TotQA(b)
Min Mean Max Min Mean Max
Legume seeds and products derived
thereof (feed)
5 YES LB 479 3,307 6,164 517 3,834 6,896
(based on L. albus) UB 479 3,307 6,164 522 3,839 6,901
Lupin middlings (feed) 15 YES LB 0.0 514 1,070 0.0 611 1,201
(based on L. albus) UB 1.5 514 1,070 9.0 616 1,206
Sweet lupins (feed) 11 NO LB 19 102 265 58 257 559
(L. angustifolius) UB 19 102 265 58 257 559
Sweet lupins (feed) 6 YES 100 3,553 7,459 396 9,571 19,004
(L. angustifolius) UB 100 3,553 7,459 396 9,571 19,004
LB: lower bound; Max: maximum; Min: minimum; N: number of samples; TotQA: total quinolizidine alkaloids; UB: upper bound.
(a): based on the FoodEx2 classiﬁcation system supplemented with information on species provided by the data providers.
(b): calculated as the sum of lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine, a-isolupanine.
37 Suspect sampling strategy is deﬁned as ‘Selection of an individual product or establishment in order to conﬁrm or reject a
suspicion of non-conformity. It is a not random sampling. The data reported refer themselves to suspect units of the
population’ according to EFSA (2011).
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9 samples for which the lupin species was not speciﬁed. Chemical occurrence data reported for
L. angustifolius as food and feed were merged, while for L. albus only food samples were available.
Table 7 shows the descriptive statistics of the ﬁnal data set.
3.2.1.3. Relative variations of main QAs in lupin seeds
Figure 5 shows the relative percentage of the 6 main QAs normalised by the sum for L. albus (n = 13)
and L. angustifolius (n = 21) seeds that were reported as food samples as well as L. angustifolius seeds
(n = 11) reported as feed samples. All suspect samples as well as the research samples were not
included.
Considering the small number of samples per category, results should be considered with caution.
Lupanine was the most abundant QA in both species, followed by 13a-OH-lupanine (especially
abundant in L. angustifolius) and angustifoline. Multiﬂorine and 13a-tigloyloxylupanine were more
abundant in L. albus than in L. angustifolius. These observations, although arising from a relatively
small number of samples, are in agreement with the scientiﬁc literature (Table 1).
Table 7: Occurrence data used for exposure assessment for farm animals, horses and companion
animals (mg/kg)
Species N Scenario
Lupanine TotQA
Min Mean Max Min Mean P75 Max
L. albus 13 LB 29 166 959 68 344 359 1,125
UB 29 166 959 71 345 359 1,130
L. angustifolius 32 LB 19 205 1,859 58 475 539 3,673
UB 19 205 1,859 58 476 539 3,676
L. angustifolius, L. albus, and
unspeciﬁed
54 LB 8.9 13 1,859 25 394 352 3,673
UB 8.9 13 1,859 25 394 352 3,673
LB: lower bound; P75: 75th percentile; TotQA: total quinolizidine alkaloids; UB: upper bound.
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Figure 5: Contribution of single quinolizidine alkaloids to the total quinolizidine alkaloid concentration (sum of lupanine, 13a-OH-lupanine, angustifoline,
multiﬂorine, 13a-tigloyloxylupanine, a-isolupanine) in lupin seeds food samples of L. albus (n = 13), L. angustifolius (n = 21) and in lupin seeds
feed samples of species L. angustifolius (n = 11) at the upper bound scenario. Box plots display from left to right: minimum, P25, median, P75
and maximum
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3.2.1.4. Occurrence data received during the public consultation
During the public consultation (EFSA, 2019), EFSA received analytical results from 121 samples of
L. albus and L. angustifolius from a company analysed by GC. The concentration of total alkaloids
ranged from 10 to 1.149 mg/kg with an average concentration of 184 mg/kg and a P90 of 368 mg/kg.
The CONTAM Panel noted the lower concentration of total alkaloids in the data received during the
public consultation compared to the data submitted to EFSA during the call for data. It was noted that
for some of the samples only lupanine and 13-OH-lupanine were analysed and based on the
assumption that these substances contribute for 85% to the total QA content, the total QA content
was calculated.
3.2.2. Peviously reported occurrence data in the open literature
Food
Two papers have been identiﬁed that describe the QA content in lupin-based foods.
Reinhard et al. (2006) studied six QAs as well as ammodendrine and gramine in food on the Swiss
market using GC-FID and GC–MS (Table 8). Except from lupin coffee, the concentrations of alkaloids
are very low compared to the concentration in seeds/ﬂours analysed in the same study (see
Appendix D, Tables D.1–D.4). However, lupin coffee is also the only food that is made solely from lupin
seeds. Primarily lupanine, 13a-OH-lupanine, and angustifoline were found in the foods. The three
QAs – a-isolupanine, 13a-angeloyloxylupanine and 13a-tigloyloxylupanine – were only present in trace
amounts in two of the lupin coffee samples, in the curry burger, the lupin tofu products and one of the
breads.
Resta et al. (2008) analysed eight samples of lupin-based commercial foods by GC-MS (see Table 9)
The results of the total QA concentration is the sum of the found QAs and is denoted ‘estimated total
alkaloids’.
Feed
No information regarding the occurrence of QAs in whole plants (which would include stems, leaves
and seeds) fed to livestock has been identiﬁed. In a few papers results from leaves are included and
these results are summarised in Appendix D, Table D.6 to give an indication of the concentrations and
Table 8: Concentration of alkaloids in different lupin-based food products (Reinhard et al., 2006)
Food product Number of samples Concentration of total alkaloids (mg/kg)
Lupin coffee 4 136–182
Curry burger 1 4
Lupin tofu 2 12–15
Lupin tofu with tomato 1 3
Bread (7–10% lupin ﬂour) 2 8–12
Falafel with lupin tofu 1 3
Lupin snack 1 6
Table 9: Concentration of total alkaloids and identiﬁed quinolizidine alkaloids in lupin-based food
products as reported by Resta et al. (2008)
Food
Concentration of
total alkaloids
(mg/kg)(a)
Quinolizidine alkaloids found
Meat imitates (tofu, steak, morsels,
cutlet, steak with mushrooms)
15–56 Albine, lupanine, 13a-angeloyloxylupanine, 13a-OH-
lupanine
Pasta (with lupin concentrate) 2.7 Lupanine
Lupin rusk (with lupin ﬂour) 4.2 Lupanine
‘Lupini beans’ < LOQ(b)
LOQ: Limit of quantiﬁcation.
(a): Estimated as sum of quinolizidine alkaloids.
(b): Given in the paper as 2 mg/kg for lupanine in ﬂour.
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distribution in plant parts other than seeds for the 11 relevant QAs. The CONTAM Panel noted that in
general the same QAs are found in seeds and leaves while the distribution of the individual QAs can
differ.
3.2.3. Factors inﬂuencing the concentration of quinolizidine alkaloids/Food and
feed processing
3.2.3.1. Debittering of lupin seeds
BL seeds need to be debittered before consumption. The traditional house-hold methods include
soaking in cold water, cooking and washing and this process lasts several days (Smith, 1987; Carvajal-
Larenas et al., 2014). In Ecuador, the National Agricultural Research Centre has proposed a
commercial debittering process which consists of soaking the seeds of L. mutabilis for 14–16 h, boiling
for 40 min and then washing at 40°C (Carvajal-Larenas et al., 2013).
Carvajal-Larenas et al. (2016) publised an overview paper about debittering of L. mutabilis seeds.
In a study at commercial scale, 93% of the alkaloid content was removed after treating lupin seeds
with warm water (40°C) for 90 h. A process where the seeds were soaked for 14–20 h (15°C), boiled
for 1/2–2 h and then washed for 96–120 h, removed 97% of the alkaloid content while cooking for 1/2
h and extraction with cold water for 72 h removed 95% of the alkaloid content. Also, debittering with
other solutions than water has been described e.g. treatment with alkaline solutions (Carvajal-Larenas
et al., 2016). According to the authors, water treatment is the only known process that is applied at
commercial scale and the CONTAM Panel also considers that water treatment is the only process of
interest for debittering at home.
Jimenez-Martinez et al. have published several papers (2001, 2004, 2009, 2010) about debittering
of seeds of a wild variety of L. campestris. The seeds were boiled for 6 h with water or in an acid or
alkaline solution. The liquid was changed every 20 min. Water treatment including boiling removed
between 89% and 99% of the original QA content.
Biological processes can also be used to debitter lupin seeds and this includes bacterial
fermentation, fungal fermentation and germination. According to Carvajal-Larenas et al. (2016),
bacterial fermentation reduced the concentration of alkaloids by < 50%, fungal fermentations reduced
the concentration with 50–91% while germination caused a reduction of 78%.
Gefrom et al. (2013) have studied the effect of ensiling on the concentration of QAs in crushed
lupin seeds. A sweet (Bora) and a bitter (Azuro) cultivar of L. angustifolius were harvested at 65% dry
matter content and four different kinds of model silages were prepared. The samples were stored at
20°C for 90 days and analysis was performed by GC–MS. The authors concluded that ensiling had no
signiﬁcant effect on the QA content.
Chilomer et al. (2010) investigated the inﬂuence of germination on the total amount of QAs as well
as on single QAs. Seeds of L. angustifolius (cv. Graf) and L. luteus (cv. Lord) were soaked and washed
before germination that was conducted in darkness for 48, 72 and 96 h at 15°C or 24°C. The samples
were analysed by GC-NPD. For both lupin varieties, the concentration decreased with time and
temperature (up to 30%), so the lowest concentration was obtained after 4 days at 24°C. Also, the
concentration of the different QAs differed with time and temperature.
De Cortes Sanchez et al. (2005) studied the change in QA concentration during the germination of
seeds from a wild variety of L. campestris from Mexico as well as bitter seeds from L. albus L. (LO-
3,923) and L. angustifolius (1,413) from Spain. Samples were taken each day until day 9 of the
germination. Determination of QAs was performed by GC-NPD and the single substances were
identiﬁed by GC–MS. For L. angustifolius, the total alkaloid concentration was the same at day 0 and
day 9, while in seeds from L. albus and L. campestris the ﬁnal concentrations were higher at day 9
than on day 0. Also, here the concentrations of the different QAs differ with time and the results for
the individual QAs from day 0 are shown in Appendix D, Tables D.1 and D.2 for L. albus and
L. angustifolius. The results from this study are not in accordance with the results from the paper by
Chilomer et al. (2010).
A completely different process was developed by Haddad et al. (2006). Seeds of L. albus and
L. mutabilis, with alkaloid concentrations of, respectively, 250 mg/kg DM and 55,000 mg/kg DM, were
cracked, dehulled, moistened and treated by instantaneous controlled pressure drop technology (DIC),
soaked for 2 h in water, and dried to a water content of 5%. The total alkaloid concentration was
determined by GC-NPD. The total alkaloid concentration decreased by 60–70%.
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3.2.3.2. Changes during production of processed food
Erbas (2010) debittered seeds from a bitter variety of L. albus grown in Turkey to produce a lupin
snack. The process consisted of cleaning, boiling, debittering and salting. After boiling the seeds were
debittered using three different processes, but only one result (mean of the three processes) was
given. The alkaloids were determined by GC-FID with sparteine as internal standard. The total amount
of alkaloids decreased from 14,400 mg/kg DM in the seeds to 6,200 mg/kg DM after boiling, to
10 mg/kg DM after debittering and below the LOQ in the snack (LOQ: ≤ 7 mg/kg). In the raw seeds
besides lupanine (87%) also multiﬂorine (11%) and small amounts of sparteine, albine and
a-isolupanine were identiﬁed (see Appendix D, Tables D.1–D.4), but during the debittering process
the QAs were removed gradually starting with sparteine after 12 h and ending with a-isolupanine after
120 h.
Resta et al. (2008) investigated the changes in QA concentration due to food preparation. In total
16 samples of lupin protein isolates (LPI); food ingredient) and model foods were prepared (see
Table 10) and analysed by GC–MS. In the protein isolates, only lupanine was identiﬁed. For the other
processed foods, made using lupin ﬂour, the authors report that the same QAs as in the seeds were
found (see Appendix D, Tables D.1–D.4) but no amounts were given for the individual QAs. As can be
seen from Table 10, the process from seeds to protein isolate is efﬁcient in reducing QAs.
Based on the available information, the CONTAM Panel concluded that between 88 and 97% of the
QAs present in seeds are removed by water treatment and boiling. Studies of the inﬂuence of
germination on the QA concentrations show no clear effect.
3.3. Exposure assessment
It should be noted that when reference is made to lupins in this section, as well as in the Annexes,
this should be understood as lupin seeds.
3.3.1. Current dietary exposure assessment for humans
Given the limited amount of data available in the EFSA occurrence database for most food groups,
as well as limited data on consumption of lupin seeds and lupin-based foods, the CONTAM
Panel decided to calculate acute dietary exposure for some speciﬁc food groups under speciﬁc
scenarios.
3.3.1.1. Occurrence data and scenarios deﬁnition
Occurrence levels used to calculate acute dietary exposure in the different scenarios are
summarised in Table 11.
Scenario 1 assumes that a consumer purchased lupin seeds and prepared them at home, upon no
application of a debittering procedure or of a completely ineffective debittering procedure. In this
scenario, it is therefore assumed that no reduction of the QA content is obtained. Occurrence results
on samples reported in the category ‘Lupins (dry) and similar-’ (n = 34) were used. However, based on
Table 10: Total alkaloid concentrations in seeds, protein isolates and lupin-based processed foods
(Resta et al., 2008)
Food Total alkaloids (mg/kg) Food Total alkaloids (mg/kg)
L. albus (cv. Ares) L. albus (cv. Typtop)
Seeds 146 Seeds 1,247
Beverage, 8.8% ﬂour 20.7 LPI-E(a) 21.4
Snacks, 40% ﬂour (N = 3) 78.5–86.5 Spaghetti, 5% LPI-E < LOQ
Biscuit, 7.5% ﬂour 50.5 Spaghetti, 10% LPI-E < LOQ
Biscuit, 15% ﬂour 83.9 LPI-M(a) 66.5
LPI-E(a) 9.0 LPI-F(a) 8.45
Biscuit, 6.75% LPI-E < LOQ L. angustifolius (cv. Boregine)
Biscuit, 13.5% LPI-E 3.1 Seeds 1,107
LPI-F(a) 37.0 LPI-E(a) 34.1
LOQ: limit of quantiﬁcation; LPI: lupin protein isolate.
(a): Different preparations of lupin protein isolates.
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the information provided, it was not possible to discriminate between sweet and bitter varieties. The
CONTAM Panel decided to calculate dietary exposure using both the mean occurrence value of TotQA
(429 mg/kg) and the highest reliable percentile (P90) to represent exposure from lupin seeds with
average and high QA content.
In scenario 2, it is assumed that the lupin seeds are debittered by soaking and boiling in water and
a reduction factor of 89% to the concentration of TotQA is applied (see Section 3.2.3). Occurrence
results reported for ‘Lupins (dry) and similar-’ (n = 34) were used but upon application of an 89%
reduction factor. As for scenario 1, exposure was calculated both for mean and P90 to represent
exposure from lupin seeds with average and high QA content.
In scenario 3, levels of TotQA in ‘Lupin seeds as canned or jarred legumes’ were used. It is
assumed that the consumer buys pre-prepared lupin seeds such as the one in brine. In this case, the
number of samples (n = 8) was insufﬁcient to calculate a reliable percentile, therefore only the mean
TotQA at the LB and UB was used for exposure calculations.
Finally, scenario 4 was elaborated to simulate the exposure to QAs via the consumption of meat
imitates. The mean TotQA concentration was used to calculated dietary exposure at the LB and UB.
Only 8 samples were available and therefore also it was not possible to calculate a high percentile.
The CONTAM Panel considered the possibility to develop scenarios reﬂecting the exposure to QAs
from lupin ﬂour as an ingredient in bread and pasta and from coffee imitates. However, the number of
samples on lupin-based bread, pasta and coffee imitates was too limited to calculate dietary exposure.
In addition, the uncertainty regarding he inclusion percentage of lupin ﬂour in bread and pasta was
too high to develop a scenario.
3.3.1.2. Consumption
The CONTAM Panel estimated acute dietary exposure to TotQA as deﬁned in Section 2.2.2 from
lupin and lupin-based products.
The latest version of the EFSA Comprehensive Database (Annex A.1) was browsed for all the
FoodEx2 categories containing lupins as a main constituent or as an ingredient. The consumption of
‘Lupins seeds without pods’ was reported only in a limited number of consumption days (63 for adults
and less than 10 subjects in all the other population groups) in the Portuguese population.
Consumption statistics in grams per day and grams per body weight per day are reported in
Annex C.1. Mean and the high percentile (as the 95th) of acute consumption (in one day) were
calculated for adults only as 0.8 and 1.8 g/kg bw per day, corresponding to 57 and 142 g/day of lupin
seeds, respectively. It is noticeable that the portion size used by the BfR (2017a) to carry out the
exposure assessment on the German population was 100 g and therefore can be considered in line
with data extracted from the EFSA Consumption Database. Mean and high consumption values in
adults for ‘Lupin seeds without pods’ were used for scenarios 1, 2 and 3.
The CONTAM Panel used the consumption of ‘Meat imitates’ retrieved in the EFSA Comprehensive
Database as a proxy for meat imitates based on lupin seeds. The consumption across different
population groups in 17 Member States is reported in Annex C.2. The largest consumers at the 95th
percentile (based on more than 60 days of consumption) were the Swedish adults with a consumption
of 6.9 g/kg bw per day corresponding to 330 g/day. Individual consumption data of ‘Meat imitates’
retrieved in EFSA comprehensive database were used for Scenario 4.
Table 11: Description of the scenarios and occurrence values used in this opinion to assess acute
exposure to TotQAs
Scenario
Mean TotQA
concentration
(mg/kg)(b)
High TotQA
concentration
(mg/kg)
Consumption data used in this
scenario
1 Consumption of lupin seeds
with no reduction of QA
content
429 958 (P90) P95 consumption in adults (Portugal only)
of ‘Lupins (without pods)’
2 Consumption of lupin
seeds with 89% reduction
of QA content
47 105 (P90) P95 consumption in adults (Portugal only)
of ‘Lupins (without pods)’
3 Consumption of jarred lupin
seeds in brine
25–26 NA(a) P95 consumption in adults (Portugal only)
of ‘Lupins (without pods)’
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3.3.1.3. Results
Results of the current dietary exposure assessment for humans are reported in Annex C, and P95
dietary exposures are summarised in Table 12.
Under scenario 1, the 95th percentile of acute exposure was 761 lg/kg bw based on lupin seeds
with average content of TotQA and 1,700 lg/kg bw for lupin seeds with high content of TotQA. Upon
application of a debittering procedure (scenario 2) leading to an 89% reduction of exposure, the P95
acute exposure was 84 and 187 lg/kg bw for lupin seeds with average and high content of TotQA,
respectively. Under scenario 3, where canned lupin seeds were considered as source of acute exposure
to QAs, the mean exposure was 20–21 lg/kg bw and the P95 44-46 lg/kg bw (LB–UB). It should be
noted that these scenarios reﬂect the exposure of adults, but also other age groups may consume
lupin seeds. However, due to limitations in the consumption data, no scenarios for other age groups,
speciﬁcally children, were calculated.
In addition, according to scenario 4, consumption of lupin-based meat imitates (Annex C.2), the
P95 highest exposure was assessed to be 194–228 lg/kg bw (LB–UB) for adults from Sweden.
3.3.2. Current dietary exposure assessment for farm animals, horses and
companion animals
Although the Lupinus genus is a widely diverse family of plants, only four species are commercially
cultivated as grain legume crops (L. angustifolius, L. luteus, L. albus and L. mutabilis). Of these, seeds
(grains) of L. angustifolius are the most commonly used as feeds for livestock (Frick et al., 2017).
Lupins are grown both for their seeds, which are used in food and feed, and for forage. Lupin
seeds contain high levels of protein and oil and may be used to replace soybean meal and other
oilseed meals in the diets of livestock and aquaculture species (Lucas et al., 2015). White lupin seeds
are predominantly used as feed for livestock and are normally ﬂaked or milled before feeding. The
crop may also be grazed or cut for ensiling or used as a green manure. However, no occurrence data
are available for QAs in whole crop or ensiled lupins, and therefore, no exposure from these feeds has
been possible.
Scenario
Mean TotQA
concentration
(mg/kg)(b)
High TotQA
concentration
(mg/kg)
Consumption data used in this
scenario
4 Consumption of lupin-based
meat imitates
28-33 NA(a) Individual consumption of ‘meat imitates’
from the EFSA comprehensive database
NA: not applicable; P90/95: 90/95th percentile; TotQA: total quinolizidine alkaloids.
(a): Not enough observations to calculate a reliable percentile.
(b): In case lower bound (LB) and upper bound (UB) values were identical, only one value is shown, otherwise the LB-UB range
is shown.
Table 12: High exposure (P95) to TotQA upon consumption of lupin seeds or lupin-based products
under the ﬁve exposure scenarios
Scenario P95 acute exposure (lg/kg bw)
1 Consumption of lupin seeds with no reduction of QA content
(based on mean QA content)
761(a)
1 Consumption of lupin seeds with no reduction of QA content
(based on high QA content)
1,700(a)
2 Consumption of lupin seeds with 89% reduction of QA
content (based on mean QA content)
84(a)
2 Consumption of lupin seeds with 89% reduction of QA
content (based on high QA content)
187(a)
3 Consumption of jarred lupin seeds in brine 44–46 (LB–UB)(a)
4 Consumption of lupin-based meat imitates 194–228 (LB–UB)(b)
LB: lower bound; QA: quinolizidine alkaloids; P95: 95th percentile; UB: upper bound.
(a): Based on consumption data from the Portuguese adult population only.
(b): Based on the most exposed population at the P95 (Adults from Sweden) according to the present assessment (see
Annex C.2).
Quinolizidine alkaloids in feed and food
www.efsa.europa.eu/efsajournal 56 EFSA Journal 2019;17(11):5860
Lupin seeds contain an outer coat (or hull) which may account for 20–30% of the weight of the
seed. For ruminants, the whole seed may be fed, although the seeds are usually ground before
feeding to high yielding dairy cows. For non-ruminant species and ﬁsh, the outer coat is removed to
improve digestibility; nevertheless, inclusion rates of kernel meal into pig and poultry diets are still
limited by the presence of non-starch polysaccharides in the kernel.
In common with other legume seeds, lupin seeds are deﬁcient in sulfur-containing amino acids,
which also restricts their use for non-ruminant livestock, ﬁsh and companion animal, although this
deﬁciency may be overcome by supplementation with synthetic amino acids in non-organic diets.
In the absence of any internationally recognised limits on the inclusion rates of lupin seed meal in
the diets of livestock and ﬁsh, the CONTAM Panel have used maximum inclusion levels recommended
in a number of Scientiﬁc publications, details of which are given in Appendix G.2. Similarly,
assumptions made for feed intake and physiological state of individual species are given in
Appendix G.1. These data, together with the levels of the QAs in lupin seeds (Table 7), have been
used to estimate daily exposure to QAs by the individual animal species. In doing so, the
Panel acknowledges that the estimated exposure levels are likely to represent the maximum – or
worst-case – exposure, rather than ‘typical’ exposures.
Estimates of mean LB dietary exposure for farm animals, horses and companion animals to TotQAs
based on occurrence data for lupin seeds (see Table 7) are presented in Table 13. The UB dietary
exposure is very similar to the LB, and differences between the mean and P75 dietary exposure were
also generally small. These exposures are shown in Appendix G.
3.4. Risk characterisation
It should be noted that this risk assessment relates to lupin seeds and lupin-derived products with
a QA proﬁle comparable with that of the submitted data (see Section 3.2.1) and should not be
extrapolated to lupin seeds with a different QA proﬁle (e.g. lupin seeds from species and/or varieties
high in sparteine).
3.4.1. Human health risk characterisation
The available data were considered insufﬁcient to propose HBGVs and instead an MOE approach is
used. The CONTAM Panel selected the lowest described single oral antiarrhythmic dose of 160 lg
sparteine/kg bw in humans as reference point to characterise the risk following acute exposure. No
Table 13: Estimates of mean lower bound exposure (mg/kg bw per day) to TotQAs(a) from lupin
seeds for farm animals, horses and companion animals
Farm animal All lupin seeds (n = 54) L. angustifolius (n = 32) L. albus (n = 13)
Dairy: high yielding 1.00 1.21 0.88
Beef: fattening 0.35 0.43 0.31
Sheep: lactating 1.03 1.25 0.90
Goats: lactating 3.34 4.04 2.92
Goats: fattening 1.18 1.43 1.03
Horses 0.39 0.48 0.34
Pig starter 2.95 3.56 2.58
Pig ﬁnisher 2.95 3.56 2.58
Lactating sow 2.36 2.85 2.06
Chickens for fattening 3.54 4.28 3.10
Laying hens 3.54 4.28 3.10
Turkeys for fattening 1.97 2.38 1.72
Ducks for fattening 2.75 3.33 2.41
Salmonids 1.57 1.90 1.38
Cats 0.59 0.71 0.52
Dogs 0.57 0.68 0.50
Rabbits 4.43 5.35 3.87
bw: body weight; TotQA: total quinolizidine alkaloids.
(a): Calculated as the sum of lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine, a-isolupanine.
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reference point for chronic exposure could be identiﬁed due to the limited data available. The CONTAM
Panel decided to calculate acute dietary exposure only for a few food groups under four speciﬁc
scenarios because of the limited occurrence and consumption data. Consequently, no full risk
characterisation was possible. Certain lupin-based foods such as pasta, bread and coffee imitates could
not be included and exposure of children was not taken into consideration for scenarios 1, 2 and 3. In
addition, insufﬁcient occurrence data were available for scenario 3 and 4 to allow calculation of the
acute dietary exposure based on the highest reliable percentile for the occurrence and only the mean
occurrence value was used.
There is uncertainty linked to the reference point of 160 lg sparteine/kg bw (see Section 3.5.4).
This reference point for QAs is based on the effects of sparteine which is the most potent QA with
respect to toxicity. However, sparteine occurs only in trace amounts according to the data submitted to
EFSA and, according to clinical experience, doses 7.5–10 times higher than the reference point ensure
a reliable antiarrhythmic effect. Therefore, the CONTAM Panel concluded that MOEs > 1 do not
indicate a health concern.
Dietary exposure to QAs from lupin seed consumption was calculated using 3 scenarios for adults
only (Table 12). Comparison of this dietary exposure to the reference point of 160 lg/kg bw per day,
results in MOE values that are presented in Table 14. A ﬁrst scenario, assuming that a consumer is
purchasing dry lupin seeds and does not debitter the seeds, resulted in MOE values below 1. The
calculated exposures for scenario 1 are within the dose-range reported for sparteine to have
therapeutic antiarrhythmic effects, or a possible oxytocic effect on the pregnant uterus. The calculated
MOEs for scenario 1 indicate that lack of debittering may result in a risk for the consumer. It was
noted that calculated exposure may reach nearly 20% of the doses of total alkaloids that have been
reported to be lethal in children.
In scenario 2, it was assumed that the seeds are debittered and a reduction factor of 89% was
applied. The calculated MOEs were 0.9 (high QA concentration) and 1.9 (average QA concentration).
For the consumption of lupin seeds with a high QA concentration that are debittered, the MOE is
below 1, which may indicate a health concern.
In scenario 3, dietary exposure to QAs from ready-to-eat lupin seeds was calculated and the
corresponding MOE was about 3.5. Due to the low number of samples for this scenario, no calculation
could be made of dietary exposure following the consumption of lupin seeds high in QA content.
In scenario 4, dietary exposure from lupin-based meat imitates, was calculated and the MOE value
was 0.8–0.7 (Table 14). However, it should be noted that the number of samples is small.
3.4.2. Animal health risk characterisation
Dietary exposure to QAs from lupin seeds was calculated for different livestock species (Table 13).
In the absence of any feed industry data on levels of lupin seeds in livestock feeds in the EU, the
CONTAM Panel has used maximum recommended inclusion levels (See Appendix G). Therefore, levels
Table 14: Margin of exposure (MOE) values for acute effects from consumption of lupin seeds or
lupin-based products under the four exposure scenarios
Scenario
P95 exposure
(lg TotQA/kg bw
per day)
MOE calculated from
P95 acute exposure
1 Consumption of lupin seeds with no reduction
(Mean QA content)
761(a) 0.2(a)
1 Consumption of lupin seeds with no reduction
(High QA content)
1,700(a) 0.1(a)
2 Consumption of lupin seeds with 89% reduction
(Mean QA content)
84(a) 1.9(a)
2 Consumption of lupin seeds with 89% reduction
(High QA content)
187(a) 0.9(a)
3 Consumption of jarred lupin seeds in brine 44–46 (LB-UB)(a) 3.6–3.5 (LB-UB)(a)
4 Consumption of lupin-based meat imitates 194–228 (LB-UB)(b) 0.8–0.7 (LB-UB)(b)
LB: lower bound; P95: 95th percentile; QA: quinolizidine alkaloids; UB: upper bound.
(a): Based on Portuguese adult population only.
(b): Based on the most exposed population at the P95 (Adults from Sweden) according to the present assessment.
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of exposure calculated in this opinion represent worst-case scenarios.38 It should be mentioned that
insufﬁcient data on levels of QAs in lupin seeds were available to allow P95 estimates of exposure to
be made. Instead P75 estimates of exposure were calculated, but since these were broadly similar to
the mean dietary exposure, they have not been included in the risk characterisation. Furthermore, no
data were available to estimate potential exposure to QAs from forage lupins (fresh or conserved)
consumed by ruminants.
For salmonids, the CONTAM Panel applied a group approach and used a NOAEL of 1 mg/kg bw per
day for the relevant QAs in this opinion (see Section 3.1.6). The mean dietary exposure of salmonids
to TotQA was 1.6 mg/kg bw per day, which is above the NOAEL but below the LOAEL of 2.5 mg/kg bw
per day. The CONTAM Panel considers the risk for adverse effects in salmonids to be low.
For the other species, the available database on adverse effects was too limited to identify overall
NOAEL/LOAELs. Instead, as an alternative approach, the CONTAM Panel identiﬁed doses of QAs
present in seeds from L. luteus, L. albus and L. angustifolius that can be tolerated with respect to
zootechnical performance. However, such a dose is only applicable to lupin seeds with similar QA
composition as used in the study from which the dose was derived, and does not allow a full
characterisation of the risk. For horses and companion animals, no reliable data ware identiﬁed that
allowed the identiﬁcation of such doses.
For cattle, 50 mg/kg bw per day was identiﬁed as a dose of the sum of lupanine and 13a-OH-
lupanine present in seeds from L. albus that can be tolerated. The mean dietary exposure of cattle to
TotQAs from L. albus ranges from 0.3 to 0.9 mg/kg bw per day, which is well below the tolerated
dose.
The mean dietary exposure of pigs to TotQAs in seeds from L. angustifolius ranged from 2.9 to
3.6 mg/kg bw per day, which is within the dose range of 1-10 mg/kg bw per day that can be tolerated
by pigs.
For chickens, 1 mg/kg bw per day was identiﬁed as a dose of lupin alkaloids present in seeds from
L. albus that can be tolerated. The mean dietary exposure of chickens to TotQAs from L. albus is
3.1 mg/kg bw per day, which is higher than the tolerated dose. For Japanese quails, a tolerated dose
of 826 mg/kg bw per day was identiﬁed but no estimation of dietary exposure was possible for this
species.
The mean dietary exposure of rabbits to TotQAs in seeds from L. albus was 3.9 mg/kg bw per day,
which is well below the dose of 30 mg/kg bw per day that can be tolerated by rabbits.
3.5. Uncertainty analysis
The evaluation of the inherent uncertainties in the assessment of exposure to QAs in lupin seeds
and lupin-based food has been performed following the guidance of the Opinion of the Scientiﬁc
Committee related to Uncertainties in Dietary Exposure Assessment (EFSA, 2007). In addition, the
report on ‘Characterizing and Communicating Uncertainty in Exposure Assessment’ has been
considered (WHO/IPCS, 2008). According to the guidance provided by the EFSA opinion (2007) the
following sources of uncertainties have been considered: Assessment objectives, exposure scenario,
exposure model, and model input (parameters).
3.5.1. Assessment objectives
The objectives of the assessment were clearly speciﬁed in the terms of reference.
3.5.2. Exposure scenario/exposure model
Due to the scarce amount of data on QAs available in the EFSA Database and in the literature, the
ﬁnal data set on occurrence of QAs in food and feed was composed of data from very few samples.
The QA proﬁle and content in seeds can largely differ between species, cultivar, crop management and
climate conditions. The occurrence data were received from 2 data providers and the
representativeness of the data for the whole of Europe is uncertain.
Assuming a reduction of QAs by 89% as a result of debittering by water treatment and boiling
represents a source of uncertainty because the obtained reduction is variable depending on how the
process is carried out. It should be noted that no standardised method for debittering is available and
the deviation from the described protocols may result in lower reductions.
38 It should be noted that some authors recommend higher inclusion rates than used in this Opinion.
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Limited consumption data on lupin seeds were available. Only for adults from one country a
sufﬁcient number of consumption days was available to calculate acute dietary exposure. On the
contrary, no sufﬁciently reliable consumption data of lupin seeds were available for the other age
groups such as children. Therefore, the exposure and consequently the risk could not be assessed for
these groups under scenarios 1, 2 and 3.
When considering scenario 4, no data on consumption of lupin-based meat imitates were present in
the EFSA Comprehensive Database; therefore, consumption of ‘meat imitates’ was considered as a
proxy of those and this may represent a source of overestimation.
For the exposure of farm animals, horses and companion animals, estimates were based on
maximum recommended levels of inclusion of lupin seed meals in feed rations. In practice, however,
inclusion rates will vary considerably, being inﬂuenced principally by the cost and availability of the
lupin seeds relative to other feeds. This and the considerable variability that exists between feeding
systems used for farm animals in Europe add to the uncertainty of animal exposure.
Levels of QAs in lupin seeds used to estimate exposure were derived from whole seeds, but both
whole and dehulled seeds are used for food and feed. It has been assumed that levels and proportions
of QAs in the seed coat and the kernel are similar, but if this is not the case then this assumption could
lead to over- or under-estimation of exposure.
3.5.3. Model input (parameters)
Currently, no ofﬁcial standard methods are available for the analysis of QAs in foods. Analytical
results used for the exposure assessment were therefore obtained using different analytical methods
and varying LOQ/LODs. The difference between LB and UB exposure estimates for TotQA was limited,
indicating that the uncertainty due to left-censored data is limited.
3.5.4. Other uncertainties
Studies in experimental animals
The acute toxicity of puriﬁed QAs has been investigated in experimental animals. Acute toxicity
studies indicate that rats are less susceptible than mice or guinea pigs. All repeated-dose toxicity data
are conﬁned to rats. Repeated-dose studies have been performed using extracts from different Lupinus
species, often containing different combinations of various QAs. Additional uncertainties in the
interpretation of these studies arise from differences in the sources of QAs (ﬂour versus seed extracts),
cultivars, presence of lupin alkaloids other than QAs relevant for this opinion and the control diets used
for the comparison.
Genotoxicity assays were performed with puriﬁed lupanine and sparteine as well as with L. termis
extracts. While negative results were obtained for lupanine in a battery of assays, the data on
sparteine are too limited to conclude regarding genotoxicity.
Observations in humans and hazard characterisation related to human health
Information on acute toxicity in humans is uncertain, as only sparse data were available from
reports of poisoning cases with lupin seeds. The outcomes vary from fatal to less severe symptoms.
Available reports do not allow to conclude on differences in toxicity of individual QAs or speciﬁc QA
mixtures involved and on differences in the toxicity of seeds from different lupin species.
The reference point of 0.16 mg QA/kg bw identiﬁed by the Panel is derived by considering 20 mg
of sparteine sulfate as the lowest single oral dose associated with pharmacological activity with respect
to the endpoint of antiarrhythmic action. Uncertainty in the value of this reference point includes that
information is missing (i) no information regarding the basis for this value, which was taken from old
pharmacological reference literature, is available (ii) to which extent adverse effects may occur below
the lowest-observed-effect-level (LOEL), (iii) where to allocate a NOEL which is covering all known
pharmacological activities including the effects on the electrical conductivity in the heart and also the
oxytocic (uterotonic) action on the pregnant uterus. Furthermore, differences in the individual
sensitivity to sparteine due to CYP2D6 genetic polymorphism are difﬁcult to be quantiﬁed and it is not
known whether this polymorphism may affect the sensitivity to QAs other than sparteine.
In the hazard characterisation of the QAs, the principle of dose addition was used and a similar
potency was assigned to all QAs relevant for this opinion which is a conservative approach considering
that sparteine is the most potent QA in terms of toxicity. As the database on relative potencies is
limited and there is no information on combined effects of exposure to multiple QAs vs exposure to
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single QAs, there is uncertainty in using dose-additivity with similar potencies in the hazard
characterisation. Whereas it is acknowledged that interaction among QAs might occur both with regard
to toxicokinetics and -dynamics, the CONTAM Panel considers it likely that grouping the QAs would
result in an overestimation rather than an underestimation of the combined QA hazard.
Studies in farm animals, horses and companion animals and hazard characterisation
related to animal health
Only sparse data are available on the kinetics of lupin QAs in farm animals, horses and companion
animals. The information is limited to ruminants and pigs and no relevant studies have been
performed with pure alkaloids.
Except for poultry and pigs, there is no information concerning the acute toxicity of QAs in livestock
species. For repeated-dose exposure, no relevant toxicity studies dealing with pure QAs could be
identiﬁed, except for salmonids. In the large majority of toxicity studies, only endpoints related to
zootechnical performances have been taken into consideration. Most studies used lupin seeds as
source of QAs in the diet and do not report the QAs present in the diet or their relative contribution to
the total QA concentration. Such studies do not allow identiﬁcation of NOAEL/LOAELs and therefore
hazard characterisation was not possible for horses, companion animals and farm animals, with the
exception of salmonids. Instead, as an alternative approach, the CONTAM Panel identiﬁed doses of
QAs present in seeds from L. luteus, L. albus and L. angustifolius that can be tolerated with respect to
zootechnical performance. Because of the wide species- and cultivar-related variation in total and
speciﬁc QA content of lupin seeds, the calculated tolerated doses could not be extrapolated to all lupin
species and cultivars.
For salmonids, similar NOAEL values were identiﬁed for lupinine and sparteine. In the absence of
data on other QAs, the CONTAM Panel used this NOAEL for a group approach to characterise the
hazard of the QAs relevant for this opinion and applied to all farmed salmonids. As for humans, the
CONTAM Panel considers it likely that this grouping approach would result in an overestimation rather
than an underestimation of the combined QA hazard.
3.5.5. Summary of uncertainties
In Table 15, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of QAs
in lupin seeds and lupin-derived products is substantial and due to the limited data on occurrence and
consumption, the risk characterisation is incomplete. Because the reference point for QAs used for
human risk assessment is based on the effects for sparteine, which is assumed to be the most potent
QA, the CONTAM Panel concluded that the risk is more likely to be overestimated than
Table 15: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of quinolizidine alkaloids in lupin seeds and lupin-derived products.
Sources of uncertainty Direction(a)
Very low number of food and feed samples available for exposure assessment +/
Extrapolation of occurrence data from 2 data providers to the whole of Europe +/
Application of a reduction factor of 89% for debittering +/
Limited consumption data of lupin seeds from one country and only for adults +/
Lack of consumption data on lupin-based foods +/
Lack of information regarding QA levels in the husk and the proportion of the husk to the kernel +/
Limited data on lupin seed consumption by farm and companion animals and horses in Europe +/
Uncertainty in the reference point: pharmacologically active dose level +/
Uncertainty in the reference point: use of sparteine as a representative for other QAs +
Uncertainty regarding the application of NOAEL/LOAELs for rainbow trout based on pure
compounds to salmonids exposed to QAs from lupin seeds
+/
QA: quinolizidine alkaloid; LOAEL: lowest-observed-adverse-effect level; NOAEL: no-observed-adverse-effect level.
(a): + = uncertainty with potential to cause over-estimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk.
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underestimated. Risk characterisation was not possible for farmed animals other than salmonids nor it
was possible for horses and companion animals.
4. Conclusions
4.1. Hazard identiﬁcation and characterisation
4.1.1. Toxicokinetics
• In humans and experimental animals, sparteine and lupanine are rapidly absorbed, widely
distributed and rapidly eliminated in urine mainly unchanged and as oxidised metabolites.
Sparteine CYP2D6-mediated oxidation in humans may be affected by defective CYP2D6 activity
occurring in about 5–10% of Caucasians due to genetic polymorphisms resulting in slow
sparteine elimination.
• In ruminants, there is extensive but slow absorption and slow elimination of lupanine and 5,6-
dehydrolupanine. In pigs, lupanine seems to be extensively absorbed and excreted in urine
mainly unmodiﬁed together with the metabolites isolupanine and OH-lupanine.
• There is no evidence of the formation of conjugated metabolites of sparteine and lupanine in
mammalian species.
• No information is available to assess transfer rates of QAs in food of animal origin; however,
based on indirect evidence possible transfer to milk should be considered.
4.1.2. Toxicity in laboratory animals
• Sparteine is approximately two- to three-fold more acutely toxic than lupanine both in mice
and guinea pigs. Mice appear to be more sensitive than rats to acute toxicity of lupanine. In
rats, the acute toxicity of lupanine and 13a-OH-lupanine is similar.
• Acute symptoms following oral administration of lupanine, 13a-OH-lupanine and sparteine are
similar in rats, mice and guinea pigs, with death resulting from respiratory failure and toxic
effects affecting the CNS.
• The identiﬁed repeated-dose toxicity studies could not be used for the evaluation of QA
toxicity.
• Several QAs were unable to bind or intercalate into DNA. Lupanine and extracts of L. termis
(main QA being lupanine) did not induce gene mutations in bacteria and in mammalian cells
in vitro or micronuclei in vivo. The data on sparteine are too limited to conclude regarding
genotoxicity.
4.1.3. Observations in humans
• Intoxication with lupin seeds do not occur frequently and rarely lead to a fatal outcome.
Reports suggest that children are more susceptible to intoxication with lupin alkaloids than
adults and that doses from 10 mg/kg bw onwards may be lethal for children. Typical
symptoms refer to the anticholinergic syndrome, are of neurological nature and may also affect
the digestive and/or cardiovascular systems.
• Intoxication have been associated with inadequate debittering of lupin seeds by consumers. No
case of poisoning has been identiﬁed which was attributed to consumption of industrially
produced lupin seed-based food.
• Sparteine was used therapeutically in the past for both its antiarrhythmic and oxytocic
properties in humans.
• In the treatment of cardiac arrhythmia, the recommended daily dosage for (-)-sparteine sulfate
ranged from 800 to 1,000 mg per day (equivalent to 6.4–8 mg sparteine/kg bw for a 70-kg
individual) for short-term use and from 400 to 500 mg/day (3.2–4 mg sparteine/kg bw) for
long-term therapy. Adverse effects of anticholinergic nature were reported at these therapeutic
doses. The lowest oral dose reported with antiarrhythmic effects was 20 mg (equivalent to
0.16 mg sparteine/kg bw).
• Sparteine sulfate may cause uterotonic (oxytocic) effects in pregnant women.
• Sparteine blocks the transmission of signals from the nerves to the muscles like curare, which
may lead to respiratory arrest and death. From a poisoning case, it is known that a dose of
30 mg of sparteine/kg bw was fatal to a young child.
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• No adverse effects were observed after administration of a single oral dose of 10 mg of
lupanine or 10 mg 13a-OH-lupanine (each equivalent to 0.14 mg/kg bw; body weight of
70 kg) to volunteers who were EMs or PMs.
4.1.4. Farm animals, horses and companion animals
• Field cases of pig poisoning by QAs are characterised by depression of feed intake and reduced
weight gain; severely affected animals show vomiting, recumbency, abortion and deaths
characterised by gastric torsion and gastro-intestinal bloat.
• LD50 values for sparteine and lupanine in poults conﬁrm the higher (two- to three-fold) toxicity
of the former observed in guinea pigs and mice.
• Most tolerance studies in food producing species were not performed with pure QAs and were
based only on lupin impact on zootechnical performances (feed intake, weight gain, milk and
egg production).
• For cattle, 50 mg/kg bw per day was identiﬁed as a tolerated dose for the sum of lupanine and
13a-OH-lupanine present in seeds from L. albus. No relevant studies were identiﬁed for sheep
and goats.
• For pigs, 1–10 and 1.5 mg/kg bw per day were identiﬁed as tolerated doses of lupin alkaloids
present in seeds from L. angustifolius and L. luteus, respectively.
• Based on zootechnical performance, 1 mg/kg bw per day was identiﬁed as a dose of lupin
alkaloids present in seeds from L. albus that can be tolerated by chickens. In one-day-old quail
chicks, 826 mg/kg bw was identiﬁed as a dose of lupin alkaloids present in seeds from L. albus
that can be tolerated (only dose tested).
• For rabbits, 30 mg/kg bw per day was identiﬁed as a tolerated dose of lupin alkaloids present
in seeds from L. albus.
• For rainbow trout a NOAEL of 1 mg/kg bw per day for lupinine and sparteine could be
calculated based on the reduction of feed intake and weight gain and the increase in
hepatosomatic index. The LOAEL was 2.5 mg/kg bw per day for lupinine and 3.5 mg/kg bw
per day for sparteine.
• No reliable data were identiﬁed for horses, cats or dogs.
4.1.5. Mode of action
• The most important mode of action of QAs in relation to acute toxicity is their binding to and
inhibitory action on AChRs producing an anticholinergic syndrome which may include paralysis
of respiratory muscles causing respiratory failure and death.
• The different QAs bind with different afﬁnity to the nAChRs or mAChRs.
• QAs may also cause, with different potencies, inhibition of voltage dependent ion channels,
e.g. sodium and potassium channels, and calcium activated potassium channels, effects
possibly underlying their antiarrhythmic effect.
• The uterotonic effects of sparteine appear to be mediated via an increased production of
prostaglandin F.
• For QAs relevant in this opinion, afﬁnities to AChRs appear to be in the same range or lower
than those of sparteine. Scarce data on other modes of action of some QAs indicate that these
QAs are similarly or less active than sparteine.
4.1.6. Possibilities for derivation of a HBGV
• Anticholinergic effects and effects on electric conductivity in the heart following acute exposure
to sparteine are considered to be the critical effects for human hazard characterisation. The
lowest described single oral antiarrhythmic dose of 0.16 mg sparteine/kg bw was selected as a
reference point to characterise the risk following acute exposure.
• Because of similar modes of action for QAs, the CONTAM Panel considers it appropriate to use
a group approach and apply the principle of dose-additivity with equal potencies of the QAs for
their combined effect.
• Overall, the available data on dose-effect relationships were considered insufﬁcient to propose
an HBGV and instead an MOE approach was used.
• No reference point could be identiﬁed to characterise the risk following chronic exposure.
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4.2. Occurrence and exposure
4.2.1. Food
• The highest mean concentrations of TotQA were found in ‘lupins (dry) and similar-’ (429 mg/kg)
and lupin-based coffee imitate (powder) (331 mg/kg). High concentrations of QAs in lupin-
based coffee imitates have also been reported in scientiﬁc literature.
• Lupanine was the most abundant QA in seeds from L. albus and L. angustifolius, followed by
13a-OH-lupanine (especially abundant in L. angustifolius) and angustifoline.
• Between 89% and 97% of the QAs present in seeds are removed by water treatment and
boiling. Studies of the inﬂuence of germination on the QA concentrations show no clear effect.
• Due to the limited occurrence and consumption data, the CONTAM Panel decided to calculate
acute dietary exposure only for a few food groups under speciﬁc scenarios.
• Three scenarios on dietary exposure of adults from lupin seeds were elaborated. The highest
exposure to TotQA from lupin seeds was calculated for a scenario in which no debittering of
the dry lupin seeds was performed, resulting in exposures up to 1,700 lg/kg bw per day.
Assuming a debittering step, resulting in a decrease of the TotQA by 89%, the P95 dietary
exposure ranges between 84 (based on average QA content) and 187 lg/kg bw per day
(based on high QA content). For a scenario based on ready-to-eat lupin seeds, the P95
exposure was 44–46 lg/kg bw per day.
• A scenario on lupin-based meat imitates showed P95 dietary exposures up to 194–228 lg/kg
bw per day (LB–UB).
4.2.2. Feed
• Analytical results from 11 samples of lupin seeds from L. angustifolius used as feed were
available with a mean TotQA concentration of 257 mg/kg. Due to the limited number of feed
samples available for the dietary exposure assessment, the data set was supplemented with
food samples.
• Lupanine and 13a-OH-lupanine accounted each for about 36% of the TotQA content in these
samples.
• Exposures to QAs by farm animals, horses and companion animals were estimated using
maximum recommended inclusion rates of lupin seeds in livestock diets and therefore are likely
to represent worst-case scenarios. In addition, insufﬁcient data on levels of QAs in lupin seeds
were available to allow P95 estimates of exposure to be made.
• In the category ‘Ruminants and horses’, the highest exposure was for lactating goats (3.3 mg/kg
bw per day). For pigs and poultry, the highest exposure was for fattening chickens and laying
hens (3.5 mg/kg bw per day). For salmonids, the exposure was 1.6 mg/kg bw per day and for
rabbits 4.4 mg/kg bw per day. For cats and dogs, the exposure was 0.6 mg/kg bw per day.
4.3. Risk characterisation
• This risk assessment relates to lupin seeds and lupin-derived products with a QA proﬁle
comparable with that of the submitted data and should not be extrapolated to lupin seeds with
a different QA proﬁle (e.g. lupin seeds from species and/or varieties high in sparteine).
4.3.1. Human health
• Due to the limited occurrence and consumption data, no full risk characterisation was possible.
The risk from certain lupin-based foods such as pasta, bread and coffee imitates could not be
assessed, nor the risk to children from lupin seed consumption.
• There is uncertainty linked to the reference point of 160 lg sparteine/kg bw. This reference
point for QAs is based on the effects of sparteine which is the most potent QA with respect to
toxicity. However, sparteine occurs only in trace amounts according to the data submitted to
EFSA and, according to clinical experience, doses 7.5–10 times higher than the reference
point ensure a reliable antiarrhythmic effect. Therefore, the CONTAM Panel concluded that
MOEs > 1 do not indicate a health concern.
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• In the event that lupin seeds were not debittered and for a scenario reﬂecting dietary
exposure from lupin-based meat imitates, the CONTAM Panel calculated MOE values in the
range of 0.1–0.8. These MOEs may indicate a concern.
• In a scenario applying a reduction factor for debittering, the calculated MOEs are of lower
concern (0.9; high QA concentration) or no concern (1.9; average QA concentration).
• MOEs ≥ 1 were calculated for ready-to-eat lupin seeds that had an average QA content.
4.3.2. Animal health
• For salmonids, the CONTAM Panel applied a group approach and used a NOAEL of 1 mg/kg bw
per day for the relevant QAs in this opinion. The mean dietary exposure of salmonids is above
the NOAEL but below the LOAEL of 2.5 mg/kg bw per day. The CONTAM Panel considers the
risk for adverse effects in salmonids to be low.
• For the other species, the available database on adverse effects was too limited to identify
overall NOAEL/LOAELs. Instead, as an alternative approach, the CONTAM Panel identiﬁed
doses of QAs present in lupin seeds that can be tolerated with respect to zootechnical
performance. However, such a dose is only applicable to lupin seeds with similar QA
composition as used in the study from which the dose was derived and does not allow a full
characterisation of the risk.
• For cattle and rabbits, the mean dietary exposure is well below the tolerated dose.
• For pigs and chickens, the mean dietary exposure is in the same range as the dose that can be
tolerated.
5. Recommendations
• Further studies on ADME of QAs in humans and animal species are needed.
• There is a need for repeated-dose toxicity studies on the QAs considered in this opinion. This
also includes studies on relative potencies and combined actions of QAs as they occur in
mixtures in food and feed.
• There is a need for more data on the transfer of QAs from feed to food of animal origin.
• More information on consumption of lupin seeds and lupin-based food in the EU is needed.
• There is a need for more occurrence data on QAs in food and feed. In relation to unprocessed
lupin seeds, data on the efﬁciency of debittering at home are needed.
• Reference standards for QAs other than lupanine, lupinine and sparteine should become
available, as well as certiﬁed reference materials and international proﬁciency tests.
Documentation provided to EFSA
Data on the alkaloid content of lupin seeds. July 2019. Submitted by Inveja during the public
consultation. (see Section 2.1).
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Abbreviations
A Australian
ACh acetylcholine
AChE acetylcholinesterase
AChR acetylcholine receptor
ADME absorption, distribution, metabolism, and excretion
AE Australian extruded
ALT alanine transaminase
ANZFA Australia New Zealand Food Authority
AST aspartate transaminase
BchE butyrylcholinesterase
BfR Bundesinstitut f€ur Risikobewertung/German Federal Institute for Risk Assessment
BL bitter lupin
bw body weight
Cmax maximum plasma concentrations
CAS Chemical Abstracts Service
CNS central nervous system
CONTAM Panel The EFSA Panel on Contaminants in the Food Chain
COT Committee on Toxicity
CYP cytochrome P450
DCL detoxiﬁed crushed lupin seeds
DIC instant controlled pressure drop technology
DM dry matter
dw dry weight
DWL ground dehulled
EC50 half maximal effective concentration
EEC European Economic Community
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EI electron impact
EM Extensive metabolisers
FAO Food and Agriculture Organization
FDA US Food and Drug Administration
FEDIAF European Pet Food Industry Federation
FEEDAP Panel The EFSA Panel on Additives and Products or Substances used in Animal Feed in the
Food Chain
FID ﬂame ionisation detector
FMO ﬂavin monooxygenase
FSANZ Food Standards Australia New Zealand
GABA c-aminobutyric acid
GBL germinated blue lupin
GC gas chromatography
GC–IT/MS gas chromatography–ion trap/mass spectrometry
GC–MS gas chromatography–mass spectrometry
GC-NPD gas chromatography with nitrogen phosphorous detector
GYL germinated yellow lupin
Hb haemoglobin
HBGV Health-based guidance value
HCT haematocrit
HPLC high-performance liquid chromatography
I Italiano
IC50 half maximal inhibition concentration
ICL intact crushed lupin seeds
ICV intracerebroventricular
i.p. intraperitoneal
i.v. intravenous
Km Michaelis constant
LB lower bound
LC liquid chromatography
LC–MS liquid chromatography–mass spectrometry
LD lethal dose
LD0 maximal non-lethal dose
LD100 dose killing all the animals
LD50 dose killing 50% of the animals
LDC lysine decarboxylase
LOAEL lowest-observed-adverse -effect-level
LOD limit of detection
LOEL lowest-observed-effect-level
LOQ limit of quantiﬁcation
mAChR muscarinic acetylcholine receptor
MCHC mean corpuscular haemoglobin concentration
MCV mean cell volume
ML maximum level
MLD minimal lethal dose
MOE margin of exposure
MRT mean residence time
MS mass spectrometry
MW molecular weight
nAChR nicotinic acetylcholine receptor
ND not determined
NIST National Institute of Standards and Technology
NMDA N-methyl-D-aspartate
NOAEL no-observed-adverse-effect level
NOEL no-observed-effect level
NPD nitrogen-phosphorus detector
NRC National Research Council
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OECD Organisation for Economic Co-operation and Development
PM poor metabolisers
PO per os (by mouth)
P95 95th percentile
PTDI provisional tolerable daily intake
QA quinolizidine alkaloid
RBL raw blue lupin
RYL raw yellow lupin
SGOT serum glutamic-oxaloacetic transaminase
SGPT serum glutamic-pyruvate transaminase
SL sweet lupin
SMBL soaked micronised bitter lupin
SSD standard samples description
SSB Single-strand break
TD coefﬁcient of crude protein digestibility
TK toxicokinetic
TG triacylglycerol
TLC thin-layer chromatography
Tmax maximum plasma concentration
TotQAs Total QAs
TTM Traditional Turkish method
UB upper bound
UF uncertainty factor
UV ultraviolet
Vmax maximum velocity
WHO World Health Organization
WL ground whole
WW wet weight
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Appendix A – Major quinolizidine alkaloids present in Lupinus and related
genera from the Genisteae tribe
Compound Chemical structure
(-)-Lupinine
CAS No: 486-70-4
C10H19NO
MW: 169.268
LogP (est): 1.2
N
H
OH
(+)-Epilupinine
CAS No: 486-71-5
C10H19NO
MW: 169.268
LogP (est): 1.1 N
H
OH
(-)-Cytisine
Synonym: Baptitoxine, sophorine
CAS No: 485-35-8
C11H14N2O
MW: 190.246
LogP (est): 0.2
N
NH
O
(-)-N-Methylcytisine
Synonym: Caulophylline
CAS No: 486-86-2
C12H16N2O
MW: 204.273
LogP (est): 1.3
N
N
O
(-)-Albine
CAS No: 53915-26-7
C41H20N2O
MW: 232.327
LogP (est): 1.3
N
H NHO
2,3-Dehydrosparteine
Synonym: 2-Dehydrosparteine
CAS No: 67528-17-0
C15H24N2
MW: 232.364
LogP (est): 2.7
N
H
N
H
5,6-Dehydrosparteine
Synonym: 5-Dehydrosparteine
CAS No: 2130-67-8
C15H24N2
MW: 232.364
LogP (est): 2.5
N
N
H
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Compound Chemical structure
(-)-Angustifoline
Synonym: Jamaicensine
CAS No: 550-43-6
C14H22N2O
MW: 234.343
LogP (est): 1.4
N
H NH
H
O
Isoangustifoline
CAS No: 82189-28-4
C14H22N2O
MW: 234.343
LogP (est): 1.4 N
H NH
H
O
(-)-Sparteine
Synonym: Lupinidine
CAS No: 90-39-1
C15H26N2
MW: 234.387
LogP (est): 2.5
N
H N
H
(-)-a-Isosparteine
Synonym: Genisteine alkaloid
CAS No: 446-95-7
C15H26N2
MW: 234.387
LogP (est): 2.5
N
H N
H
(+)-Sparteine
Synonym: Pachycarpine
CAS No: 492-08-0
C15H26N2
MW: 234.387
LogP (est): 2.5
N
N
H
H
(-)-Anagyrine
Synonym: Monolupine, rhombinine
CAS No: 486-89-5
C15H20N2O
MW: 244.338
LogP (est): 1.6
N
N
H
O
(-)-Multiﬂorine
CAS No: 529-80-6
C15H22N2O
MW: 246.354
LogP (est): 1.5
N
H N
H
O
11,12-seco-12,13-Didehydromultiﬂorine
Synonym: N-Methylalbine
C15H22N2O
MW: 246.354
LogP (est): 1.7
N
H NO
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Compound Chemical structure
5,6-Didehydrolupanine
CAS No: 32101-29-4
C15H22N2O
MW: 246.354
LogP (est): 1.3
N
N
H
O
Tetrahydrorhombifoline
CAS No: 3382-84-1
C15H24N2O
MW: 248.370
LogP (est): 1.8
N
H N
O
(+)-Lupanine
Synonym: D-Lupanine, 2-oxosparteine
CAS No: 550-90-3
C15H24N2O
MW: 248.370
LogP (est): 1.6
N
H N
H
O
(+)-a-Isolupanine
Synonym: 11-Isolupanine
CAS No: 486-87-3
C15H24N2O
MW: 248.370
LogP (est): 1.6
N
H N
H
O
(-)-17-Oxosparteine
CAS No: 489-72-5
C15H22N2O
MW: 248.370
LogP (est): 1.7 N
H N
H
O
3b-OH-lupanine
Synonym: 4-OH-lupanine
CAS No: 129443-39-6
C15H24N2O2
MW: 264.369
LogP (est): 0.6
N
H N
H
O
OH
(+)-13a-OH-lupanine
Synonym: Jamaidine, luparine
CAS No: 15358-48-2
C15H24N2O2
MW: 264.369
LogP (est): 0.6
N
H N
H
O
OH
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Compound Chemical structure
3b,13a-diOH-lupanine
CAS No: 101512-24-7
C15H24N2O3
MW: 280.368
LogP (est): -0,4 N
H N
H
O
OH
OH
13a-Angeloyloxylupanine
CAS No: 72822-06-1
C20H30N2O3
MW: 346.471
LogP (est): 2.4 N
H N
H
O
O
O
13a-Tigloyloxylupanine
CAS No: 57943-34-7
C20H30N2O3
MW: 346.471
LogP (est): 2.4 N
H N
H
O
O
O
13a-cis-cinnamoyloxylupanine
CAS No: 86707-49-5
C24H30N2O3
MW: 394.515
LogP (est): 3.3
N
H N
H
O
O
O
13a-trans-cinnamoyloxylupanine
CAS No: 5835-04-1
C24H30N2O3
MW: 394.515
LogP (est): 3.3 N
H N
H
O
O
O
CAS: Chemical Abstracts Service; MW: molecular weight.
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Appendix B – Other relevant alkaloids present in Lupinus and related
genera from the Genisteae tribe
Compound Chemical structure
Gramine
Synonym: 3-(Dimethylaminomethyl)indole
CAS No: 87-52-5
C11H14N2
MW: 174.247
LogP (est): 1.8 N
H
N
Ammodendrine
Synonym: Spherocarpine
CAS No: 494-15-5
C12H20N2O
MW: 208.305
LogP (est): 0.3
N
H
N
O
CAS: Chemical Abstracts Service; MW: molecular weight.
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Appendix C – Biosynthetic pathway of ester-type quinolizidine alkaloids in Lupinus species (Bunsupa et al.,
2013)39
LDC: lysine decarboxylase; HMT/HLT: tigloyl-CoA: (-)-13a-hydroxymultiﬂorine/(+)-13a-hydroxylupanine O-tigloyltransferase; ECT/EFT-LCT/LFT, p-coumaroyl-
CoA/feruloyl-CoA: (+)-epilupinine/(-)-lupinine O-coumaroyl/feruloyltransferase.
39 Reprinted by permission from Springer: Springer Berlin Heidelberg, Biotechnology for Medicinal Plants: Micropropagation and Improvement, (Eds Chandra S, Lata H and Varma A), Bunsupa S,
Saito K and Yamazaki M. Molecular Biology and Biotechnology of Quinolizidine Alkaloid Biosynthesis in Leguminosae Plants, 263–273, 2013.
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Appendix D – Occurrence of QAs in lupin seeds
Tables D.1–D.4 give an overview of concentrations of QAs in seeds of the species L. albus,
L. luteus, L. angustifolius and L. mutabilis. Papers in which the analytical method is not described, or
when titration or TLC was used for determination, are not included. The columns ‘QA composition’ and
‘concentration ranges of QAs’ show the concentration of the 11 QAs that are considered as relevant for
this opinion while the occurrence of other QAs as well as other alkaloids is shown in ‘Comments’. The
relevant QAs are sorted according to concentration so the QA with the highest concentration is
mentioned ﬁrst.
In many papers, the ‘total alkaloid’ concentration is reported. However, it is not always clear
whether this refers to the total of QAs or the total of all alkaloids. It should be noted that some of the
applied analytical methods are not speciﬁc for QAs so it cannot be concluded that ‘total’ only included
QAs. In some papers, it is clearly stated that ‘total’ means the sum of the found QAs and this is
indicated in the tables. When the authors have indicated if the seeds can be considered as bitter or
sweet, this is also noted in the table. Where the stereochemistry was not provided in the paper, the
CONTAM Panel assumed that the isomer present is the naturally occurring form in that lupin species,
e.g. 13a-OH-lupanine in case of 13-OH-lupanine and a-isolupanine in case of isolupanine.
It has been tried to give all results in percentage of the total even though other units have been
used in the papers. If this was not possible, the unit is stated in the tables. Due to rounding, the sum
of the percentages for the individual QAs is not necessarily 100%. Some of the concentrations are
given on a dry matter basis, but due to high dry matter content of the seeds, concentrations given on
wet weight and dry matter are not very different.
Table D.5 summarises the outcome of different reviews regarding the occurrence of QAs in the four
relevant lupin species and Table D.6 summarises the results on QA occurrence in lupin leaves.
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Table D.1: Occurrence of QAs in seeds of L. albus
Variety/cultivar/
breed
Total QA
concentration in
seeds
QA composition
Concentration ranges
of QAs (%)(e)
Analytical method
LOD/LOQ if
available
Comment e.g. other
alkaloids present
Reference
Multitalia, P2, P3, 4-3,
7-44, 7-7, 8-28, 8-483
47–6,392 mg/kg(a) Lupanine
Multiﬂorine
Albine
13a-OH-lupanine
13a-Angeloyloxylupanine
Angustifoline
a-Isolupanine
13a-Tigloyloxylupanine
5,395 mg/kg
Not detected-616 mg/kg
10–167 mg/kg
Not-detected-126 mg/kg
Not detected-112 mg/kg
Not detected-84 mg/kg
Not detected-75 mg/kg
Not detected-38 mg/kg
GC–MS All varieties grown at
two different places in
Italy in two growing
seasons
Annicchiarico et al.
(2014)
48 types, rich in
alkaloids (world-wide)
< 1,000–about
16,000 mg/kg(a),(c)
Lupanine
Other QAs: albine > 13a-OH-
lupanine >
angustifoline > 13a-
angeloyloxylupanine
88–92 GC–MS Boschin et al. (2008)
Alkaloid-poor: Adam,
Ares, Energy, Lucky,
Ludic, Lustar
50–565 mg/kg(f) Lupanine
13a-Angeloyloxylupanine
13a-OH-Lupanine
Albine
13a-Tigloyloxylupanine
Angustifoline
a-Isolupanine
26–256 mg/kg
Not detected-88 mg/kg
7–79 mg/kg
10–68 mg/kg
Not detected-28 mg/kg
Not detected-22 mg/kg
Not detected-22 mg/kg
GC–MS Dehulled seeds Boschin et al. (2008)
LO-3923, bitter
(N = 8)
23,600 mg/kg Lupanine
Albine
Multilﬂorine
Angustifoline
13a-OH-Lupanine
a-Isolupanine
13a-Tigloyloxylupanine
58
19
7.6
1.1
0.68
0.30
0.08
GC-NPD and GC–MS From Spain
Ammodendrine,
5,6-Dehydrolupanine,
11,12-seco-12,13-
didehydromultiﬂorine
de Cortes Sanchez
et al. (2005)
Bitter 14,400 mg/kg
DM(a)
Lupanine
Multiﬂorine
a-Isolupanine
Albine
Sparteine
87
11
1.0
0.63
0.13
GC-FID Erbas (2010)
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Variety/cultivar/
breed
Total QA
concentration in
seeds
QA composition
Concentration ranges
of QAs (%)(e)
Analytical method
LOD/LOQ if
available
Comment e.g. other
alkaloids present
Reference
Luxor, Rosetta 38–75 mg/kg(a) Lupanine
13a-OH-Lupanine
Angustifoline
a-Isolupanine
18–33 mg/kg
3.8–13.4 mg/kg
4.9–6.3 mg/kg
1.8–2.5
GC–MS
LOQ = 0.2–0.4 mg/kg
Grown in Italy
11,12-
Dehydrolupanine
Gresta et al. (2010)
Multitalia 1,664(a) mg/kg Lupanine
13a-OH-Lupanine
Angustifoline
a-Isolupanine
Sparteine
1,499 mg/kg
99 mg/kg
34 mg/kg
9.1 mg/kg
2.1 mg/kg
GC–MS
LOQ = 0.2–0.4 mg/kg
Grown in Italy
11,12-
Dehydrolupanine
Gresta et al. (2010)
Present and old
cultivars, 59 in total
200–49,100 mg/kg Lupanine
13a-OH-Lupanine
Multiﬂorine
Albine
Angustifoline
28–72
2.4–33
1.0–22
0.02–16
0.29–10
GC(d) Seeds from Poland
11,12-seco-12,13-
Didehydromultiforine
Kroc et al. (2017)
Amiga, Lumen, Estoril,
2 9 Multitalia
220–52,380 mg/kg(b) Lupanine
13a-OH-Lupanine
Angustifoline
a-Isolupanine
Lupinine
160–46,240 mg/kg
0–4,710 mg/kg
10–750 mg/kg
10–250 mg/kg
Not quantiﬁed-50 mg/kg
GC-FID and GC–IT-MS Grown in France,
Portugal and Italy
11,12-
Dehydrolupanine
Magalh~aes et al.
(2017)
Bitter and sweet 143–226 mg/kg(b) 13a-OH-Lupanine
Lupanine
Angustifoline
Albine
a-Isolupanine
13a-Angeloyloxylupanine
13a-Tigloyloxylupanine
48–117 mg/kg
69–111 mg/kg
9–12 mg/kg
Traces
Traces
Traces
Traces
GC-FID and GC–MS Ammodendrine
Dihydroxylupanine
Reinhard et al.
(2006)
Ares 146 mg/kg(a) Lupanine
13a-Angeloyloxylupanine
13a-OH-Lupanine
Albine
13a-Tigloyloxylupanine
43
23
14
11
8.9
GC–MS Resta et al. (2008)
Typtop 1,247 mg/kg Lupanine
13a-OH-Lupanine
Albine
13a-Angeloyloxylupanine
Multilﬂorine
77
11
6.0
3.7
2.6
GC–MS Resta et al. (2008)
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Variety/cultivar/
breed
Total QA
concentration in
seeds
QA composition
Concentration ranges
of QAs (%)(e)
Analytical method
LOD/LOQ if
available
Comment e.g. other
alkaloids present
Reference
Aster, Lutteur, Luxor,
Rosetta, Multitalia 1
(sweet)
67–1,656 mg/kg(b) Lupanine(h)
Albine
13a-OH-Lupanine
Angustifoline
13a-Tigloyloxylupanine
Tetrahydrorhombifoline
30–1,379 mg/kg
12–162 mg/kg
3–157 mg/kg
3.6–65 mg/kg
6.4–44 mg/kg
1.0–13 mg/kg
GC–MS Grown in Italy
3b-Tigloyloxylupanine
Romeo et al. (2018)
Lublanc(g) 14,516 mg/kg(b) Lupanine(h)
Albine
13a-OH Lupanine
Angustifoline
13a-Tigloyloxylupanine
Tetrahydrorhombifoline
11,219 mg/kg
1,012 mg/kg
492 mg/kg
268 mg/kg
102 mg/kg
24 mg/kg
GC–MS Grown in Italy
3b-Tigloyloxylupanine
Romeo et al. (2018)
Multitalia 2,3 and 4,
Puglia, Molise,
Basilicata, Scicli,
Modica, Calabria 1, 2,
3, 4
3,185–19,340 mg/
kg(b)
Lupanine(h)
Albine
13a-OH-Lupanine
Angustifoline
13a-Tigloyloxylupanine
Tetrahydrorhombifoline
2,161–14,480 mg/kg
375–2,596 mg/kg
158–893 mg/kg
42–518 mg/kg
51–348 mg/kg
6.5–44 mg/kg
GC–MS Grown in Italy
3b-Tigloyloxylupanine
Romeo et al. (2018)
Not given Not given Lupanine
Albine
13a-OH-Lupanine
Multiﬂorine
Sparteine
Angustifoline
a-Isolupanine
13a-Angeloyloxylupanine
Unknown QAs
70
15
8
3
< 1
< 1
< 1
< 1
< 1
GC–MS Analysis of 56 lupin
species for 100 QAs
Wink et al. (1995)
DM: dry matter; FID: ﬂame ionisation detector; GC–IT-MS: gas chromatography–ion trap mass spectrometry; GC–MS: gas chromatography–mass spectrometry; LOD: limit of detection; LOQ: limit of
quantiﬁcation; N: number of samples; NPD: nitrogen-phosphorus detector; QA: quinolizidine alkaloids.
(a): Sum of individual QAs.
(b): Sum of alkaloids.
(c): Total for all 48 types; numbers read from a ﬁgure with a broad scale.
(d): Detector not reported.
(e): Given as percentage of total QA, unless another unit is given. In the latter case, the percentage of the individual QAs was not reported by the authors.
(f): Not all QAs found in all samples so the lowest total amount is not the sum of the lowest amounts of the individual QAs.
(g): It is stated in the paper to be a sweet variety but with a total concentration of more than 10,000 m/kg it is not included as sweet in this opinion but as bitter.
(h): Only results for QAs found in all varieties are shown in the paper.
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Table D.2: Occurrence of QAs in seeds of L. angustifolius
Variety/cultivar/
breed
Total QA
concentration in
seeds
QA composition
Concentration ranges
of QAs (%)(d)
Analytical method
LOD/LOQ if
available
Comment e.g. other
alkaloids present
Reference
Alkaloid poor:
Arabella, Jindalee,
Quilinoc
141–701 mg/kg(a) Lupanine
13a-OH-Lupanine
Angustifoline
a-Isolupanine
92–426 mg/kg
26–183 mg/kg
12–63 mg/kg
8–34 mg/kg
GC–MS Boschin et al. (2008)
Graf 1,450 mg/kg(a) Lupanine
13a-OH-Lupanine
a-Isolupanine
Angustifoline
69
24
5.8
0.66
GC-NPD From a Polish breeding
station
Ammodendrine
3b-OH-Lupanine
Chilomer et al.
(2010)
W26, Polonez (sweet) 840–1,800 mg/kg
DM(a)
Lupanine
13a-OH-Lupanine
a-Isolupanine
Angustifoline
Sparteine
Tetrahydrorhombifoline
4.0–50
19–21
6.4–14
2.7–4.4
2.5–4.8
0.0–1.0
GC–MS Isoangustifoline Christiansen et al.
(1997)
Zubr (bitter) 20,600 mg/kg
DM(a)
Lupanine
13a-OH-Lupanine
Angustifoline
Tetrahydrorhombifoline
a-Isolupanine
Sparteine
71
17
5.8
2.8
1.2
0.1
GC–MS Isoangustifoline Christiansen et al.
(1997)
Not given (N = 8) 14,740 mg/kg(a) Lupanine
Angustifoline
13a-OH-Lupanine
Multiﬂorine
36
30
25
0.95
GC-NPD and GC–MS From Spain
Isoangustifoline, 5,6-
Dehydrolupanine,
11,12-seco-12,13-
Didehydromultiﬂorine
Unidentiﬁed ester
de Cortes Sanchez
et al. (2005)
Wonga, Jindale, Sonet 15–55 mg/kg(a) 13a-OH-Lupanine
Lupanine
Angustifoline
Sparteine
5.6–26 mg/kg
7.4–17.9 mg/kg
< LOQ–11.2 mg/kg
< LOQ–0.59 mg/kg
GC–MS
LOQ = 0.2-0.4 mg/kg
Grown in Italy Gresta et al. (2010)
Past and present
cultivars, 78 in total
652–19,176 mg/kg(a) Lupanine
13a-OH-Lupanine
Angustifoline
a-Isolupanine
43–54
29–37
14–17
1.4–5.8
GC(c) Seeds from Poland Kamel et al. (2016)
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Variety/cultivar/
breed
Total QA
concentration in
seeds
QA composition
Concentration ranges
of QAs (%)(d)
Analytical method
LOD/LOQ if
available
Comment e.g. other
alkaloids present
Reference
Azuro, Sonet 690–24,950
mg/kg(b)
Lupanine
Angustifoline
a-Isolupanine
Sparteine
550–20,570 mg/kg
90–3,830 mg/kg
40–550 mg/kg
Not detected–10 mg/kg
GC-FID and GC–IT-MS Grown in Portugal and
Poland
11,12-Dehydrolupanine
Magalh~aes et al.
(2017)
Bitter (N = 3) 10,800–19,800
mg/kg(b)
Lupanine
13a-OH-Lupanine
a-Isolupanine
4,000–12,900 mg/kg
5,000–6,600 mg/kg
213–237 mg/g
GC-FID and GC–MS Reinhard et al.
(2006)
Sweet (N = 8) 44–2,120 mg/kg 13a-OH-Lupanine
Lupanine
Angustifoline
a-Isolupanine
18–943 mg/kg
18–862 mg/kg
7–226 mg/kg
37–90 mg/kg
GC-FID and GC–MS a-Isolupanine only in
samples from Australia
Reinhard et al.
(2006)
Boregine 1,107 mg/kg Lupanine
Angustifoline
13a-OH-Lupanine
13a-Isolupanine
50
23
15
12
GC–MS Resta et al. (2008)
Not given Not given Lupanine
13a-OH-Lupanine
Angustifoline
Sparteine
Tetrahydrorhombifoline
a-Isolupanine
70
12
10
< 1
< 1
< 1
GC–MS Analysis of 56 lupin
species for 100 QAs
Wink et al. (1995)
DM: dry matter; FID: ﬂame ionisation detector; GC–IT-MS: gas chromatography–ion trap mass spectrometry; GC–MS: gas chromatography–mass spectrometry; LOD: limit of detection; LOQ: limit
of quantiﬁcation; N: number of samples; NPD: nitrogen-phosphorus detector; QA: quinolizidine alkaloids.
(a): Sum of individual QAs.
(b): Sum of alkaloids.
(c): Detector not reported.
(d): Given as percentage of total QA, unless another unit is given. In the latter case, the percentage of the individual QAs was not reported by the authors.
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Table D.3: Occurrence of QAs in seeds of L. luteus
Variety/cultivar/
breed
Total QA
concentration in
seeds
QA composition
Concentration
ranges of QAs
(%)(d)
Analytical method
LOD/LOQ if available
Comment e.g. other
alkaloids present
Reference
Lord 1,020 mg/kg Sparteine
Lupinine
13a-OH-Lupanine
Lupanine
56
27
6.3
2.9
GC-NPD From a Polish breeding
station
Gramine
Ammodendrine
17-Oxosparteine
Chilomer et al. (2010)
Dukat, Mister, Taper 9–14 mg/kg(a) Sparteine
13a-OH-Lupanine
Lupanine
7.1-13.6 mg/kg
< LOQ-1.1 mg/kg
< LOQ-0.5 mg/kg
GC–MS
LOQ = 0.2-0.4 mg/kg
Grown in Italy Gresta et al. (2010)
Dukat, Taper, 2 x
Mister, Nacional
130–10,630 mg/kg Sparteine
Lupinine
13a-OH-Lupanine
120-7,890 mg/kg
0-2,420 mg/kg
Not-detected-10
mg/kg
GC-FID
GC–IT-MS
Grown in Poland and
Portugal
11,12-Dehydrolupanine
Gramine
Magalh~aes et al. (2017)
Stated as sweet 500–895 mg/kg(b) Sparteine
Lupinine
2-50 mg/kg
3-10 mg/kg
GC-FID and GC–MS Gramine (450-893 mg/kg) Reinhard et al. (2006)
Dukat, Mister, Taper
(sweet)
389–639 mg/kg(a) Lupinine(e)
Sparteine
Lupanine
177-281 mg/kg
120-234 mg/kg
6.4-37 mg/kg
GC–MS Grown in Italy
Ammodendrine
Feruloyllupinine
b-Isosparteine
Romeo et al. (2018)
Not stated Not given Lupinine
Sparteine
Tetrahydrorhombifoline
Lupanine
60
30
< 1
< 1
GC–MS Analysis of 56 lupin species
for 100 QAs
Wink et al. (1995)
FID: ﬂame ionisation detector; GC–IT: gas chromatography–ion trap mass spectrometry; GC–MS: gas chromatography–mass spectrometry; LOD: limit of detection; LOQ: limit of quantiﬁcation;
NPD: nitrogen-phosphorus detector; QA: quinolizidine alkaloids.
(a): Sum of individual QAs.
(b): Sum of alkaloids.
(c): Detector not reported.
(d): Given as percentage of total QA, unless another unit is given. In the latter case, the percentage of the individual QAs was not reported by the authors.
(e): Only results for QAs found in all varieties are shown in the paper.
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Table D.4: Occurrence of QAs in seeds of L. mutabilis
Variety/
cultivar/breed
Total QA
concentration in
seeds
QA composition
Concentration of
QAs (%)
Analytical method
Comment e.g. other
alkaloids present
Reference
Not given 31,000 mg/kg DM Lupanine
13a-OH-Lupanine
Sparteine
Tetrahydrorhombifoline
13a-Angeloyloxylupanine
13a-Tigloyloxylupanine
a-Isolupanine
Multiﬂorine
58
15
7.4
3.5
1.6
0.3
0.3
0.14
GC–MS and GC-NPD From Peru
3b-OH-Lupanine(a)
3b,13a-diOH-Lupanine(b)
13a-Benzoyloxylupanine
13a-Cinnamoyloxylupanine
6 QAs tentatively identiﬁed
3 un-identiﬁed QAs
Hatzold et al. (1983)
Not given Not given Lupanine
Sparteine
13a-OH-Lupanine
Tetrahydrorhombifoline
13a-Angeloyloxylupanine
Angustifoline
13a-Tigloyloxylupanine
a-Isolupanine
Multiﬂorine
47
16
7
2
2
1
1
< 1
< 1
GC–MS 3b-OH-Lupanine, 12% of total
Analysis of 56 lupin species for
100 QAs
Wink et al. (1995)
QA: quinolizidine alkaloids; DM: dry matter; NPD: nitrogen-phosphorus detector; GC–MS: gas chromatography–mass spectrometry.
(a): Reported by the authors under its synonym 4-OH-lupanine.
(b): Reported by the authors under its synonym 4,13-diOH-lupanine.
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Table D.5: Occurrence of quinolizidine alkaloids reported in overview papers
Concentration of total
alkaloids
QA composition
Ranges of
QAs (%)
References
L. albus
Bitter varieties: 320–29,600
mg/kg DM
Sweet varieties: < 100–4,200
mg/kg DM
Not known: 370–8,050 mg/kg
DM
Lupanine
a-isolupanine
13a-OH-lupanine
Multiﬂorine
Albine
11,12-seco-12,13-
Didehydromultiﬂorine
Angustifoline
13a-OH-Multiﬂorine
13a–Tigloyloxylupanine
Sparteine
13a-Angeloyloxylupanine
17-Oxolupanine
57–70
< 1–25
0–20
0–18
< 0.1–15
< 0.1–13
< 1–8.9
1–1.5
0.5–1.4
0–0.7
0.2–0.6
0.2–0.4
Pilegaard and Gry (2008)
50–3,670 mg/kg DM Lupanine
Albine
13a-OH-Lupanine
Multiﬂorine
70
15
8
3
Carvajal-Larenas et al. (2016)(a)
Sweet: 50–500 mg/kg DM
Bitter: Up to 80,000 mg/kg in
wild types
Lupanine
Albine
Multiﬂorine
13a-OH-Lupanine
13a-Angeloyloxylupanine
Minor:
Angustifoline
a-Isolupanine
Sparteine
Tetrahydrorhombifoline
55–75
6–15
3–14
4–12
1–3
BfR (2017a)
L. angustifolius
Bitter: 14,400–25,511 mg/kg
DM
Sweet: 20–1,918 mg/kg DM
Not stated: 250–6,670 mg/kg
DM
Lupanine
13a-OH-Lupanine
Isoangustifoline
Angustifoline
a-Isolupanine
Sparteine
Tetrahydrorhombifoline
Other alkaloids
24–72
12–52
0.5–31
1.9–16
< 1–15
0.03–5
< 1–2.9
< 1–10
Pilegaard and Gry (2008)
950–14,000 mg/kg seed DM Lupanine
13a-OH-Lupanine
Angustifoline
70
12
10
Carvajal-Larenas et al. (2016)(a)
Sweet: < 500 mg/kg Lupanine
Angustifoline
13a-OH-Lupanine
Minor:
Isoangustifoline
a-Isolupanine
17-Oxolupanine
Sparteine
Tetrahydrorhombifoline
66–75
10–15
10–15
BfR (2017a)
L. luteus
4,700–15,000 mg/kg seed DM Lupinine
Sparteine
60
30
Carvalja-Larenas et al. (2016)(a)
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Concentration of total
alkaloids
QA composition
Ranges of
QAs (%)
References
Sweet: < 1,000 mg/kg
Bitter: 5,000–20,000 mg/kg
Lupinine
Sparteine
Minor:
Feruloyllupinine
b-Isosparteine
Lupanine
17-Oxosparteine
Tetrahydrorhombifoline
60
30
BfR (2017a)
L. mutabilis
70–45,000 mg/kg seed DM Lupanine
Sparteine
13a-OH-Lupanine
3b-OH-Lupanine(b)
Tetrahydrorhombifoline
Angustifoline
3b,13a-diOH-Lupanine(c)
13a-Angeloyloxylupanine
cis-13a-
Cinnamoyloxylupanine
Multiﬂorine
13–85
6.6–19
1.6–15
1.1–8.7
2.0–3.5
0.6–5.4
2.1
1.6–2.0
1.2
0.2–2.0
0.1–1.8
Carvajal-Larenas et al. (2016)
Sweet: < 1,000 mg/kg
Bitter: 10,000–40,000 mg/kg
Lupanine
3b-OH-Lupanine
13a-OH-Lupanine
Sparteine
Tetrahydrorhombifoline
Minor:
13a-Angeloyloxylupanine
Angustifoline
11,12-Dehydrosparteine
3,13-diOH-Lupanine
a-Isolupanine
Multiﬂorine
17-Oxosparteine
13-Tigloyloxylupanine
Various esters of 13a-OH-
lupanine, 3b-OH-lupanine
and 3b,13a-diOH-lupanine
37–75
4–22
4–20
3–20
0.1–4
BfR (2017a)
DM: dry matter; QA: quinolizidine alkaloids.
(a): Same data as in Wink et al. (1995).
(b): Reported by the authors as 4-OH-lupanine.
(c): Reported by the authors as 4,13-diOH-lupanine.
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Table D.6: Occurrence of quinolizidine alkaloids in leaves of L. albus, L. angustifolius, L. luteus and
L. mutabilis
Species
Total
concentration of
QAs (mg/kg)
Quinolizidine
alkaloids identiﬁed
Contribution of
individual QAs
Reference
L. albus Not stated(b) Lupanine
13a-OH-lupanine
Multiﬂorine
13a-tigloyloxylupanine
Albine
Angustifoline
Sparteine
Tetrahydrohombifoline
a-Isolupanine
13a-Angeloyloxylupanine
50%
12%
10%
10%
6%
3%
< 1%
< 1%
< 1%
< 1%
Wink et al. (1995)
L. angustifolius Not stated Lupanine
13a-OH-Lupanine
Angustifoline
Tetrahydrorhombifoline
a-Isolupanine
33%
20%
20%
< 1%
< 1%
Wink et al. (1995)
L. angustifolius 64–20,205(a) a-Isolupanine
13a-OH-Lupanine
Lupanine
Angustifoline
Tetrahydrorhombifoline
13a-Tigloyloxylupanine
Multiﬂorine
Sparteine
4.5–9,478 mg/kg
20–3,433 mg/kg
10–2,623 mg/kg
6.3-2,504 mg/kg
3.0–2,348 mg/kg
7.2–1,029 mg/kg
0–40 mg/kg
0–26 mg/kg
Philippi et al. (2016)(c)
L. luteus Not stated Sparteine
Lupinine
Tetrahydrorhombifoline
Lupanine
55%
20%
< 1%
< 1%
Wink et al. (1995)
L. mutabilis Not stated Lupanine
13a-Tigloyloxylupanine
13a-OH-Lupanine
Tetrahydrorhombifoline
13a-Angeloyloxylupanine
Sparteine
Angustifoline
a-Isolupanine
35%
25%
9%
7%
7%
3%
1%
< 1%
Wink et al. (1995)
(a): Concentration of total alkaloids.
(b): In Wink et al. (1995) the analysed cultivars are not stated and the total amount of QAs are also not given.
(c): The paper of Philippi et al. (2016) describes results for the analysis by GC-FID of leaves from 46 different varieties of
L. angustifolius.
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Appendix E – Identiﬁcation and selection of relevant scientiﬁc literature
and reports
Formation, Occurrence, Exposure
Search terms
TOPIC: (lupanine OR lupinine OR isolupanine OR isoangustifoline OR sparteine OR
cytisine OR methylcytisine OR albine OR angustifoline OR isosparteine OR anagyrine OR
thermopsine OR multiﬂorine OR tetrahydrorhombifoline OR OH-lupanine OR
angeloyloxylupanine OR tigloyloxylupanine OR cinnamoyloxylupanine OR quinolizidine OR
lupin*) AND TOPIC: (occurrence OR exposure OR levels OR concentrat* OR formation OR
content OR food OR feed OR livestock)
Numbers of papers 5,741
ADME and Mode of action
Search terms TOPIC: (lupanine OR lupinine OR isolupanine OR isoangustifoline OR sparteine OR
cytisine OR methylcytisine OR albine OR angustifoline OR isosparteine OR anagyrine OR
thermopsine OR multiﬂorine OR tetrahydrorhombifoline OR hydroxylupanine OR
angeloyloxylupanine OR tigloyloxylupanine OR cinnamoyloxylupanine OR quinolizidine OR
lupin*) AND TOPIC: (toxicokinetic* OR metabolism OR distribution OR excretion OR
absorption OR mode of action OR mechanism of action OR biotransformation OR
elimination OR reduction OR detoxiﬁcation OR activity OR genetic polymorphism OR poor
metaboliser OR extensive metaboliser OR acetylcholine receptors OR sodium channel
blocker OR potassium channel blocker OR antiarrhytmic OR uterus contract* OR oxytocic
Numbers of papers 4,347
Processing
Search terms TOPIC: (lupanine OR lupinine OR isolupanine OR isoangustifoline OR sparteine OR
cytisine OR methylcytisine OR albine OR angustifoline OR isosparteine OR anagyrine OR
thermopsine OR multiﬂorine OR tetrahydrorhombifoline OR hydroxylupanine OR
angeloyloxylupanine OR tigloyloxylupanine OR cinnamoyloxylupanine OR quinolizidine OR
lupin*) AND TOPIC: detoxiﬁcation OR debittering OR processing OR soaking OR stability
OR reduction
Numbers of papers 1,948
Animal toxicity
Search terms TOPIC: (lupanine OR lupinine OR isolupanine OR isoangustifoline OR sparteine OR
cytisine OR methylcytisine OR albine OR angustifoline OR isosparteine OR anagyrine OR
thermopsine OR multiﬂorine OR tetrahydrorhombifoline OR hydroxylupanine OR
angeloyloxylupanine OR tigloyloxylupanine OR cinnamoyloxylupanine OR quinolizidine OR
lupin*) AND TOPIC: (toxicity OR toxi* OR acute OR subacute OR subchronic OR chronic
OR mutagen* OR carcino* OR genotox* OR reprotox* OR nephrotox* OR neurotox* OR
hepatotox* OR immunotox* OR haemotox* OR hematotox* OR cytotox* OR develop*
toxicity OR teratogen* OR rat OR mouse OR animal* OR dog OR cow OR heifer OR
calves OR sheep OR goats OR horse OR ﬁsh OR ruminant OR pig OR piglet OR swine OR
sow OR livestock
Numbers of papers 3,050
Human observations
Search terms TOPIC: (lupanine OR lupinine OR isolupanine OR isoangustifoline OR sparteine OR
cytisine OR methylcytisine OR albine OR angustifoline OR isosparteine OR anagyrine OR
thermopsine OR multiﬂorine OR tetrahydrorhombifoline OR hydroxylupanine OR
angeloyloxylupanine OR tigloyloxylupanine OR cinnamoyloxylupanine OR quinolizidine OR
lupin*) AND TOPIC: (biomarker OR biological marker OR case stud* OR incidental
poisoning OR poisoning OR human poisoning OR epidem*)
Number of papers 195
Data base used Web of Science
Total number 8,545
Considered
relevant(a)
37
(a): This is not the total number of relevant publications, but that of those considered as relevant in addition to those in the
previous search (N = 175).
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Appendix F – EFSA guidance documents on risk assessment
EFSA (European Food Safety Authority), 2007. Guidance of the Scientiﬁc Committee on a request from EFSA
related to uncertainties in Dietary Exposure Assessment. EFSA Journal 2007;4(12):438, 54 pp. https://doi.org/
10.2903/j.efsa.2007.438
EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on transparency in the
scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: General principles. EFSA Journal 2009;6
(5):1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051
EFSA (European Food Safety Authority), 2010. Management of left-censored data in dietary exposure assessment
of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. https://doi.org/10.2903/j.efsa.2010.1557
EFSA (European Food Safety Authority), 2011. Scientiﬁc opinion on genotoxicity testing strategies applicable to
food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. https://doi.org/10.2903/j.efsa.2011.
2379
EFSA (European Food Safety Authority), 2011. Overview of the procedures currently used at EFSA for the
assessment of dietary exposure to different chemical substances. EFSA Journal 2011;9(12):2490, 33 pp.
https://doi.org/10.2903/j.efsa.2011.2490
EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012. Guidance
for the preparation of dossiers for sensory additives. EFSA Journal 2012;10(1):2534, 26 pp. https://doi.org/10.
2903/j.efsa.2012.2534
EFSA Scientiﬁc Committee, 2012. Guidance on selected default values to be used by the EFSA Scientiﬁc
Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579,
32 pp. https://doi.org/10.2903/j.efsa.2012.2579
EFSA Scientiﬁc Committee, 2012. Scientiﬁc Opinion on Risk Assessment Terminology. EFSA Journal 2012;10
(5):2664, 43 pp. https://doi.org/10.2903/j.efsa.2012.2664
EFSA Scientiﬁc Committee, 2017. Update: use of the benchmark dose approach in risk assessment. EFSA Journal
2017;15(1):4658, 48 pp. https://doi.org/10.2903/j.efsa.2017.4658
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Appendix G – Feed intakes and diet composition (livestock)
Information on the amount of total diet consumed per day, the inclusion rate of lupins in the diet
and the concentration of QAs in the lupin seeds is needed in order to estimate daily exposure to
quinolizidine alkaloids (QAs) by farm animals, horses and companion animals. Details of the feed
intakes and live weights for different farm animals, horses and companion animals used to estimate
exposures in this Opinion have been obtained from a number of different sources, details of which are
given in the tables below. Inclusion rates for lupin seeds in diets of different livestock species have
been obtained from publications in which maximum recommended levels have been published, in
order to estimate total daily intake of lupins. These data have been combined with levels of QAs in
lupin seeds (see Section 3.3.2 for details) to estimate daily exposure to QAs.
G.1. Feed intakes
G.1.1. Ruminants and horses
Dairy cows
The amounts of feed given to lactating dairy cows varies according to the amount and quality of
forages and other feeds available, the weight of the cow and its milk yield. In this Opinion, it is
assumed that non-forage (i.e. complementary) feeds are fed at the rate of 0.3 kg/kg of milk produced
(Nix, 2010). Exposures to QAs have been estimated for a 650-kg dairy cow. Assumptions on the
amounts of forages and non-forage feed are given in Table G.1.
Beef cattle
There are a wide variety of beef production and husbandry systems in Europe. They may be
categorised broadly as forage-based or cereal-based systems, although combinations of these systems
are commonly found. In this opinion, an exposure estimate has been made for a 500 kg animal with a
daily dry matter intake of 12 kg (Table G.1).
Sheep and goats
Many breeds and systems of management have been developed for sheep and goats to suit the land,
climate and husbandry conditions in the EU. As for other ruminants, forages may be the only feeds used
after weaning (NRC, 2007a). Common exceptions to this are pregnant and lactating animals, whose feed
is usually supplemented with non-forage feeds or manufactured compound (complementary) feeds
(AFRC, 1993; NRC, 2007a). In this Opinion, exposure estimates have been made for lactating sheep and
goats. The CONTAM Panel has used a daily dry matter intake of 2.8 kg for an 80-kg lactating sheep
feeding twin lambs to estimate the exposures. For lactating goats, the CONTAM Panel has used a daily
dry matter intake of 3.4 kg for a 60-kg goat for milking (4 kg milk/day). For fattening goats, a body
weight of 40 kg and feed intake of 1.4 kg DM/day has been assumed (Table G.1).
Horses
Horses are non-ruminant herbivores. They typically consume 2–3.5% of their body weight in feed
(dry matter) each day, of which a minimum of 50% should be as forage (pasture grass or hay) (NRC,
2007b). Assumed intakes are given in Table G.1.
Quinolizidine alkaloids in feed and food
www.efsa.europa.eu/efsajournal 96 EFSA Journal 2019;17(11):5860
G.1.2. Non-ruminant animals
Pigs
Although there is a considerable range of pig production systems in Europe, exposure estimates
have been made for piglets (pig starter), ﬁnishing pigs and lactating sows (using feed intakes
proposed by EFSA FEEDAP Panel, 2012). Details are given in Table G.2.
Poultry
The CONTAM Panel applied the live weights and feed intakes for fattening chickens (broilers),
laying hens and turkeys proposed by EFSA FEEDAP Panel (2012) and for ducks by Leeson and
Summers (2008) (Table G.2).
Farmed ﬁsh (salmonids)
Commercially reared species include Atlantic salmon, rainbow trout, sea bass, sea bream, cod,
halibut, tuna, eel and turbot. In this Scientiﬁc Opinion exposures to QAs been made for farmed
salmon. Details of the body weights and feed intakes used are given in Table G.2.
Rabbits
Feed intakes of 65–80 g/kg bw per day have been reported (Carabano and Piquer, 1998). For the
exposure estimates, the CONTAM Panel have assumed a live weight of 2 kg, and a daily feed intake of
75 g/kg bw (derived from Carabano and Piquer, 1998).
Table G.1: Live weights, growth rate/productivity, dry matter intake for cattle, sheep, goats and
horses, and the proportions of the diet as non-forage
Animal species
Live
weight
(kg)
Growth rate or
productivity
Dry matter
intake (kg/day)
% of diet as
non-forage feed
Reference
Dairy cows,
lactating(a)
650 40 kg milk/day 25 40 OECD (2013)
Fattening cattle:
beef(b)
500 1 kg LWG/day 12 15 OECD (2013)
Sheep: lactating 80 Feeding twin lambs 2.8 50 OECD (2013)
Goats: milking 60 6 kg milk/day 3.4 65 NRC (2007a)
Goats: fattening 40 0.2 kg LWG/day 1.4 65 NRC (2007a)
Horses 450 Moderate activity 9.0 50 NRC (2007b)
LWG: live weight.
(a): Months 2–3 of lactation.
(b): Housed castrated cattle, medium maturing breed.
Table G.2: Live weights and feed intake for pigs, poultry (EFSA FEEDAP Panel, 2012), ducks
(Leeson and Summers, 2008) and ﬁsh
Species Live weight (kg)
Feed intake (kg dry
matter/day)
Reference
Pigs: starter 20 1.0 EFSA FEEDAP Panel (2012)
Pigs: ﬁnishing 100 3.0 EFSA FEEDAP Panel (2012)
Pigs: lactating sows 200 6.0 EFSA FEEDAP Panel (2012)
Poultry: broiler starters 0.7 0.075 Leeson and Summers (2008)
Poultry: broilers(a) 2 0.12 EFSA FEEDAP Panel (2012)
Poultry: laying hens 2 0.12 EFSA FEEDAP Panel (2012)
Turkeys: fattening turkeys 12 0.40 EFSA FEEDAP Panel (2012)
Ducks: fattening ducks 3 0.14 Leeson and Summers (2008)
Salmonids 2 0.04 EFSA FEEDAP Panel (2012)
(a): Fattening chickens.
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Companion animals: dogs and cats
The amount of food consumed is largely a function of the mature weight of the animal, level of
activity, physiological status (e.g. pregnancy or lactation) and the energy content of the diet. In this
Scientiﬁc Opinion, the CONTAM Panel assumed body weights (kg) and feed intakes (g dry matter/day)
for dogs and cats of 25/360 and 4/60, respectively (derived from NRC, 2006).
G.2. Inclusion rates of lupins in the diets of farm animals, horses and
companion animals
It has not been possible to obtain, from feed manufacturers, typical inclusion rates of lupins in the
diets of farm animals, horses or companion animals. Therefore, where possible published reported
maximum levels of inclusion that resulted in no adverse effects on animal health or productivity have
been used to establish possible ‘worst-case’ scenarios. It should be noted however that recommended
inclusion levels vary according to authors, and where recommended levels vary widely a conservative
approach has been adopted. For some livestock, the data have been reviewed and reported in
Feedipedia, an EU/FAO online feed database,40 unless otherwise stated.
G.2.1. Cattle, sheep, goats and horses
While forages are essential feeds to ruminants and horses, they are normally supplemented with
non-forage feeds such as cereals, cereal by-products, oilseed meals and by-products of human food
production. Whole-crop lupins may be fed to livestock, as the sole crop or grown in combination with
other forages and may be fed fresh or ensiled. However, no data are available on levels of QAs in the
whole plant and, therefore, it is assumed that it makes no contribution to exposure.
G.2.2. Pigs and poultry
High levels of non-starch polysaccharides in lupin seeds restrict their use in pig and poultry diets.
For pigs, OECD (2013) recommends maximum inclusion rates of 15% in diets for young and breeding
pigs, and 20% for ﬁnishing (fattening) pigs. However, other authors have suggested that higher levels
may be tolerated, and (Kim et al., 2011) have recommend maximum inclusion rates in grower diets of
20% and in fattener diets up to 35%.
Based on a review of published studies in which lupin seeds or meal were fed to poultry, Jeroch
et al. (2016) recommended a maximum inclusion rate of 15% in diets of laying hens, broiler chickens,
growing turkeys and fattening ducks and geese. Similar maximum inclusion rates have been proposed
by Smulikowska et al. (2014), although Yule and McBride (1975) reported reductions in feed utilisation
when broilers were fed diets containing 16% lupin meal (compared to 8%). Differences may have
been due to the use of different lupin cultivars used.
G.2.3. Rabbits
Rabbits are usually fed a pelleted diet (in the form of complete feedingstuffs) consisting of dried
forages, cereals and vegetable proteins supplemented with minerals, vitamins and trace elements.
The usual recommended inclusion rate in rabbit diets ranges from 10% to 20%, although higher
levels have been used in experimental studies without adverse effects. No general guidelines on the
maximum inclusion rates of lupins in rabbit diets have been identiﬁed. Volek and Marounek (2008)
Table G.3: Assumed inclusion rates (%) of lupin meal in the complementary (i.e. non-forage) feeds
of ruminants and horses (El Otmani et al., 2013; OECD, 2013)
Non-forage feed
materials
Dairy
cows
Beef
cattle
Lactating
sheep
Lactating
goats
Fattening
goats
Horses
Lupin meal (%) 20(a) 25(a) 15(a) 20(a) 20(b) 10(a)
% of non-forage feeds in
the diet
40 15 50 75 40 50
(a): OECD (2013).
(b): El Otmani et al. (2013).
40 www.feedipedia.org
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reported a study in which fattening rabbits (from 37 to 79 days of age) were fed a diet containing
15% L. albus meal. No adverse effects on feed intake, growth rate or the health of the rabbits were
noted. Therefore, in this Opinion, an inclusion rate of 15% lupin meal in the diet of fattening rabbits
has been assumed.
G.2.4. Farmed ﬁsh (salmonids)
Traditionally, the principal raw materials used for the manufacture of ﬁsh feeds in Europe have
been ﬁshmeal and ﬁsh oils, although alternative sources of oil and protein, including lupin seeds, are
increasingly replacing ﬁsh-derived feeds.
The digestibility of lupin meals is strongly inﬂuenced by the high levels of non-starch
polysaccharides (NSP) within the grain, and since most aquaculture species lack the ability to deal with
dietary NSP almost all of the NSP in lupins is defaecated. At high levels, it is also likely that NSP may
act as an anti-nutrient, effectively acting like ﬁbre and inhibiting the digestive process for other
nutritionally important components of the feed. However, improvements in dry matter digestibility may
be achieved with the removal of the lupin seed coat, which is concomitant with a reduction in the
levels of NSP within the meals (Smith et al., 2000).
There is considerable variability in the maximum recommended inclusion level of lupin meals in
diets for aquaculture species, with values ranging from 20% to 70% (De la Higuera et al., 1988;
Robaina et al., 1995; Burel et al., 1998; Williams, 1998). Based on a review of the literature available
at the time, Carter et al. (2002) reported that the addition of 20% dehulled lupin to a commercial
extruded salmon feed produced excellent growth performance under commercial aquaculture
conditions, and this value has been used to estimate the maximum exposure for salmon.
G.2.5. Companion animals (dogs and cats)
Limited information is available on recommended levels of lupin seed or meal in dog or cat feeds.
Brown (2009) reported a study which concluded that inclusion of lupins in diets for dogs at levels
greater than 15% ‘may be problematic’ due to the presence of non-starch polysaccharides in the
seeds. The European Pet Food Industry Federation (FEDIAF41) has provided EFSA with information on
typical inclusion levels of certain feed ingredients; although this did not include any reference to lupins,
the formulations included up to 8% soybean meal in dry cat and dog food. Therefore, the CONTAM
Panel has assumed an inclusion rate of 10% lupins in dog and cat feeds as an alternative to soybean
meal, to account (in part) for the lower protein content of lupins while remaining within the limit
proposed by Brown (2009).
G.3. Calculated dietary exposure for farm animals, horses and
companion animals
Estimates of mean LB and UB dietary exposure to TotQAs are given below for farm animals, horses
and companion animals based on occurrence data for lupin seeds from L. angustifolius and L. albus
(Table G.4; n = 54), as well as from both plant species separately (Tables G.5 and G.6).
41 The European Pet Food Industry Federation (FEDIAF), Personal communication by email, May 2016.
Quinolizidine alkaloids in feed and food
www.efsa.europa.eu/efsajournal 99 EFSA Journal 2019;17(11):5860
Table G.4: Estimates of mean LB and UB exposure to TotQAs(a) (n = 54) are given below for farm
animals, horses and companion animals
Species
Diet concentration
(mg/kg)
Intake mg/day Intake mg/kg bw
Mean P75 Mean P75 Mean P75
Dairy: high yielding LB 31.5 28.2 652 583 1.00 0.90
UB 31.5 28.2 652 583 1.00 0.90
Beef: fattening LB 14.8 13.2 142 127 0.35 0.32
UB 14.8 13.2 142 127 0.35 0.32
Sheep: lactating LB 29.5 26.4 82.6 74.0 1.03 1.23
UB 29.5 26.4 82.7 74.0 1.03 1.23
Goats: lactating LB 59.0 52.8 201 180 3.34 2.99
UB 59.1 52.8 201 180 3.35 2.99
Goats: fattening LB 31.5 28.2 47.2 42.3 1.18 1.06
UB 31.5 28.2 47.3 42.3 1.18 1.06
Horses LB 19.7 17.6 177 158 0.39 0.35
UB 19.7 17.6 177 158 0.39 0.35
Pig starter LB 59.0 52.8 59.0 52.8 2.95 2.64
UB 59.1 52.8 59.1 52.8 2.95 2.64
Pig ﬁnisher LB 98.4 88.1 295 264 2.95 2.64
UB 98.5 88.1 295 264 2.95 2.64
Lactating sow LB 78.7 70.4 472 423 2.36 2.11
UB 78.8 70.4 473 423 2.36 2.11
Chickens for fattening LB 59.0 52.8 7.08 6.34 3.54 3.17
UB 59.1 52.8 7.09 6.34 3.54 3.17
Laying hens LB 59.0 52.8 7.08 6.34 3.54 3.17
UB 59.1 52.8 7.09 6.34 3.54 3.17
Turkeys for fattening LB 59.0 52.8 23.6 21.1 1.97 1.76
UB 59.1 52.8 23.6 21.1 1.97 1.76
Ducks for fattening LB 59.0 52.8 8.26 7.40 2.75 2.47
UB 59.1 52.8 8.27 7.40 2.76 2.47
Salmonids LB 78.7 70.4 3.15 2.82 1.57 1.41
UB 78.8 70.4 3.15 2.82 1.58 1.41
Cats LB 39.4 35.2 2.36 2.11 0.59 0.53
UB 39.4 35.2 2.36 2.11 0.59 0.53
Dogs LB 39.4 35.2 14.2 12.7 0.57 0.51
UB 39.4 35.2 14.2 12.7 0.57 0.51
Rabbits LB 59.0 52.8 8.85 7.92 4.43 3.96
UB 59.1 52.8 8.86 7.92 4.43 3.96
bw: body weight; LB: lower bound; P75: 75th percentile; TotQA: total quinolizidine alkaloids; UB: upper bound.
(a): Calculated as the sum of lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine, a-isolupanine.
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Table G.5: Estimates of mean LB and UB exposure to TotQAs(a) from L. angustifolius (n = 32) are
given below for farm animals, horses and companion animals
Species
Diet concentration
(mg/kg)
Intake mg/day Intake mg/kg bw
Mean P75 Mean P75 Mean P75
Dairy: high yielding LB 38.0 43.1 787 892 1.21 1.37
UB 38.0 43.1 787 892 1.21 1.37
Beef: fattening LB 17.8 20.2 171 194 0.43 0.48
UB 17.8 20.2 171 194 0.43 0.48
Sheep: lactating LB 35.6 40.4 100 113 1.25 1.89
UB 35.7 40.4 100 113 1.25 1.89
Goats: lactating LB 71.3 80.8 242 275 4.04 4.58
UB 71.3 80.8 243 275 4.04 4.58
Goats: fattening LB 38.0 43.1 57.0 64.7 1.43 1.62
UB 38.0 43.1 57.1 64.7 1.43 1.62
Horses LB 23.8 26.9 214 242 0.48 0.54
UB 23.8 26.9 214 242 0.48 0.54
Pig starter LB 71.3 80.8 71.3 80.8 3.56 4.04
UB 71.3 80.8 71.3 80.8 3.57 4.04
Pig ﬁnisher LB 119 135 356 404 3.56 4.04
UB 119 135 357 404 3.57 4.04
Lactating sow LB 95.0 108 570 647 2.85 3.23
UB 95.1 108 571 647 2.85 3.23
Chickens for fattening LB 71.3 80.8 8.55 9.70 4.28 4.85
UB 71.3 80.8 8.56 9.70 4.28 4.85
Laying hens LB 71.3 80.8 8.55 9.70 4.28 4.85
UB 71.3 80.8 8.56 9.70 4.28 4.85
Turkeys for fattening LB 71.3 80.8 28.5 32.3 2.38 2.69
UB 71.3 80.8 28.5 32.3 2.38 2.69
Ducks for fattening LB 71.3 80.8 10.0 11.3 3.33 3.77
UB 71.3 80.8 10.0 11.3 3.33 3.77
Salmonids LB 95.0 108 3.80 4.31 1.90 2.16
UB 95.1 108 3.80 4.31 1.90 2.16
Cats LB 47.5 53.9 2.85 3.23 0.71 0.81
UB 47.6 53.9 2.85 3.23 0.71 0.81
Dogs LB 47.5 53.9 17.1 19.4 0.68 0.78
UB 47.6 53.9 17.1 19.4 0.68 0.78
Rabbits LB 71.3 80.8 10.7 12.1 5.35 6.06
UB 71.3 80.8 10.7 12.1 5.35 6.06
bw: body weight; LB: lower bound; P75: 75th percentile; TotQA: total quinolizidine alkaloids; UB: upper bound.
(a): Calculated as the sum of lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine, a-isolupanine.
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Table G.6: Estimates of mean LB and UB exposure to TotQAs(a) from L. albus (n = 13) are given
below for farm animals, horses and companion animals
Species
Diet concentration
(mg/kg)
Intake (mg/day) Intake (mg/kg bw)
Mean P75 Mean P75 Mean P75
Dairy: high yielding LB 27.5 28.7 570 595 0.88 0.92
UB 27.6 28.7 571 595 0.88 0.92
Beef: fattening LB 12.90 13.5 124 129 0.31 0.32
UB 12.93 13.5 124 129 0.31 0.32
Sheep: lactating LB 25.8 26.9 72.2 75.4 0.90 1.26
UB 25.9 26.9 72.4 75.4 0.90 1.26
Goats: lactating LB 51.6 53.9 175 183 2.92 3.05
UB 51.7 53.9 176 183 2.93 3.05
Goats: fattening LB 27.5 28.7 41.3 43.1 1.03 1.08
UB 27.6 28.7 41.4 43.1 1.03 1.08
Horses LB 17.2 18.0 155 162 0.34 0.36
UB 17.2 18.0 155 162 0.34 0.36
Pig starter LB 51.6 53.9 51.6 53.9 2.58 2.69
UB 51.7 53.9 51.7 53.9 2.59 2.69
Pig ﬁnisher LB 86.0 89.8 258 269 2.58 2.69
UB 86.2 89.8 259 269 2.59 2.69
Lactating sow LB 68.8 71.8 413 431 2.06 2.16
UB 68.9 71.8 414 431 2.07 2.16
Chickens for fattening LB 51.6 53.9 6.19 6.47 3.10 3.23
UB 51.7 53.9 6.20 6.47 3.10 3.23
Laying hens LB 51.6 53.9 6.19 6.47 3.10 3.23
UB 51.7 53.9 6.20 6.47 3.10 3.23
Turkeys for fattening LB 51.6 53.9 20.6 21.6 1.72 1.80
UB 51.7 53.9 20.7 21.6 1.72 1.80
Ducks for fattening LB 51.6 53.9 7.22 7.54 2.41 2.51
UB 51.7 53.9 7.24 7.54 2.41 2.51
Salmonids LB 68.8 71.8 2.75 2.87 1.38 1.44
UB 68.9 71.8 2.76 2.87 1.38 1.44
Cats LB 34.4 35.9 2.06 2.16 0.52 0.54
UB 34.5 35.9 2.07 2.16 0.52 0.54
Dogs LB 34.4 35.9 12.4 12.9 0.50 0.52
UB 34.5 35.9 12.4 12.9 0.50 0.52
Rabbits LB 51.6 53.9 7.74 8.08 3.87 4.04
UB 51.7 53.9 7.76 8.08 3.88 4.04
bw: body weight; LB: lower bound; P75: 75th percentile; TotQA: total quinolizidine alkaloids; UB: upper bound.
(a): Calculated as the sum of lupanine, 13a-OH-lupanine, angustifoline, multiﬂorine, 13a-tigloyloxylupanine, a-isolupanine.
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Appendix H – Hazard identiﬁcation and characterisation
H.1. Summary of acute studies with quinolizidine alkaloids42
Route of
administration
Alkaloid/tested material Species (N)
Dose (mg/kg bw)
Reference
LD50 MLD
(a) LD0
(b) LD100
(c)
i.p. Lupanine Rats (12) ND 180–192 Gordon and Henderson (1951)
Wistar rats (5) 177 154 Petterson et al. (1987)
Guinea pigs (13) ND 210–225 Gordon and Henderson (1951)
Mice (39) 80 75–85 Gordon and Henderson (1951)
Swiss mice (10) 175 Yovo et al. (1984)
Swiss mice (5) 64 250 Pothier et al. (1998)
13a-OH-Lupanine Wistar rats (5) (starved) 199 169 Petterson et al. (1987)
Sparteine Swiss mice (10) 36 Yovo et al. (1984)
Swiss mice (5) 25 100 Pothier et al. (1998)
PO Lupanine Wistar rats (5) 1,664 Petterson et al. (1987)
Swiss mice (10) 410 Yovo et al. (1984)
Sparteine Swiss mice (10) 220 Yovo et al. (1984)
i.v. Lupanine Hartley Guinea pigs (5) 78 Yovo et al. (1984)
Sparteine Hartley Guinea pigs (5) 27 Yovo et al. (1984)
i.p. L. mutabilis seed extracts Swiss mice (5) 64 250 Pothier et al. (1998)
PO L. angustifolius seed extracts Wistar rats (5) (fed) 2,279 Petterson et al. (1987)
Wistar rats (5) (starved) 2,401 Petterson et al. (1987)
bw: body weight; i.p.: intraperitoneal; PO: per os; i.v.: intravenous; MLD: minimal lethal dose; LD: lethal dose; N: number of animals per group.
(a): Minimal lethal dose: Lowest amount of a substance that, when introduced into the body, may cause death to individual species of test animals under a deﬁned set of conditions.42
(b): LD0: the maximal non-lethal dose represents the dose at which no individuals are expected to die. This is just below the threshold for lethality.
43
(c): LD100: dose killing all the animals.
42 https://goldbook.iupac.org/html/M/M03933.html
43 https://toxtutor.nlm.nih.gov/02-004.html
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H.2. Effects of orally administered quinolizidine alkaloids in repeated dose studies in experimental animals
Species (number
animals/group)
Source of QA Dosage (mg/kg bw per day) Duration Outcome
Doses not associated
with effects
Reference
Charles River rats
(12/group); sex
unspeciﬁed
20% lupin protein diet L. albus (510 mg
alkaloids/kg seeds; 45 mg/kg bw per day)
20% lupin protein diet L. luteus (910 mg
alkaloids/kg seeds; 81 mg/kg bw per day)
Casein diet as control group
112 days Normal weight gain
Normal weights for several
organs
45 mg/kg bw per day
(only dose tested)
81 mg/kg bw per day
(only dose tested)
Ballester et al. (1980)
Sprague–Dawley male
and female rats
(40/group)
15% lupin protein diet L. mutabilis (water
debittered seeds, 160 mg alkaloids/kg;
equivalent to 14.4 mg/kg bw per day). Casein
diet as control group
84 days Normal weight gainNormal
weights for several
organsNormal haematological
parameters and clinical
chemistry
14.4 mg/kg bw per day
(only dose tested)
Schoeneberger et al.
(1987)
Sprague–Dawley
males and female rats
(20/group)
Diet (20% lupin protein) based on L.
angustifolius ﬂour spiked to provide 250, 1,050
and 5,050 mg alkaloids/kg diet (equivalent to
25, 105, 505 mg/kg bw/day). The reference diet
contained a background level of 50 mg
alkaloids/kg (equivalent to 4.5 mg/kg bw per
day)
90–98 days Normal weight gain
Normal weights for several
organs
Increase in relative liver
weights in females (all doses)
Some altered liver foci (both
sexes)
ND Butler et al. (1996)
Sprague–Dawley
males and female rats
(20/group)
Diet based on L. angustifolius ﬂour containing 0,
100, 330, 1,000 and 5,000 mg alkaloids/kg diet
(equivalent to 10, 33, 100 and 500 mg/kg bw per
day). The control basal diets were commercial
preparations +/ 4.5% maltodextrin
90 days Lower weight gains (both
sexes, two highest doses)
Increases in relative liver
weights (both sexes, highest
dose)
No liver lesions
100 mg/kg bw per day
based on increased
relative liver weight
Robbins et al. (1996)
Male Wistar rats
(8/group)
Diet (10% lupin protein) based on L.
angustifolius seeds (90, 110, 150 mg alkaloids/
kg feed in Baron, Zeus and Wersal cultivars,
respectively. These values are equivalent to 8.1,
9.9 and 13.5 mg alkaloids/kg bw per day
28 days Lower weight gain and food
intake(a) Decreased liver
weights
Increased TG (all cultivars)
Decreased ALT (Zeus and
Wersal). Liver lesions
ND Stanek et al. (2015)
ALT: alanine transaminase; bw: body weight; LOAEL: lowest-observed-adverse-effect level; ND: not determined; NOAEL: no-observed-adverse-effect level; QA: quinolizidine alkaloids; TG:
triacylglycerols.
(a): The CONTAM Panel noted that previous experiments with 10% protein without DL-methionine supplementation showed that animals performed poorly.
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H.3. Repeated dose toxicity studies of limited relevance for the risk
assessment
Ballester et al. (1982) studied the toxic effects of a diet containing 51.8 g ﬂour from L. albus (var.
Multolopa) per 100 g diet (supplemented with 0.2% DL-methionine) in comparison to a control diet fed
to groups of 20 male and 20 female Wistar rats for up to 9 months. The control diet contained the
same protein levels (20%) obtained by defatted soybean ﬂour, ﬁshmeal and dried skimmed milk. The
alkaloid concentration of the test diet was 0.025% (corresponding to 12.5 mg/kg bw per day). At 24
and 36 weeks the weight of several organs and their histology were examined. Haematological
parameters (haemoglobin (Hb), haematocrit (HCT), leukocytes) and tests of liver functions (serum
glutamic-pyruvate transaminase (SGPT) and serum glutamic-oxaloacetic transaminase (SGOT) were
analysed. The test diet was well tolerated throughout the experiment, with food consumption and food
conversion efﬁciency being similar in all dietary groups. The lupin feed had no adverse effects on
growth, mortality, haematology or blood chemistry. In comparison to the control group, the treatment
group showed a reduction in the relative liver weights. The histology of the liver, kidneys, brain,
gonads and small intestine did not differ from the controls. The CONTAM Panel noted inconsistencies
in the reporting of this study (discrepancies between the text/Table and the Abstract/Conclusions on
the reduction of relative liver weights).
Long-term consumption (700 days) of diets based on L. angustifolius seeds (320 g/kg) was
compared to a control diet (lactalbumin, maize and potato starch, glucose and maize oil) in male
Hooded-Lister rats (Rowett strain) (27 and 39 animals, respectively)(Grant et al., 1995). The alkaloid
concentration in the seeds was not reported. After 30, 250 and 700 days, animals were sacriﬁced and
several organs were analysed (stomach, small intestine, caecum and colon, liver, kidney, adrenals,
pancreas, spleen, thymus, lungs, heart, thyroid and muscles). Feed conversion efﬁciency was reduced
in lupin-fed rats and body weights were signiﬁcantly decreased at all time points when compared to
controls. Growth was retarded over the initial 250 days and later on body weights gains were similar
to controls. Consumption of the lupin-diet did not reduce net protein or lipid deposition in tissues. No
signiﬁcant difference in body composition was identiﬁed as a result of lupin seed consumption. Caecum
and colon weights were signiﬁcantly increased in lupin-fed rats (less prominent increases in stomach
and small intestine). The CONTAM Panel noted that the lack of information on the alkaloid
concentration of the seeds does not allow a toxicological evaluation of these data.
With the aim of investigating whether a lupin seed diet resulted in pancreatic enlargement, male
Hooded Lister rats (48 animals) were fed a diet based on L. angustifolius seeds (320 g/kg) (no
information on QA levels) and followed for 800 days. In comparison to the control diet (lactalbumin,
maize and potato starch, glucose and maize oil), no pancreatic enlargement was observed (Grant
et al., 1993).
The inﬂuence of the alkaloids and oligosaccharide concentration on the utilisation of casein diets
was studied in male and female Wistar rats (27–30 days old, 8 animals/group) (Zdunczyk et al., 1998).
Animals were fed with a casein diet supplemented with extracts of QAs and oligosaccharides from
high- and low-alkaloid L. albus seeds (0.15 and 0.32 g/kg bw, respectively). Feed consumption and
body weights were recorded for 4 weeks. Absorption of nutrients (glucose, methionine and
phosphorus) in the small intestine was also determined by a controlled ﬂow of perfusion ﬂuid through
the small intestine of anaesthetized rats. Finally, the effect of the alkaloid and oligosaccharide
concentration on the nutritional value of lupin seeds was determined in a diet (supplemented with
DL-methionine and L-tryptophan) in which lupin seeds were the sole protein source. The alkaloid
concentration of 0.32 g/kg did not reduce feed intake or weight gains of a casein-based dietary intake
and only slightly lowered the coefﬁcient of crude protein digestibility (TD) in comparison to the control
group. Decreased glucose and methionine absorption in the small intestine did not correlate with the
alkaloid but with the oligosaccharide concentration. Different levels of alkaloids and oligosaccharides in
the diets containing lupin seeds had no signiﬁcant effect on feed intake, weight gains of the animals or
TD coefﬁcients. The CONTAM Panel noted that the design of this study was not suitable for evaluating
possible toxic effects of QAs.
In an experimental model of type 2 diabetes mellitus, sparteine, lupanine and 2-thionosparteine
were administered in non-diabetic and streptozotocin-induced diabetic Wistar rats (8 weeks old, 280–
300 g bw, 10 animal/group) (Bobkiewicz-Kozlowska et al., 2007). Administration of sparteine and 2-
thionosparteine (8 mg/kg) and lupanine (22.1 mg/kg) were by single i.p. injections. Blood glucose
levels were estimated 60, 90 and 120 min after injection and insulin serum concentration at 120 min.
Quinolizidine alkaloids in feed and food
www.efsa.europa.eu/efsajournal 105 EFSA Journal 2019;17(11):5860
Lupanine did not exert hypoglycaemic effects in diabetic and non-diabetic animals. In contrast,
injection of sparteine and 2-thionosparteine lowered blood glucose levels in diabetic rats and showed
hypoglycaemic effects similar to the glibenclamide positive control. However, no increase in plasma
insulin concentration was observed.
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H.4. Summary of genotoxicity studies on quinolizidine alkaloids
Compound Source Test system Experimental system
Concentration/
treatment
Result Comments Reference
Lupanine Puriﬁed by the
authors from
L. termis
Bacterial reverse
mutation assay (Ames
test)
Salmonella Typhimurium
TA97, TA98, TA100,
TA102, TA1535, TA1538
5, 20, 100 lg/plate + S9
100 lg/plate - S9
Negative No toxicity Santiago Quiles
et al. (2010)
Extracts
L. termis
Ethanol
extraction from
L. termis
Bacterial reverse
mutation assay (Ames
test)
S. Typhimurium TA97,
TA98, TA100, TA102,
TA1535, TA1538
5, 20, 100 lg/plate + S9
100 lg/plate - S9
Negative No toxicity
Mouse lymphoma
assay
L5178Y TK+/cells 984, 1,161, 1,370, 1,617,
1,908, 2,251 lg/mL
S9: 24 h and 4 h
+S9: 4 h
Negative No signiﬁcant toxicity
at maximal solubility
level (2,251 lg/mL)
Mouse micronucleus
assay
Balb C mice single i.p. injection: 635
mg/kg bw sampling time:
24 h and 48 h
Negative Dose corresponding to
50% of LD50
Sparteine Commercial SSBs by Comet assay Tradescantia (clone
4430)
0.01, 0.1, 0.5, 1 mM Positive:
Only at 0.5 mM
Non-standard test
No dose response
Silva et al.
(2014)
Extracts
L. mexicanus
and
L. montanus
Ethanol
extraction
SSBs by Comet assay Tradescantia (clone
4430)
0.01, 0.1, 0.5, 1 mM Positive:
All doses
No dose response
bw: body weight; i.p.: intraperitoneal; SSB: single-strand break; LD50: lethal dose killing half of the animals.
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H.5. Studies on adverse effects in farm animals, horses and
companion animals that are of limited relevance for the risk
assessment
Cattle
In a kinetic study by Gardner and Panter (1993; mentioned also in Section 3.1.1.2 on Toxicokinetics
in farm animals, horses and companion animals), two cows of unspeciﬁed breed and age received a
single oral dose (3 g/kg bw) of ground dried L. caudatus (aerial plant material) containing 19,200 mg
QAs/kg, with lupanine (8%), 5,6-dehydrolupanine (22%), and anagyrine (22%) as the major QAs
identiﬁed. The dose corresponded to 57.6 mg QAs/kg bw, including 4.8 mg lupanine/kg bw and
12.7 mg 5,6-dehydrolupanine/kg bw. Within 30 min, dosed animals showed protrusion of the
nictitating membrane, frothing at the mouth, depression and slight incoordination of the hindquarter.
Cows of unspeciﬁed age, breed and weight with (group A, N = 6) or without (group B, N = 6) a
history of delivering calves affected by lupin-induced arthrogryposis44 (also referred to as ‘crooked calf
disease’) were orally gavaged with a single dose (2 g/kg bw) of dried and ground L. leucophyllus. The
administered plant material contained 1,000  100 mg/kg lupanine (i.e. 2.0 mg/kg bw), 3,900 
400 mg/kg 5,6-dehydrolupanine (i.e. 7.8 mg/kg bw), and 3,300  300 mg/kg anagyrine (the total QA
concentration was not reported) (Gay et al., 2004, see Section 3.1.1 on Toxicokinetics). One to 4 h
after dosing, 7 out of 12 cows exhibited mild signs of toxicosis including uncoordinated gait, muscle
fasciculations or coarse muscle tremors, and exaggerated response to external stimuli.
In a trial aimed at investigating the main TK parameters of lupin alkaloids in cattle cited above
(Green et al., 2015a, see Section 3.1.1 on Toxicokinetics), four Holstein steers (289  13 kg bw)
received a single oral dose of dried ground L. leucophyllus plant material with calculated dosages of
lupanine, 5,6-dehydrolupanine, anagyrine and a further unidentiﬁed alkaloid amounting to 17.2, 9.9,
12.9 and 6.7 mg/kg bw, respectively. No clinical adverse effects were reported. Likewise, six of each
Angus and Holstein pregnant heifers did not exhibit clinical signs of intoxication following the oral
administration of a single dose of the same dried ground L. leucophyllus as described above (Green
et al., 2015a) corresponding to an equivalent dose of 7.6 mg/kg bw lupanine, 4.0 mg/kg bw 5,6-
dehydrolupanine, 3.0 mg/kg bw unidentiﬁed alkaloid, and 5.7 mg/kg bw anagyrine (Green et al.,
2015b).
Sheep
Lopez-Ortiz et al. (2004) investigated the effects of body conditions on the disposition of L.
argenteus alkaloids (see Section 3.1.1). Ten Columbia ewes (age not mentioned) were administered
with a single oral dose of dried seedpods (8.5 g/kg bw) containing 16,400 mg/kg total alkaloids (DM
basis), which corresponded to 139 mg total alkaloids/kg bw. Besides three unidentiﬁed alkaloids,
lupanine (8.2%), 5,6-dehydrolupanine (11.5%) and anagyrine (28.8%) were the main components.
No clinical signs were observed at any time after dosing. Accordingly, no signs of intoxication were
noticed in sheep following the single oral administration of ground dried L. caudatus (7.8 g/kg bw)
containing 19,200 mg/kg QAs (Gardner and Panter, 1993, see Section 3.1.1), which amounted to
approximately 150 mg/kg bw. Based on the available literature, sheep appear more resistant than
cattle to the acute effects of QAs. In consideration of the higher blood levels and the longer
persistence observed in the ovine species compared to the bovine one after a single QA
administration, the apparent lower sensitivity to QA of sheep is likely not attributable to differences in
kinetics.
Goats
No clinical signs of poisoning occurred in two goats after the single oral exposure to ground dried
L. caudatus (7.8 g/kg bw) containing 19,200 mg/kg of QAs (Gardner and Panter, 1993; see
Section 3.1.1).
Pigs
In an already mentioned study (see Section 3.1.1.2; Wasilewko et al., 1997), the effects of graded
levels of dietary lupanine in pigs were compared to those from total QAs present in L. albus. Five
piglets (unspeciﬁed sex and breed, initial body weight of 15 kg) were ﬁtted with a post valvular
44 Congenital joint contracture in two or more areas of the body.
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T-shape caecum cannula and subjected to one of the following consecutive experimental treatments
(washout period – if any – not speciﬁed): (i) a control barley-casein QA free diet for 7 days (control 1),
(ii) a 9-day period on control diet plus increasing lupanine concentrations (100, 150 and 200 mg/kg
diet, each three consecutive days), (iii) a lupin diet containing 200 mg/kg total QAs and (iv) the same
control diet described above for 10 days (referred to as control 2). Blood sampling (fasted animals)
was performed at the end of each treatment. Increase in blood AST activity, in the ratio AST/ALT, and
in the bilirubin level were consistently recorded in the lupanine-treated animals; such changes are
suggestive of liver impairment and were less pronounced in the animals fed with lupin QAs. This was
also the case for haematological parameters (haemoglobin, haematocrit, mean cell volume (MCV),
mean corpuscular haemoglobin concentration (MCHC)). The authors concluded that the apparent
lower toxicity of an equivalent amount of total QAs with respect to pure lupanine may be related to
the lower concentration of lupanine, which represents 30–90% of total QA present in L. albus
(Table 1). Due to a poor experimental design (treatment protocol, washout period not speciﬁed), the
CONTAM Panel concluded that this study is unﬁt for deriving safe levels in pigs.
A study was carried out to establish safe dietary inclusion levels for different sweet lupin species
(L. albus, L. angustifolius, L. luteus) and cultivars grown in Poland (Buraczewska et al., 1993). The
total alkaloid concentration (estimated by TLC) in L. albus ranged from 600 to 950 mg/kg and from
400 to 510 mg/kg in L. angustifolius; in both species lupanine predominates over 13a-OH-lupanine and
multiﬂorine. L. luteus showed a different picture, total alkaloids (ranging from 230 to 1,300 mg/kg)
being composed mainly of lupinine, gramine (an indole-derivative), and sparteine. Piglets (N = 6,
unspeciﬁed breed, weight range 20–45 kg) were offered a diet containing 12–35% lupins of different
species and cultivars for 10–14 days. The total alkaloid concentration in the diet ranged between 88
and 180 mg/kg for L. angustifolius cultivars and around 120 mg/kg for L. albus cultivars and up to 455
mg/kg for L. luteus cultivars. As detected by feed intake depression, the tolerated total alkaloid levels
of dietary inclusion differed according to the Lupinus species and cultivar. However, due to the poor
experimental design, also including a restriction in feeding level, the CONTAM Panel decided not to
consider this study.
Quinolizidine alkaloids in feed and food
www.efsa.europa.eu/efsajournal 109 EFSA Journal 2019;17(11):5860
H.6. No-observed-adverse-effect levels, tolerated concentrations and doses of quinolizidine alkaloids in
repeated dose studies in livestock
Species (number
of animals/group)
Source of QA/duration
Measured substance
tested concentration in
feed (mg/kg diet)
Tested parameters
Tolerated concentration
(mg/kg diet) and endpoint
Tolerated dose (mg/kg bw
per day)
Reference
Cattle (Jersey
heifers) (6/group)
Low alkaloid cultivar of
L. albus for 70 days
Control diet based on
soybean
Total alkaloids (QA composition
not reported)
Concentration: 131 mg/kg DM
Feed intake, weight gain, feed
efﬁciency, serum biochemistry
131 mg/kg DM for the lack of
effects on feed intake, weight
gain, feed efﬁciency, serum
biochemistry
4.5 mg/kg bw per day
Johnson et al.
(1986)
Cattle (Friesian
dairy cows)
(5/group)
Intact (I) or heat detoxiﬁed
(HD) lupin seeds (L. albus)
at 150 or 300 g/kg diet DM
for 70 days
Control diet included
sunﬂower meal as a protein
source
The sum of the lupanine and
13a-OH-lupanine
Concentrations: 0, 2,100, 3,800,
5,200, 8,000 mg/kg DM
Feed intake and milk yield 2,100 mg/kg DM for reduced
feed intake
52 mg/kg bw per day
Mukisira et al.
(1995)
Pigs (Large White
x Landrace)
(8/group (Exp 1)
or 15/group
(Exp 2))
– L. angustifolius seeds
(mixture of ‘sweet’ cultivars)
for 63 days (Exp 1)
– L. angustifolius seeds
(‘bitter’ Fest cultivar) for 49
days (Exp 2)
No control group
Total alkaloids (QA composition
not reported)
Concentrations: Exp 1: 120, 200,
280, 360, 440, 520 mg/kg diet
(WW)
Exp 2: 50, 200, 350 mg/kg diet
(WW)
Exp 1: 136, 227, 318, 409, 500,
591 mg/kg diet (DM)
Exp 2: 57, 227, 398 mg/kg diet
(DM)
Growth rate, feed intake, feed
conversion ratio
Liver and kidney gross and
microscopic pathology (Exp 2
only)
227 mg/kg DM for reduced
growth rate and feed intake
9 mg/kg bw per day
Godfrey et al.
(1985)
Pigs (Polish Large
White x Pietrain
Barrows)
(6/group)
– L. angustifolius seeds of
different cultivars (Wersal,
Zeus, Baron) for 62 days
Control diet based on
soybean
Total alkaloids (QA composition
not reported)
Concentrations: 0, 97, 119, 156
mg/kg diet (DM)
Final body weight, daily weight
gain, clinical signs and liver,
kidney, pancreas and gastro-
intestinal gross and
microscopic pathology
119 mg/kg diet DM for
reduction in daily weight gain
Dose calculation not
possible
Rotkiewicz et al.
(2007)
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Species (number
of animals/group)
Source of QA/duration
Measured substance
tested concentration in
feed (mg/kg diet)
Tested parameters
Tolerated concentration
(mg/kg diet) and endpoint
Tolerated dose (mg/kg bw
per day)
Reference
Pigs (10/group) Raw and germinated seeds
of L. luteus and L.
angustifolius for 33 days
Control diet based on
soybean
Total alkaloids (Main QAs
reported)
Concentrations in L. luteus-diets:
10, 15, 17, 24 mg/kg diet (DM)
Concentrations in L.
angustifolius-diets: 18, 27, 31,
47 mg/kg diet (DM)
Final body weight, feed intake,
average daily gain and feed
conversion ratio, clinical signs,
blood enzymes (the latter
tested for some
concentrations)
L. luteus: 24 mg/kg diet DM; no
effects for zootechnical
performance
1.5 mg/kg bw per day
L. angustifolius: 18 mg/kg diet
DM for reduced feed intake
1 mg/kg bw per day
Kasprowicz-Potocka
et al. (2013)
Laying hens
(12 or 30/group)
Debittered lupin grist (16%
in the ration) from one of
the following: L. albus P, L.
albus G, L. mutabilis for 168
days
Control: no lupin inclusion
Total alkaloids (QA composition
not reported)
Concentrations: 1.1, 1.2, 6.2,
9.6 mg/kg diet (WW)
1.2, 1.3, 6.9, 10.7 mg/kg diet
DM
Feed intake, feed efﬁciency,
laying rate, egg weight, and
egg fertility/hatchability
10.7 mg/kg diet DM; no effects
for any of the tested
parameters
0.77 mg/kg bw per day
Vogt et al. (1987)
Single comb white
leghorn laying
hens
(75–300/group)
Raw and processed seeds
from L. albus cv. Ultra Up to
32 weeks
Control: basal diet
Lupanine
Concentrations in diets
containing raw lupin seeds: 0, 8,
12, 16, 20, 24 mg/kg feed(a)
Mortality, feed consumption,
egg production and egg weight
16 mg/kg feed for egg weight
and production
0.9 mg/kg bw per day
Watkins and Mirosh
(1987)
Japanese quails
(90/group)
Raw, processed and
extruded seeds of L. albus
for 6 weeks
Control: no lupin inclusion
Total alkaloids (> 80% lupanine)
Concentration in diet containing
raw lupin seeds: 4,771 mg/kg
feed DM
Zootechnical performances
(feed consumption, live weight,
and feed conversion efﬁciency)
4,771 mg/kg feed DM; no
effects for any of the tested
parameters
826 mg/kg bw per day
Arslan and Seker
(2002)
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Species (number
of animals/group)
Source of QA/duration
Measured substance
tested concentration in
feed (mg/kg diet)
Tested parameters
Tolerated concentration
(mg/kg diet) and endpoint
Tolerated dose (mg/kg bw
per day)
Reference
New Zealand
White rabbits
(16/group)
Seeds from 2 different L
albus cultivars (extruded or
not) for 80 days
Control: no lupin inclusion
Total alkaloid (QA composition
not reported)
Group I: 0, 460 and 930 mg/kg
DM
Group A: 0, 430 and 860 mg/kg
DM
Group AE: 0, 130 and 260
mg/kg DM
Zootechnical performances
(growth rate, feed intake, feed
efﬁciency)
Group I: 460 mg/kg feed DM
for feed consumption, ﬁnal
weight and daily weight gain
30 mg/kg bw per day
Group A: 430 mg/kg feed DM
for ﬁnal weight and daily weight
gain
30 mg/kg bw per day
Group AE: 260 mg/kg feed DM;
no effects for any of the tested
parameters
19 mg/kg bw per day
Battaglini et al.
(1991)
Rainbow trout
(10/group)
Pure lupinine added to the
diet for 60 days
Pure lupinine
Concentrations: 0, 53, 79, 107,
264, 532 or 1,071 mg/kg DM
Weight gain, feed intake, feed
efﬁciency organ somatic index
and organ histology
107 mg/kg feed DM for reduced
feed intake, growth rate and
hepatosomatic index
1.1 mg/kg bw per day
(NOAEL)
Serrano et al.
(2011)
Juvenile rainbow
trout (16/group)
Pure sparteine added to the
diet for 62 days
Pure sparteine
Concentrations: 0, 54, 108, 269,
538, 1,073, 2,662 or 5,482 mg/
kg DM
Weight gain, feed intake, feed
efﬁciency organ somatic index
and organ histology
108 mg/kg feed DM for reduced
body weight, weight gain, feed
intake and hepatosomatic index
1.4 mg/kg bw per day
(NOAEL)
Serrano et al.
(2012)
bw: body weight; DM: dry matter; Exp: experiment; NOAEL: no-observed-adverse-effect level; QA: quinolizidine alkaloids; WW: wet weight.
(a): Unclear in the paper whether this is expressed on DM basis.
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Annex A – Dietary surveys and occurrence data in food submitted to EFSA
Annex A can be found as a separate document at: https://doi.org/10.5281/zenodo.3471613.
Annex B – Occurrence data in feed submitted to EFSA
Annex B can be found as a separate document at: https://doi.org/10.5281/zenodo.3471613.
Annex C – Results of acute dietary exposure assessment to quinolizidine
alkaloids
Annex C can be found as a separate document at: https://doi.org/10.5281/zenodo.3471613.
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